On this page
Quick Reference
Overview and Recommendations
Background
- •Preeclampsia is a multisystem progressive disorder unique to pregnancy, defined by new-onset hypertension (systolic ≥140 mmHg or diastolic ≥90 mmHg) after 20 weeks' gestation, with proteinuria (≥300 mg/24 h or protein/creatinine ratio ≥0.3) or, in its absence, evidence of maternal end-organ dysfunction. It complicates 2-8% of pregnancies globally and accounts for approximately 10% of maternal deaths in low- and middle-income countries, as well as a substantial proportion of iatrogenic preterm births.
- •The disorder is not a single disease but a syndrome with multiple etiologies converging on a common pathway of placental dysfunction and systemic endothelial injury. The mechanistic chain begins with defective trophoblast invasion of spiral arteries in the first trimester, leading to high-resistance uteroplacental circulation, placental ischemia, and oxidative stress.
- •The ischemic placenta releases excessive antiangiogenic factors, notably soluble fms-like tyrosine kinase 1 (sFlt-1), which neutralizes vascular endothelial growth factor (VEGF) and placental growth factor (PlGF), while placental PlGF production falls. The resulting rise in the sFlt-1/PlGF ratio typically precedes clinical disease by weeks and is a hallmark of evolving preeclampsia. A second antiangiogenic factor, soluble endoglin (sEng), amplifies endothelial injury.
- •Two major clinical subtypes exist: early-onset preeclampsia (diagnosed before 34 weeks), driven predominantly by placental dysfunction and severe angiogenic imbalance, and late-onset preeclampsia (≥34 weeks), linked more to maternal cardiovascular maladaptation with subtler placental changes. Approximately 20-30% of cases are early-onset, carrying higher maternal and fetal morbidity.
- •The syndrome manifests through systemic endothelial dysfunction: vasospasm causes hypertension, glomerular endotheliosis leads to proteinuria, cerebral edema can trigger eclampsia, and hepatic inflammation may produce HELLP syndrome (hemolysis, elevated liver enzymes, low platelets). Magnesium sulfate reduces eclamptic seizures by more than half through cerebral vasospasm reduction.
- •Low-dose aspirin (≥100 mg daily) started before 16 weeks of gestation reduces the risk of preterm preeclampsia by 62% (RR 0.38, 95% CI 0.20-0.74), as demonstrated in the ASPRE trial. The USPSTF recommends screening for preeclampsia with blood pressure measurements throughout pregnancy, and first-trimester combined screening using maternal factors, mean arterial pressure, uterine artery Doppler, and PlGF can detect 76% of preterm cases at a 10% false-positive rate.
Evaluation
- •Suspect preeclampsia in any pregnant woman after 20 weeks' gestation presenting with new-onset hypertension (systolic ≥140 mmHg or diastolic ≥90 mmHg) on two occasions at least 4 hours apart, or with symptoms such as headache, visual disturbances (scotomata, photophobia, blurred vision), epigastric or right upper quadrant pain, or dyspnea.
- •Ask about the classic triad of symptoms: headache (often frontal or occipital, not relieved by acetaminophen), visual changes (flashing lights, floaters, blurring), and epigastric or right upper quadrant pain. Additionally, screen for 10 newly identified prodromal symptoms with high odds ratios for impending eclampsia, including twitching/jerking limbs, hearing loss, impaired speech, confusion, feelings of doom, severe vertigo, jitters, difficulty concentrating, weakness/paralysis, and altered mental status.
- •Examine the patient: measure blood pressure with a validated automated device after 5 minutes of rest in a seated position, using an appropriately sized cuff. Confirm an elevated reading with a repeat measurement. Perform fundoscopic examination for arteriolar spasm, assess for hyperreflexia (≥3+ or clonus), and evaluate for peripheral edema (though not specific). Sustained clonus (≥5 beats) or any twitching/jerking should prompt immediate consideration of magnesium sulfate.
- •Order laboratory studies: complete blood count (platelet count <100,000/μL indicates severe features), serum creatinine (>1.1 mg/dL or doubling from baseline), liver enzymes (AST/ALT >2× upper limit of normal), and urinalysis. If dipstick proteinuria is ≥1+, send a spot protein-to-creatinine ratio (≥0.3 mg/mg is diagnostic) or start a 24-hour urine collection (≥300 mg/24 h is gold standard).
- •Obtain an sFlt-1/PlGF ratio if there is diagnostic uncertainty, especially at 24-36 weeks. A ratio ≤38 has a negative predictive value of 99.3% for ruling out preeclampsia within 1 week, allowing safe outpatient management. A ratio >38 mandates close surveillance or admission. The ratio also stratifies risk of adverse neonatal outcomes.
- •Perform obstetric ultrasound to assess gestational age, fetal number, amniotic fluid volume, and fetal growth. For confirmed preeclampsia, initiate serial assessment of fetal biometry, umbilical artery Doppler (pulsatility index >95th percentile or absent/reversed end-diastolic flow defines placental insufficiency), middle cerebral artery Doppler, and cerebroplacental ratio. Abnormal findings indicate fetal hypoxemia and may prompt delivery consideration.
- •Diagnostic criteria per ACOG/ISSHP: new-onset hypertension after 20 weeks plus either proteinuria (≥300 mg/24 h or protein/creatinine ratio ≥0.3) OR one or more of the following end-organ abnormalities: thrombocytopenia, renal insufficiency, impaired liver function, pulmonary edema, or new-onset cerebral/visual symptoms. Proteinuria is sufficient but not necessary.
- •Classify severity: severe features include systolic BP ≥160 mmHg or diastolic ≥110 mmHg on two occasions, platelet count <100,000/μL, AST/ALT >2× upper normal, serum creatinine >1.1 mg/dL or doubling, pulmonary edema, or new-onset cerebral/visual disturbances. The presence of any one severe feature reclassifies the patient as having preeclampsia with severe features.
- •Consider differential diagnoses: systemic lupus erythematosus with nephritis, hemolytic uremic syndrome/thrombotic thrombocytopenic purpura (profound thrombocytopenia, microangiopathic hemolysis), acute fatty liver of pregnancy (marked transaminase elevation), pheochromocytoma (paroxysmal hypertension), and chronic kidney disease exacerbation. Also consider gestational hypertension (hypertension without proteinuria or end-organ dysfunction).
- •For women with chronic hypertension, suspect superimposed preeclampsia when there is new-onset proteinuria or a sudden increase in blood pressure or end-organ dysfunction after 20 weeks. The sFlt-1/PlGF ratio may be less discriminatory in this population because baseline sFlt-1 levels are already elevated.
Management
- •Admit all patients with preeclampsia with severe features to a labor and delivery unit or high-dependency unit for continuous maternal and fetal monitoring. ICU admission is indicated for persistent severe hypertension despite first-line therapy, eclampsia, pulmonary edema, or need for mechanical ventilation.
- •Initiate antihypertensive therapy within 30-60 minutes of confirmed severe hypertension (systolic ≥160 mmHg or diastolic ≥110 mmHg) to prevent maternal stroke. First-line agents: intravenous labetalol 20 mg, repeat every 10-20 minutes up to 80 mg per episode (total 300 mg); intravenous hydralazine 5 mg, repeat every 20 minutes up to 10 mg per episode (total 20 mg); or immediate-release oral nifedipine 10 mg, repeat every 20-30 minutes up to 20 mg per episode (total 50 mg).
- •If blood pressure remains uncontrolled after two doses of one agent, switch to an alternative first-line agent. Failure to achieve control after three agents or persistent severe hypertension despite maximal doses warrants emergent consultation with maternal-fetal medicine, anesthesiology, and/or critical care.
- •Administer magnesium sulfate for seizure prophylaxis in all patients with preeclampsia with severe features, eclampsia, or HELLP syndrome. Standard regimen: 4-6 g IV loading dose over 15-20 minutes, followed by a maintenance infusion of 1-2 g/h for 24 hours postpartum. The Cochrane review (11,444 women) showed magnesium sulfate halves the risk of eclampsia (RR 0.41, 95% CI 0.29-0.58; NNT = 100).
- •Monitor for magnesium toxicity: respiratory depression (<12 breaths/min), loss of deep tendon reflexes, oliguria. Keep calcium gluconate 1 g IV readily available as an antidote. Discontinue magnesium if signs of toxicity occur. For women who have received a minimum 8-hour predelivery infusion, discontinuation immediately after delivery is safe and reduces time to ambulation and lactation initiation.
- •For term pregnancies (≥37 weeks) with preeclampsia without severe features, recommend induction of labor immediately. The HYPITAT trial demonstrated that induction reduces composite poor maternal outcome from 44% to 31% (RR 0.71, 95% CI 0.59-0.86; NNT = 8). For preeclampsia with severe features at term, deliver promptly regardless of gestational age.
- •For late preterm preeclampsia (34 to <37 weeks), planned delivery reduces maternal composite outcome (PHOENIX trial: 65% vs 75%; aRR 0.86, 95% CI 0.79-0.94) but increases neonatal unit admissions (42% vs 34%). Discuss the trade-off with the patient. Administer antenatal corticosteroids (betamethasone 12 mg IM × 2 doses 24 hours apart) if delivery is anticipated before 34 weeks.
- •For early-onset preeclampsia (<34 weeks), consider expectant management in stable women without severe features, with daily maternal and fetal surveillance. Use the fullPIERS model to predict adverse maternal outcome within 48 hours: gestational age, chest pain/dyspnea, oxygen saturation, platelet count, creatinine, AST. Score ≥30 indicates risk >20% and prompts expeditious delivery.
- •Route of delivery: vaginal delivery is appropriate when the cervix is favorable and fetal status is reassuring. Cesarean section is reserved for standard obstetric indications (malpresentation, non-reassuring fetal status, failed induction). No randomized trial has shown that cesarean improves maternal outcomes in preeclampsia per se.
- •Postpartum care: continue antihypertensive therapy to maintain BP <150/100 mmHg (per ACOG). Blood pressure often peaks 3-6 days after delivery. Continue magnesium sulfate for 24 hours postpartum. For women who develop postpartum preeclampsia de novo (new-onset hypertension 48 hours to 6 weeks after delivery), treat similarly with antihypertensives and magnesium if severe features are present.
- •What NOT to do: do not use ergometrine for postpartum hemorrhage prophylaxis or treatment in women with preeclampsia (causes severe vasoconstriction and hypertensive crisis). Do not use ACE inhibitors or ARBs during pregnancy (fetal nephrotoxicity). Do not use vitamins C and E for prevention or treatment (no benefit, possible harm). Do not use pravastatin for treatment of early-onset preeclampsia (no reduction in sFlt-1 levels).
- •For long-term prevention in subsequent pregnancies, initiate low-dose aspirin (81-162 mg daily) starting between 12 and 16 weeks of gestation and continue until delivery for all women with prior preeclampsia. The ASPRE trial showed that 150 mg daily reduces preterm preeclampsia by 62% (OR 0.38, 95% CI 0.20-0.74). ACOG recommends 81 mg daily; NICE recommends 75-150 mg daily.
- •Discharge criteria: stable blood pressure <150/100 mmHg on oral antihypertensives, no severe features, no signs of end-organ dysfunction, adequate diuresis, and fetal status reassuring if undelivered. Arrange postpartum follow-up: blood pressure check within 72 hours, at 1 week, and then annually for all women following a preeclamptic pregnancy to monitor for chronic hypertension and cardiovascular risk.
- •Refer to maternal-fetal medicine for early-onset preeclampsia (<34 weeks), preeclampsia with severe features, superimposed preeclampsia on chronic hypertension, HELLP syndrome, eclampsia, or when delivery timing is uncertain. Also refer for first-trimester combined screening for preterm preeclampsia using the Fetal Medicine Foundation algorithm.
Board Review — High Yield
- •Definition, New-onset hypertension (≥140/90 mmHg) after 20 weeks with proteinuria or end-organ dysfunction.
- •Pathophysiology, Defective trophoblast invasion → placental ischemia → antiangiogenic factors (sFlt-1, sEng) → endothelial dysfunction.
- •sFlt-1/PlGF ratio, ≤38 rules out preeclampsia for 1 week (NPV 99.3%); >655 predicts delivery within 2 weeks.
- •Severe features, BP ≥160/110, platelets <100K, AST/ALT >2× ULN, Cr >1.1, pulmonary edema, cerebral/visual symptoms.
- •Magnesium sulfate, Halves eclampsia risk (RR 0.41; NNT 100); standard dose 4-6 g IV load then 1-2 g/h for 24 h.
- •Acute hypertension, Treat within 30-60 min with IV labetalol, IV hydralazine, or oral nifedipine.
- •Delivery timing, Term: immediate induction (HYPITAT NNT 8). Late preterm: planned delivery reduces maternal morbidity but increases NICU admissions. Early preterm: expectant management if stable.
- •Aspirin prophylaxis, 81-150 mg/day started ≤16 weeks reduces preterm preeclampsia by 62% (ASPRE trial).
- •HELLP syndrome, Hemolysis, elevated liver enzymes, low platelets; severe variant requiring prompt delivery.
- •Long-term risks, Recurrence rate ~40%; increased lifetime cardiovascular disease risk; annual BP monitoring recommended.
Deep Dive — Evidence Details
Definition, Classification & Nomenclature
- ▸Preeclampsia is defined by new-onset hypertension after 20 weeks plus proteinuria OR maternal end-organ dysfunction; a broad definition (ISSHP/ACOG) better identifies women at risk for adverse outcomes than proteinuria alone [5].
- ▸Classification by onset (early vs late, cut-off 34 weeks) and severity (with or without severe features) drives management: early-onset disease is primarily placental, late-onset more cardiovascular [27].
- ▸The sFlt-1/PlGF ratio is a key diagnostic adjunct, with a cut-off of 38 ruling out progression within 1-2 weeks in suspected cases [36,46].
Preeclampsia is a multisystem progressive disorder unique to pregnancy, defined by new-onset (systolic blood pressure ≥140 mmHg or diastolic ≥90 mmHg) after 20 weeks of gestation accompanied by proteinuria (≥300 mg/24 hours or urine protein-to-creatinine ratio ≥0.3) or, in its absence, evidence of maternal end-organ dysfunction [2]D5[5]B2b[22]D5.
Also Called
Pregnancy-induced hypertension (PIH), toxemia of pregnancy, preeclamptic toxemia (PET), gestational hypertension with proteinuria (historical). The term "toxemia" has been abandoned because no circulating toxin has been consistently demonstrated [22]D5.
Key Terms Used Throughout This Article
- Gestational hypertension: new-onset hypertension after 20 weeks without proteinuria or end-organ dysfunction [25]D5.
- Preeclampsia without severe features: hypertension plus proteinuria or end-organ involvement without any severe-feature criterion.
- Preeclampsia with severe features: hypertension (systolic ≥160 mmHg or diastolic ≥110 mmHg) plus thrombocytopenia (<100,000/μL), serum creatinine >1.1 mg/dL or doubling, hepatic transaminases >2× upper-normal, pulmonary edema, or new-onset cerebral/visual symptoms [2]D5.
- Superimposed preeclampsia: new-onset proteinuria or end-organ dysfunction in a woman with chronic hypertension [24]D5.
- Eclampsia: generalized tonic-clonic seizures in a woman with preeclampsia, not attributable to other causes [1]A1c[22]D5.
- HELLP syndrome: , elevated liver enzymes, low platelets-a severe variant that may appear without hypertension or proteinuria.
- Early-onset preeclampsia: diagnosed before 34 weeks; driven primarily by placental dysfunction and angiogenic imbalance (elevated sFlt-1, low PlGF) [27]D5[37]B3b.
- Late-onset preeclampsia: diagnosed at ≥34 weeks; linked more to maternal cardiovascular maladaptation, with subtler placental changes [27]D5.
Classification Systems
Two major classification frameworks coexist. ISSHP (International Society for the Study of Hypertension in Pregnancy) defines preeclampsia broadly: new-onset hypertension plus either proteinuria OR one or more maternal end-organ abnormalities (renal, hepatic, hematologic, neurological) [5]B2b[37]B3b. This broad definition identifies women at risk for adverse outcomes more sensitively than the traditional proteinuria‑dependent definition (sensitivity 62-79% vs 36-50% for composite adverse outcome) [5]B2b. ACOG (American College of Obstetricians and Gynecologists) similarly accepts end-organ involvement but retains proteinuria as a sufficient criterion [2]D5. The Fetal Medicine Foundation further stratifies by gestational age for risk prediction (early, preterm [<37 weeks], term) [13]B2b[37]B3b.
| Category | Subtype | Defining Features |
|---|---|---|
| Gestational age | Early-onset (<34 wk) | High sFlt-1/PlGF, severe placental lesions [27]D5[37]B3b |
| Late-onset (≥34 wk) | Lower sFlt-1/PlGF, maternal CV risk [27]D5 | |
| Severity | Without severe features | BP <160/110, no severe end-organ findings |
| With severe features | BP ≥160/110 or any severe-organ criterion [2]D5 | |
| Underlying status | Superimposed | New proteinuria/dysfunction in chronic hypertension [24]D5 |
Clinical Significance
Preeclampsia complicates 2-8% of pregnancies globally and remains a leading cause of maternal and perinatal morbidity, accounting for ~10% of maternal deaths in low‑ and middle‑income countries and a substantial proportion of iatrogenic preterm birth [21]D5[22]D5[30]D5[49]A1a. Long-term maternal cardiovascular risk is also elevated, a theme revisited in the Prognosis section.
The pathophysiology that explains why early- and late-onset disease follow such different trajectories is examined in the next section.
Pearl: The sFlt-1/PlGF ratio is a key diagnostic adjunct, with a cut-off of 38 ruling out progression within 1-2 weeks in suspected cases [36]B3b[46]D5.
| Category | Subtype | Defining Features |
|---|---|---|
| Gestational age | Early-onset (<34 wk) | High sFlt-1/PlGF, severe placental lesions [27]D5[37]B3b |
| Late-onset (≥34 wk) | Lower sFlt-1/PlGF, maternal CV risk [27]D5 | |
| Severity | Without severe features | BP <160/110, no severe end-organ findings |
| With severe features | BP ≥160/110 or any severe-organ criterion [2]D5 | |
| Underlying status | Superimposed | New proteinuria/dysfunction in chronic hypertension [24]D5 |
Pathophysiology & Mechanism
- ▸Defective spiral artery remodeling leads to placental ischemia and release of antiangiogenic factors (sFlt-1, sEng) that create the systemic endothelial dysfunction of preeclampsia.
- ▸The sFlt-1/PlGF ratio >38 is both a diagnostic and prognostic tool; a ratio ≤38 at 24-34 weeks has a 99.3% negative predictive value for preeclampsia within 1 week.
- ▸Syncytiotrophoblast stress is the final common pathway unifying early-onset (placental) and late-onset (demand-supply mismatch) preeclampsia.
The preceding classification underscores that preeclampsia is not a single disease but a syndrome with multiple etiologies converging on a common pathway of placental dysfunction and systemic endothelial injury [22]D5[97]D5. The mechanistic chain begins in the first trimester with defective trophoblast invasion of the maternal spiral arteries. Normally, extravillous trophoblasts migrate into the decidua and myometrium, replacing the endothelial lining and muscular wall of the spiral arterioles to create low-resistance, high-capacitance vessels. In preeclampsia, this physiologic transformation is shallow and incomplete. The invading trophoblasts fail to remodel the spiral arteries adequately, leaving them narrow, muscular, and vasoreactive [97]D5[101]D5[139]D5. The resultant high-resistance uteroplacental circulation leads to placental ischemia and oxidative stress.
Angiogenic Imbalance: the sFlt-1/PlGF Axis
The ischemic placenta responds by secreting excessive amounts of antiangiogenic factors into the maternal circulation. The most studied is soluble fms-like tyrosine kinase 1 (sFlt-1), a truncated splice variant of the VEGF receptor that binds and neutralizes circulating vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) [69]B2a[109]B3b. Simultaneously, placental production of PlGF, a proangiogenic factor, falls [75]B2b[92]D5. The resulting rise in the sFlt-1/PlGF ratio, typically weeks before clinical disease, is a hallmark of evolving preeclampsia [69]B2a[111]D5. An sFlt-1/PlGF ratio >38 in women with suspected preeclampsia at 24-34 weeks predicts the development of preeclampsia within 4 weeks (sensitivity 66.2%, specificity 83.1%) and a ratio ≤38 virtually excludes preeclampsia for the next week (negative predictive value 99.3%) [108]B2b. The ratio also stratifies risk of adverse neonatal outcomes: an elevated ratio within 4 weeks of delivery is independently associated with small-for-gestational-age (aOR 2.52) and need for prolonged parenteral nutrition (aOR 6.92) [78]B3b.
Soluble Endoglin and Syncytiotrophoblast Stress
A second antiangiogenic factor, soluble endoglin (sEng), amplifies endothelial injury by blocking TGF-β signaling and acting synergistically with sFlt-1 to induce severe vascular damage [109]B3b. Circulating sEng levels rise sharply 2-3 months before clinical onset and correlate with severity [109]B3b. The placenta also releases inflammatory cytokines (TNF-α, IL-6), free radicals, procoagulant factors, and exosomal microRNAs that propagate systemic injury [127]D5[144]D5[145]D5. The syncytiotrophoblast itself becomes stressed, by ischemia, inflammation, or sheer mechanical overload, and this stress triggers the shedding of proapoptotic debris and antiangiogenic proteins into the maternal blood, a process termed syncytiotrophoblast stress [22]D5[97]D5. This concept unifies early-onset preeclampsia (driven by poor placentation and severe angiogenic imbalance) and late-onset preeclampsia (where a fetoplacental demand-supply mismatch or maternal cardiovascular limitations produce similar stress in a histologically normal placenta) [22]D5[98]D5.
Inflammation, Endothelial Dysfunction, and the Final Common Pathway
Circulating antiangiogenic factors and inflammatory mediators attack the maternal endothelium throughout the body. VEGF and PlGF are necessary for endothelial health; their sequestration by sFlt-1 causes endothelial cell activation, vasoconstriction, capillary leak, and a procoagulant state (increased thromboxane, reduced prostacyclin) [92]D5[105]D5[145]D5. Systemic endothelial dysfunction explains the protean manifestations: from vasospasm, proteinuria from glomerular endotheliosis, cerebral edema leading to eclampsia, and hepatic inflammation causing HELLP syndrome [92]D5[99]D5. Maternal cardiovascular maladaptation may precede or amplify this cascade; women destined for preeclampsia often have subclinical cardiac dysfunction and elevated arterial stiffness weeks before clinical onset [98]D5. Magnesium sulfate prevents eclamptic seizures by reducing cerebral vasospasm and blood-brain barrier disruption, an intervention that more than halves the risk of eclampsia (RR 0.41, 95% CI 0.29-0.58; NNT 100) [117]A1a.
Controversies and Guideline Disagreement
| Question | Position A | Position B | Strength | Implication |
|---|---|---|---|---|
| Is preeclampsia primarily a placental or cardiovascular disorder? | Placental origin: defective placentation → antiangiogenic release → maternal syndrome [97]D5[101]D5. | Cardiovascular origin: preexisting or gestational maternal hemodynamic dysfunction → secondary placental ischemia [98]D5. | Moderate; evidence supports both models. | Early-onset preeclampsia aligns more with placental pathogenesis; late-onset may be driven by maternal cardiovascular reserve. Risk-reduction strategies ( , antihypertensives) target both pathways. |
Pearl: When a pregnant woman at 24-34 weeks presents with suspected preeclampsia, an sFlt-1/PlGF ratio ≤38 effectively rules out preeclampsia for the next week (NPV 99.3% [108]B2b), allowing safe outpatient ; a ratio >38 mandates close surveillance or admission.
| Mediator | Source | Direction in Preeclampsia | Effect | Reference |
|---|---|---|---|---|
| sFlt-1 | Syncytiotrophoblast | ↑↑↑ | Binds VEGF/PlGF, causes endothelial dysfunction | [69]B2a[92]D5 |
| PlGF | Syncytiotrophoblast | ↓↓↓ | Reduced proangiogenic protection | [75]B2b[111]D5 |
| Soluble endoglin (sEng) | Syncytiotrophoblast | ↑↑↑ | Blocks TGF-β, synergizes with sFlt-1 | [109]B3b |
| TNF-α, IL-6 | Placenta/immune cells | ↑↑ | Promotes oxidative stress, vascular inflammation | [145]D5 |
| Thromboxane A₂ | Platelets/placenta | ↑↑ | Vasoconstrictor, platelet aggregator | [21]D5[39]A1a |
| Prostacyclin | Endothelium | ↓↓ | Vasodilator, anti-aggregatory | [39]A1a |
| Copeptin (AVP) | Neurohypophysis | ↑↑ | Marker of AVP secretion; may reflect stress | [132]B2a |
Epidemiology, Etiology & Risk Factors
- ▸Preeclampsia complicates 4% of US pregnancies, with substantially higher rates in Black women (2-fold) and in low-income countries (eclampsia 5-15% of deliveries).
- ▸Obesity, chronic hypertension, pregestational diabetes, multiple gestation, and IVF with cryopreserved embryos are among the strongest modifiable and non-modifiable risk factors.
- ▸First-trimester combined screening identifies 76% of preterm preeclampsia at 10% false-positive rate, guiding aspirin prophylaxis that reduces risk by 62%.
The angiogenic imbalance and placental ischemia central to preeclampsia arise in a population whose clinical risk architecture is now well-defined. Preeclampsia complicates approximately 4% of pregnancies in the United States and accounts for 6% of preterm births and 19% of medically indicated preterm births [153]A1c[79]B2a. The burden is higher in low- and middle-income countries, where eclampsia incidence reaches 50-151 per 10,000 deliveries compared with 1.6-10 per 10,000 in developed nations [99]D5. Black women carry a 2-fold higher risk of total preeclampsia and a 2.5-fold higher risk of preterm disease after adjustment for confounders, and case fatality rates are 3 times higher than in White women [169]B2b[154]A1c. South Asian women have a 1.5-fold increased risk of preterm preeclampsia [169]B2b. Despite decades of research, the incidence of preeclampsia has remained relatively stable, in part because the underlying pathophysiology is not fully modifiable with current prevention strategies [21]D5.
The risk architecture is dominated by both modifiable and non-modifiable factors, summarized in the table below.
| Risk Factor | Odds Ratio / Relative Risk | Evidence Level |
|---|---|---|
| Prior preeclampsia | RR 4.7 (95% CI 3.6-6.1) for ESRD; recurrent disease risk elevated [193]B2b | 2b |
| Chronic | aOR 2.58 (95% CI 1.33-5.01) for preeclampsia [163]B2a | 2a |
| BMI ≥30 kg/m² | OR 2.51 (95% CI 2.31-2.74) for any pregnancy complication [168]B2a | 2a |
| Nulliparity | Well-established; included in all screening models [190]A1c[71]B2b | 1c |
| Maternal age ≥35 years | Independent risk factor; aOR ~1.3-1.5 (varies) [177]B2b[190]A1c | 2b |
| OR 1.37 (95% CI 1.06-1.77) [185]B2b | 2b | |
| Chronic kidney disease | aOR 2.58 (95% CI 1.33-5.01) [163]B2a | 2a |
| SLE | OR 3.20 (95% CI 2.54-4.20) [176]B2a | 2a |
| Liver cirrhosis | OR 3.8 (95% CI 2.2-6.5) [173]B2a | 2a |
| Family history of preeclampsia | OR ~2-3 [190]A1c | 2b |
Modifiable Factors and Prevention Opportunities
Maternal overweight and obesity account for an estimated 23.9% of all pregnancy complications, and excessive gestational weight gain contributes to 31.6% of large-for-gestational-age infants [168]B2a. Adherence to a initiated in the first trimester reduced the risk of preterm birth by 55% (RR 0.45, 95% CI 0.26-0.76) and showed a trend toward lower preeclampsia (RR 0.82, 95% CI 0.54-1.22) [167]A1b. Low-dose (≥100 mg daily started ≤16 weeks) reduces preterm preeclampsia by 62% (RR 0.38, 95% CI 0.20-0.74) [155]A1b[164]A1a. Calcium supplementation (≥1 g daily) in populations with low dietary intake reduces preeclampsia risk by approximately 20% (RR 0.80, 95% CI 0.61-1.06) [152]A1b.
Seasonal and Geographic Variation
Seasonal variation is inconsistently reported; higher rates have been observed in winter months in some temperate regions, but the effect is confounded by latitude, diet, and vitamin D status. Socioeconomic deprivation is independently associated with higher preeclampsia incidence, with rates rising from 2.0% in the least deprived quintile to 3.0% in the most deprived quintile, though this effect is largely mediated by race and other established risk factors [197]B2b.
Pearl: The strongest predictors, prior preeclampsia, chronic hypertension, and pregestational diabetes, carry ORs ≥4. First-trimester screening that combines maternal factors, mean arterial pressure, uterine artery pulsatility index, and placental growth factor detects 76% of preterm preeclampsia at a 10% false-positive rate, enabling targeted aspirin prophylaxis [71]B2b[164]A1a.
Clinical Presentation
- ▸Only 2.4% of eclamptic women lack prodromal symptoms; actively screen for the 10 novel high-OR symptoms (twitching, hearing loss, confusion, speech difficulty, doom, vertigo, jitters, poor concentration, weakness, altered mind state) to identify those at highest seizure risk [261].
- ▸A broad definition of preeclampsia, including new-onset end-organ dysfunction without proteinuria, identifies more women at risk for adverse maternal outcomes than the classic hypertension-plus-proteinuria definition [5].
- ▸Postpartum preeclampsia typically presents within 7-10 days of delivery, often with headache; risk factors include older age, Black race, obesity, and cesarean delivery [96].
From risk factors and predisposing conditions, the clinician now faces the bedside challenge: recognizing preeclampsia across its protean manifestations. The syndrome typically declares itself after 20 weeks' gestation with and proteinuria, but the presenting symptoms, often subtle, reflect widespread endothelial dysfunction driven by angiogenic imbalance [238]D5.
Presenting Symptoms
Headache, visual disturbances (scotomata, photophobia, blurred vision), and epigastric or right upper quadrant pain are the classic triad. However, a two-country case-control study identified 10 novel prodromal symptoms with far stronger associations with impending eclampsia than the classic triad: twitching/jerking limbs (OR 42.03, 95% CI 23.66-74.68) [261]B3b, affected hearing (OR 36.00), impaired speech (OR 33.12), confusion (OR 20.52), feelings of doom (OR 23.71), severe vertigo (OR 26.59), jitters (OR 18.16), difficulty concentrating (OR 15.18), weakness or paralysis (OR 10.49), and altered mind state (OR 33.60) [261]B3b. Only 2.4% of eclamptic women had no prodromal symptoms [261]B3b. Symptoms typically progress over days to weeks, with a nadir of neurologic manifestations at 2-4 weeks after onset.
Neurological Examination Findings
Examination may reveal hyperreflexia (≥3+ or clonus), but absence does not exclude disease. Altered mental status, motor weakness (often transient), and cranial nerve deficits (especially oculomotor palsy from posterior reversible encephalopathy syndrome) can occur. Sustained clonus (≥5 beats) or any twitching/jerking should prompt immediate magnesium sulfate consideration [261]B3b.
Phenotypic Variants
| Variant | Key Features | Frequency |
|---|---|---|
| Early-onset (<34 weeks) | Higher sFlt-1/PlGF ratio, more severe IUGR, higher maternal morbidity [106]D5 | ~20-30% of all PE |
| Late-onset (≥34 weeks) | More metabolic risk factors, lower angiogenic imbalance, better perinatal outcomes [106]D5 | ~70-80% |
| Superimposed on chronic hypertension | Worsening BP, new proteinuria or end-organ dysfunction after 20 weeks [2]D5 | Common in chronic HTN |
| HELLP syndrome | (LDH ≥600 U/L), elevated AST (≥70 U/L), platelets <100,000/μL [2]D5 | 10-20% of severe PE |
| Postpartum preeclampsia | New-onset hypertension 48 h to 6 weeks after delivery, often with headache; risk factors: older age, Black race, obesity, cesarean delivery [96]D5 | ~5-10% of all PE |
Red Flags
Any of the 10 high-OR prodromal symptoms listed above requires urgent evaluation. Additional red flags: MAP ≥120 mmHg [183]B2b, new-onset visual loss, pulmonary edema (dyspnea, O2 sat <95%), oliguria (<30 mL/h), platelets <50,000/μL, AST >500 U/L, total bilirubin >15.9 μmol/L, and serum urea >7.5 mmol/L are independently associated with maternal adverse outcome [183]B2b. FVC <15 mL/kg or respiratory distress mandates intubation planning.
Atypical Presentations
Preeclampsia may present without the classic findings. Atypical cases include onset before 20 weeks (e.g., with molar pregnancy, antiphospholipid syndrome, or severe fetal growth restriction) [240]D5, onset >48 hours postpartum (delayed postpartum preeclampsia) [96]D5, or hypertension without proteinuria but with new-onset thrombocytopenia, elevated liver enzymes, or cerebral symptoms [5]B2b. A broad definition, including any maternal end-organ dysfunction (headache, visual symptoms, lab abnormalities), better identifies women at risk for adverse outcomes than proteinuria alone [5]B2b.
Pearl: The 10 newly identified prodromal symptoms (twitching limbs, hearing loss, confusion, altered speech, etc.) have odds ratios >10 for impending eclampsia and should be actively screened in all women with preeclampsia, headache and visual changes alone are insufficient [261]B3b.
Diagnosis & Workup
- ▸Diagnosis requires new-onset hypertension ≥140/90 mmHg after 20 weeks plus proteinuria or end-organ dysfunction; proteinuria is sufficient but not necessary.
- ▸The sFlt-1/PlGF ratio ≤38 has a 99.3% negative predictive value for ruling out preeclampsia within 1 week and can reduce unnecessary hospitalization.
- ▸Point-of-care glycosylated fibronectin testing shows pooled sensitivity 0.80 and specificity 0.84 but is not yet incorporated into major guidelines.
Given the clinical presentation described above, the diagnostic workup centers on confirming , quantifying proteinuria, and assessing end-organ involvement. The gold-standard diagnostic test is the clinical diagnosis per ACOG/ISSHP criteria: new-onset hypertension (≥140 mmHg systolic or ≥90 mmHg diastolic) after 20 weeks’ gestation, accompanied by proteinuria (≥300 mg/24 h or protein/creatinine ratio ≥0.3 mg/mg) or other evidence of maternal end-organ dysfunction [263]A1c[264]A1c. Proteinuria is sufficient but not necessary, if absent, look for thrombocytopenia (platelets <100 000/μL), elevated liver enzymes (AST or ALT twice normal), new renal insufficiency (creatinine >1.1 mg/dL), pulmonary edema, or cerebral/visual symptoms [24]D5[2]D5.
History and Physical
Ask about headache, visual scotomata, epigastric or right-upper-quadrant pain, and dyspnea. Measure blood pressure with a validated automated device after the patient rests for 5 minutes in a seated position, using an appropriately sized cuff [298]A1a[2]D5. Confirm an elevated reading with a repeat measurement 4 hours apart (or sooner if severe). Fundoscopic examination may reveal arteriolar spasm, and peripheral edema is common but not specific.
Laboratory Studies
| Test | Finding | Timing | Sensitivity | Specificity |
|---|---|---|---|---|
| 24‑h urine protein | ≥300 mg | After diagnosis | Gold standard | , |
| Protein/creatinine ratio | ≥0.3 mg/mg | Spot urine | ≥90% (rule‑out) | ~80% [24]D5 |
| Platelet count | <100 000/μL | At presentation | , | , |
| AST, ALT | >2× upper normal | At presentation | , | , |
| Creatinine | >1.1 mg/dL | At presentation | , | , |
| sFlt‑1/PlGF ratio | ≤38 for rule‑out | 24-36 weeks | 80% (rule‑out 1 wk) | 78% [108]B2b |
The sFlt‑1/PlGF ratio is the most validated angiogenic biomarker. A ratio ≤38 has a negative predictive value of 99.3% for ruling out preeclampsia within 1 week [108]B2b. The PARROT trial demonstrated that revealed PlGF testing reduced time to diagnosis and severe maternal adverse outcomes [64]A1b; however, repeat testing (PARROT‑2) did not improve perinatal outcomes [65]A1b. The ratio also aids in risk stratification for adverse outcomes [68]B2a[111]D5. Point‑of‑care tests such as glycosylated fibronectin show pooled sensitivity 0.80 and specificity 0.84, but they are not yet standard in most guidelines [270]A1a.
Imaging
Obstetric ultrasound is performed to assess gestational age, fetal number, and amniotic fluid volume; detailed fetal biometry, Doppler, and antenatal surveillance are covered in the dedicated Fetal Assessment section. Ophthalmic artery Doppler (first diastolic peak velocity >23.3 cm/s) has shown modest predictive value for early‑onset preeclampsia (AUC 0.68) but remains investigational [279]A1a[283]D5.
Diagnostic Algorithm
Step 1: Measure blood pressure. If ≥140/90 mmHg, confirm with repeat measurement. Step 2: Obtain urinalysis. If dipstick ≥1+, send spot protein/creatinine ratio or start 24‑h urine collection. Step 3: If proteinuria is present, diagnose preeclampsia. If absent, evaluate for end‑organ dysfunction (platelets, AST/ALT, creatinine, symptoms). Step 4: If diagnostic uncertainty remains (e.g., chronic hypertension, renal disease), measure sFlt‑1/PlGF ratio. A ratio ≤38 effectively rules out preeclampsia for 1 week [108]B2b. Step 5: Classify severity: severe features defined by BP ≥160/110, thrombocytopenia, elevated liver enzymes, creatinine >1.1 mg/dL, pulmonary edema, or cerebral/visual symptoms [263]A1c.
Differential Diagnosis
Consider with nephritis, hemolytic uremic syndrome/thrombotic thrombocytopenic purpura, , pheochromocytoma, and exacerbation [281]D5[227]C4[221]C4[287]A1c. Key distinguishing features include profound thrombocytopenia and microangiopathic in TTP/aHUS, marked transaminase elevation in AFLP, and paroxysmal hypertension in pheochromocytoma.
Pearl: The sFlt‑1/PlGF ratio ≤38 is the most powerful rule‑out tool for preeclampsia in the short term; use it to avoid unnecessary hospital admission when clinical suspicion is moderate [108]B2b[64]A1b.
Fetal Assessment, Antenatal Surveillance & Prenatal Diagnosis
- ▸First-trimester combined screening using the FMF algorithm (maternal factors, MAP, UtA-PI, PlGF) detects ~73% of preterm preeclampsia at a 10% screen-positive rate, far outperforming NICE/ACOG risk scoring [13].
- ▸Non-reportable cell-free DNA results carry a 7-fold increase in subsequent preeclampsia risk and warrant heightened antenatal surveillance [324, 335].
- ▸In established preeclampsia, the combination of serial EFW, umbilical artery Doppler, cerebroplacental ratio, and sFlt-1/PlGF ratio stratifies risk for composite adverse perinatal outcome with AUC 0.75-0.86 [341, 343].
Once the maternal diagnosis is established (or suspected), the clinical lens must broaden to the fetus, preeclampsia's placental origins carry equal if not greater risk for the pregnancy's second patient. The same angiogenic imbalance that drives maternal endothelial activation also undermines fetal growth, perfusion, and well-being, making fetal assessment an inseparable pillar of the workup.
Aneuploidy Screening and the Placental Signal
First-trimester aneuploidy screening offers an early window into placental health. Low pregnancy-associated plasma protein-A (PAPP-A) in the first trimester predicts related to , small-for-gestational-age (SGA), or preeclampsia with positive likelihood ratios of 6.3 to 14.1 [73]B2a. Non-reportable cell-free DNA (cfDNA) screening, failure to obtain a result, carries a markedly elevated risk of subsequent preeclampsia (11% vs 1.5% in the general obstetric population) [324]B2b; in a large multicenter cohort, nonreportable results were associated with higher rates of preterm birth at <28, <34, and <37 weeks and a composite adverse outcome [335]B2b. A second nonreportable result further increased these risks [335]B2b. Conversely, a first-trimester crown-rump length (CRL) that is 8-14 days smaller than expected from the last menstrual period is associated with increased odds of preeclampsia (adjusted OR 1.19, 95% CI 1.10-1.29) [354]B3b.
First- and Second-Trimester Preeclampsia Risk Assessment
Formal first-trimester screening for preterm preeclampsia (<37 weeks) combines maternal factors, mean arterial pressure (MAP), uterine artery pulsatility index (UtA-PI), and serum placental growth factor (PlGF) using the Fetal Medicine Foundation (FMF) competing-risks model. At a 10% screen-positive rate, the FMF model detects 82.7% of early preeclampsia (<34 weeks) and 72.7% of preterm preeclampsia, with an area under the receiver-operating-characteristics curve (AUC) of 0.911 [13]B2b. The NICE and ACOG risk-scoring systems detect only 46.7% and 65.9% of preterm cases, respectively, at similar screen-positive rates [13]B2b. First-trimester UtA-PI alone has a sensitivity of 47.8% and specificity of 92.1% for early-onset preeclampsia [81]B2a. Adding first-trimester placental volume and vascular indices may further improve prediction: placental volume is significantly lower in pregnancies that develop preeclampsia (mean difference -12.61 mL, 95% CI -19.05 to -6.17) [347]B3a.
Mid-gestational (19-24 weeks) UtA-PI assessment can re-stratify risk after first-trimester screening. Among women designated low-risk in the first trimester, those with elevated UtA-PI in the second trimester have a 3.3% prevalence of preterm preeclampsia (vs 0.2% in those with persistently low-risk indices), justifying escalation of surveillance [323]B2b. A contingent screening strategy, using maternal factors and MAP in all pregnancies, then reserving UtA-PI and PlGF for only 30-50% of the population, can achieve detection rates nearly equivalent to universal biomarker testing (71% vs 74% at 11-13 weeks) [342]B2b.
Fetal Growth and Doppler Surveillance
Once the diagnosis of preeclampsia is made, serial assessment of fetal growth, amniotic fluid volume, and fetoplacental Doppler is mandatory. In severe preeclampsia, estimated fetal weight (EFW) is reduced from 22 to 38 weeks compared with normotensive pregnancies [338]B2b. The core Doppler panel includes:
- Umbilical artery (UA) Doppler: pulsatility index (PI) >95th percentile or absent/reversed end-diastolic flow defines placental insufficiency.
- Middle cerebral artery (MCA) Doppler and cerebroplacental ratio (CPR): cerebral redistribution (low MCA PI, low CPR) indicates fetal hypoxemia. An umbilicocerebral ratio (UCR, the inverse of CPR) that is persistently abnormal in late-preterm SGA fetuses is independently associated with composite adverse perinatal outcome (CAPO) [4]A1b.
- Ductus venosus (DV) Doppler: abnormal a-wave (absent or reversed) signals advancing fetal compromise, particularly in early-onset FGR, and was used for delivery timing in the TRUFFLE trial [267]B2b.
In the DRIGITAT cohort of SGA fetuses at 32-36+6 weeks, the combination of EFW multiple of the median (MoM), sFlt-1/PlGF ratio at diagnosis, and the highest UCR value predicted CAPO with an AUC of 0.75; at a 10% false-positive rate, sensitivity was 44.2% [343]B2b. A prediction model incorporating PlGF alone in early-onset SGA achieved an AUC of 0.862 for CAPO, not significantly improved by adding fetal Doppler [341]B2b.
Antenatal Testing and Monitoring
In the inpatient setting, cardiotocography (CTG) remains the standard for fetal well-being. Home telemonitoring using electrophysiological CTG (eCTG) for hospitalized high-risk women is being investigated [346]D5; in a pilot program of home monitoring for preeclampsia and FGR, the median monitoring duration was 7 days and readmission occurred in 32.6%, with no maternal or fetal deaths [351]B3b.
Twin Pregnancies
Twin gestations carry a heightened risk of preeclampsia and its fetal consequences. Intertwin growth discordance progresses substantially throughout pregnancy in women who develop preeclampsia compared with normotensive twins [339]B2b. First-trimester CRL discordance ≥10% is independently associated with a birth-weight-based proxy of FGR (adjusted OR 7.79, 95%; AUC 0.736) [352]B3b.
Pearl: In any woman with suspected or confirmed preeclampsia, the combination of serial EFW, umbilical artery Doppler, and sFlt-1/PlGF ratio, starting at diagnosis and repeated according to gestational age, provides the most robust risk stratification for adverse perinatal outcome; an abnormal UCR or CPR at 32+ weeks should prompt delivery consideration but only within a clinical trial context if <37 weeks [4]A1b[343]B2b.
| Modality | Timing | Finding | Clinical Significance |
|---|---|---|---|
| Uterine artery Doppler (first trimester) | 11-14 weeks | PI >95th percentile | Sensitivity 48% for early-onset PE (specificity 92%) [81]B2a |
| Uterine artery Doppler (second trimester) | 19-24 weeks | Elevated PI, persistent notching | Re-stratifies risk after first-trimester screen [323]B2b |
| Umbilical artery Doppler | At diagnosis, then serial q2-4w | PI >95th %, absent/reversed EDV | Defines placental insufficiency; dictates delivery timing |
| Middle cerebral artery / CPR (UCR) | At diagnosis, then serial | CPR <5th %, UCR >95th % | Identifies cerebral redistribution (fetal hypoxia); UCR predicts CAPO [4]A1b[343]B2b |
| Ductus venosus Doppler | In early-onset FGR (<32w) | Absent/reversed a-wave | Indicates advanced fetal compromise; used in TRUFFLE protocol [267]B2b |
| sFlt-1/PlGF ratio | At diagnosis in SGA fetus | Ratio >38 (≥28w) or >5.78 (<28w) | Strongly associated with placental MVM; predicts CAPO [327]B2b[341]B2b |
| Nonstress test (CTG) | Daily to weekly (inpatient) | Non-reassuring pattern | Prompt intervention if fetal compromise suspected |
| Serial EFW / abdominal circumference | q3-4w | AC <10th %, EFW <3rd % | Quantifies growth restriction severity; EFW MoM part of CAPO prediction [338]B2b[343]B2b |
Severity, Staging & Risk Stratification
- ▸Severe features (BP ≥160/110, thrombocytopenia, liver/renal dysfunction, pulmonary edema, cerebral symptoms) shift management to urgent delivery regardless of proteinuria level.
- ▸The sFlt-1/PlGF ratio (cutoff <38 before 34 wk, <85 after 34 wk) has a high negative predictive value for ruling out imminent adverse outcomes and is recommended by NICE for suspected preterm preeclampsia.
- ▸Risk stratification scores (fullPIERS, PREP-S) outperform clinical gestalt in predicting short-term maternal adverse events and should guide decisions on transfer, corticosteroid administration, and timing of delivery.
Once fetal surveillance identifies signs of compromise, or at the time of diagnosis, severity grading and risk stratification determine the urgency of intervention and the level of monitoring required. Modern guidelines (ACOG, ISSHP) classify preeclampsia as without severe features or with severe features, replacing the older "mild" vs "severe" dichotomy [370]D5. Severe features include systolic BP ≥160 mmHg or diastolic BP ≥110 mmHg on two occasions, thrombocytopenia (platelets <100 ×10⁹/L), impaired liver function (AST/ALT >2× upper limit of normal), renal insufficiency (serum creatinine >1.1 mg/dL or doubling), pulmonary edema, or new-onset cerebral/visual disturbances. The presence of any one criterion shifts toward urgent delivery. In parallel, early-onset disease (<34 weeks' gestation) carries a substantially worse prognosis and mandates more intensive surveillance than late-onset disease [267]B2b[330]D5.
Risk Stratification Scores for Adverse Outcomes
Several validated models map clinical and laboratory variables onto short-term risk of maternal adverse events, enabling individualized management planning. The fullPIERS model (gestational age, chest pain/dyspnea, oxygen saturation, platelet count, creatinine, AST) predicts adverse maternal outcome within 48 hours; at a score threshold of ≥30 the risk exceeds 20 %, prompting expeditious delivery (AUC ~0.88 in derivation cohorts). The miniPIERS (low-resource adaptation) uses fewer variables and achieves an AUC of ~0.77. For early-onset PE, the PREP-S model predicts delivery within 7 days and 14 days, aiding the decision to transfer to a tertiary center or to administer a complete course of corticosteroids. A systematic review of prediction models in preeclampsia [378]B2a found that few are consistently recommended in guidelines and many are used outside their validated setting.
Angiogenic Biomarkers in Risk Stratification
Circulating sFlt-1/PlGF ratio has emerged as a high-negative-predictive-value tool to rule out imminent adverse outcomes [238]D5. Before 34 weeks, a ratio <38 has a NPV of >95 % for the absence of PE within 7 days; after 34 weeks the cutoff is <85. A ratio >655 identifies women who will likely require delivery within 2 weeks. While ACOG does not mandate routine use, NICE recommends sFlt-1/PlGF testing for suspected preterm PE. First-trimester models combining maternal factors, MAP, uterine artery Doppler, and PlGF achieve a median AUC of 0.75 [358]B2a, but methodological deficiencies and high risk of bias limit clinical adoption [10]D5. Early-pregnancy biomarkers such as first-trimester miR-21 (AUC 0.75 for predicting subsequent PE) and atherogenic index of plasma in GDM (AUC 0.78 for severe PE) show promise but lack external validation [316]B3b[382]B3b.
Risk of Recurrence
A history of preeclampsia confers increased risk in subsequent pregnancies, with the magnitude dependent on gestational age at onset and severity. Recurrence rates range from 10-20% after term disease to 25- after early-onset (<34 weeks) disease [330]D5. Women with prior severe features, fetal growth restriction, or preexisting medical disorders carry the highest risk. Early-pregnancy labs (platelet count, urine protein-to-creatinine ratio, liver enzymes) are associated with recurrence but exhibit limited predictive performance as stand-alone tests [381]B3b. Current guidelines recommend low-dose (81-162 mg/d) from 12 weeks' gestation for all women with prior PE, and intensified maternal-fetal surveillance.
Risk Stratification in Special Populations
Certain conditions amplify baseline risk and require customized thresholds. In chronic , the risk of superimposed PE is ~20 %; angiogenic biomarkers are less discriminatory because baseline sFlt-1 levels are already elevated [284]D5. Chronic kidney disease increases preeclampsia risk 8-fold (aOR 8.13) [163]B2a, with risk rising by CKD stage. Oocyte donation raises the odds 5-fold (OR 5.09) [16]A1a; multiple pregnancy, especially with selective fetal growth restriction, carries an OR of 3.72 for preeclampsia [373]B3b. Conversely, maternal HIV infection is associated with a 58 % lower risk (RR 0.42) [17]B2b.
Pearl: The presence of any one severe feature - even without proteinuria - should reclassify preeclampsia as "with severe features" and prompt delivery planning, as adverse outcome risk depends more on end-organ involvement than on quantitative proteinuria [24]D5.
Controversies and Guideline Disagreement
| Question | Position A | Position B | Strength | Implication |
|---|---|---|---|---|
| Should sFlt-1/PlGF ratio be used for risk stratification? | NICE recommends it for suspected preterm PE (Category 2A) | ACOG does not mandate it, citing limited impact on outcomes [238]D5[370]D5 | Moderate | Use NICE thresholds (≤38 before 34 wk, ≤85 after 34 wk) to rule out PE; a positive result should be combined with clinical judgment |
| Is proteinuria quantification necessary for severity staging? | ACOG includes proteinuria ≥5 g/24 h as a severe feature | ISSHP and recent evidence downplay proteinuria, emphasizing end-organ dysfunction [24]D5[370]D5 | Weak | Severe features should be diagnosed without reliance on proteinuria thresholds |
| Model | Setting | Variables | Outcome Predicted | Performance | Recommendation |
|---|---|---|---|---|---|
| fullPIERS | Tertiary care | GA, chest pain/dyspnea, SpO₂, platelet count, Cr, AST | Adverse maternal event within 48 h | AUC ~0.88 | Used in high-resource settings to guide urgent delivery |
| miniPIERS | Low-resource | GA, proteinuria, headache, chest pain, O₂ sat, creatinine, platelet count | Adverse maternal event | AUC ~0.77 | Suitable where lab capacity is limited |
| PREP-S | Early-onset (<34 wk) | GA, parity, BP, proteinuria, sFlt-1/PlGF, fetal biometry | Delivery within 7 d, 14 d | AUC ~0.89 | Aids decision on expectant management vs delivery |
| sFlt-1/PlGF ratio | Suspected PE | sFlt-1, PlGF | PE diagnosis within 7 d | NPV >95 % for ratio <38 (<34 wk) | NICE-recommended for suspected preterm PE; ACOG does not mandate [238]D5[370]D5 |
| FMF first-trimester algorithm | Asymptomatic screening | Maternal factors, MAP, UtA-PI, PlGF, PAPP-A | Any PE | AUC ~0.75 | High risk of bias; not universally adopted [358]B2a |
Acute Management
- ▸Severe hypertension (≥160/110 mmHg) requires urgent treatment within 30-60 minutes with IV labetalol, IV hydralazine, or oral nifedipine to prevent maternal stroke.
- ▸Magnesium sulfate halves the risk of eclampsia (RR 0.41, NNT 100) and is indicated for all patients with severe preeclampsia.
- ▸Delivery is the definitive treatment; timing depends on gestational age, severity, and maternal-fetal status.
Once the diagnosis of preeclampsia and its severity are established, acute must address three critical axes: control of severe , seizure prophylaxis, and determination of delivery timing. The following protocol applies to patients with severe preeclampsia (systolic blood pressure ≥160 mmHg or diastolic ≥110 mmHg, or any blood pressure elevation with severe features) and guides initial action within the first 30-60 minutes.
Step 1: Initial Assessment and Severity Triage
Reconfirm severity classification immediately. Severe preeclampsia is defined by a systolic blood pressure ≥160 mmHg or diastolic ≥110 mmHg on two occasions, or any blood pressure elevation with severe features (thrombocytopenia <100 000/μL, impaired liver function [AST or ALT >2× upper limit of normal], renal insufficiency [creatinine >1.1 mg/dL or doubling from baseline], pulmonary edema, new-onset cerebral or visual disturbances). Patients with severe preeclampsia require admission to a labor and delivery unit or high-dependency unit for continuous maternal and fetal monitoring. Those with nonsevere (mild-to-moderate) hypertension without severe features may be managed on an inpatient ward or, in select cases, as outpatients with close follow-up. ICU admission is indicated for persistent severe hypertension despite first-line therapy, eclampsia, pulmonary edema, or need for mechanical ventilation [2]D5[191]A1c.
Step 2: Management of Severe Hypertension
Severe hypertension must be treated urgently to prevent maternal stroke. The ACOG Committee Opinion 767 recommends that antihypertensive therapy be initiated as soon as possible within 30-60 minutes of confirmed severe hypertension [191]A1c. First-line agents include intravenous labetalol, intravenous hydralazine, or immediate-release oral nifedipine [2]D5[191]A1c. The following algorithm summarizes the management pathway:
Table 1: First-Line Agents for Acute Severe Hypertension in Pregnancy
| Drug | Starting dose | Maximum dose per episode | Route | Key monitoring |
|---|---|---|---|---|
| Labetalol | 20 mg IV | 80 mg IV (total 300 mg) | IV bolus, repeat q10-20min | Heart rate (avoid bradycardia), maternal hypotension |
| Hydralazine | 5 mg IV | 10 mg IV (total 20 mg) | IV bolus, repeat q20min | Maternal hypotension, fetal heart rate, reflex tachycardia |
| Nifedipine (immediate-release) | 10 mg PO | 20 mg PO (total 50 mg) | PO, repeat q20-30min | Maternal hypotension, reflex tachycardia |
Doses from ACOG Committee Opinion 767 [191]A1c. Magnesium sulfate is not an antihypertensive and should not be used for blood pressure control.
Step 3: Seizure Prophylaxis
Magnesium sulfate reduces the risk of eclampsia by more than half. A Cochrane meta-analysis of 6 trials (11 444 women) demonstrated a risk ratio of 0.41 (95% CI 0.29-0.58) for eclampsia, with an NNT of 100 (95% CI 50-100) [117]A1a (1a). The standard regimen is a 4-6 g IV loading dose over 15-20 minutes, followed by a maintenance infusion of 1-2 g/h for 24 hours postpartum [2]D5[117]A1a. Magnesium sulfate is indicated for all patients with severe preeclampsia, eclampsia, or HELLP syndrome, and is considered for those with nonsevere preeclampsia who have additional risk factors (e.g., multiple gestation, prior eclampsia, rapidly escalating blood pressure). Signs of toxicity include respiratory depression (<12 breaths/min), loss of deep tendon reflexes, and oliguria; calcium gluconate 1 g IV should be readily available as an antidote.
Step 4: Monitoring and Escalation
Once therapy is initiated, measure blood pressure every 15 minutes until stable, then every 4 hours. Monitor for symptoms of end-organ damage (headache, visual changes, epigastric pain, dyspnea). Serial laboratory studies should include , liver enzymes, and creatinine every 6-12 hours while severe features persist. If systolic blood pressure remains ≥160 mmHg or diastolic ≥110 mmHg despite two doses of a first-line agent, switch to an alternative first-line agent. Failure to achieve control after three agents or persistent severe hypertension despite maximal doses warrants emergent consultation with maternal-fetal medicine, anesthesiology, and/or critical care [191]A1c.
Step 5: Delivery Planning
Delivery is the definitive treatment for preeclampsia. The timing of delivery depends on gestational age, severity of disease, and maternal and fetal status. For term pregnancies (≥37 weeks) with gestational hypertension or mild preeclampsia, induction of labor is recommended to reduce maternal morbidity (HYPITAT trial: RR 0.71, 95% CI 0.59-0.86) [63]A1b (1b). For preterm severe preeclampsia, expectant management may be considered between 24 + 0 and 33 + 6 weeks in selected cases, provided maternal and fetal status are stable, with administration of antenatal corticosteroids (see section 9: Definitive Management).
What NOT to Do
- Do not use ergometrine for prophylaxis or treatment in women with preeclampsia, as it can cause severe vasoconstriction and hypertensive crisis [2]D5.
- Do not use renin-angiotensin-aldosterone system inhibitors (ACE inhibitors, ARBs) during pregnancy due to fetal nephrotoxicity [2]D5.
- Do not use vitamins C and E for prevention or treatment of preeclampsia; large RCTs show no benefit and possible harm (RR 1.07, 95% CI 0.91-1.25) [67]A1b (1b).
- Do not use pravastatin for treatment of early-onset preeclampsia; a proof-of-concept trial found no reduction in sFlt-1 levels (difference 292 pg/mL, 95% CI -1175 to 592) [61]A1b (1b).
- Do not use calcium supplementation in women with adequate dietary calcium intake for prevention of preeclampsia; high-quality evidence from large trials shows no effect (RR 0.92, 95% CI 0.79-1.05) [40]A1a (1a).
Controversies and Guideline Disagreement
| Question | Position A | Position B | Strength of disagreement | Implication for practice |
|---|---|---|---|---|
| Duration of postpartum magnesium sulfate | ACOG/SMFM, 24 hours postpartum for severe preeclampsia | Okonkwo 2022 meta-analysis, 12 hours or less may be sufficient; RD -0.01 (95% CI -0.02 to 0.01) for eclampsia | Moderate (evidence base underpowered for firm conclusions) [388]A1a (1a) | Many centers continue 24 hours; shorter regimens may reduce side effects and length of stay, but individualize based on clinical trajectory |
| Magnesium sulfate for late postpartum severe hypertension (>48 h after delivery) | Cagino 2023, recommend reserving for patients with neurologic symptoms | ACOG, no explicit guidance; many protocols administer magnesium for any severe hypertension postpartum | Moderate (expert opinion, no RCTs) [239]D5 (5) | For late postpartum severe hypertension without neurologic symptoms, optimize antihypertensive regimen first; consider magnesium only if headache, visual changes, or other cerebral symptoms present |
Pearl: Initiate antihypertensive therapy within 30-60 minutes of confirmed severe hypertension to prevent maternal stroke [191]A1c; administer magnesium sulfate for seizure prophylaxis in all patients with severe preeclampsia (NNT = 100) [117]A1a; and remember that delivery is the definitive cure, refer to the next section for timing and operative considerations.
Definitive Management: Medical Optimization and Delivery
- ▸Definitive management of preeclampsia is delivery; induction at ≥37 weeks reduces maternal morbidity (RR 0.71).
- ▸Magnesium sulfate prophylaxis reduces eclampsia by 59% (RR 0.41; NNT 100).
- ▸No significant difference in outcomes between labetalol and nifedipine for blood pressure control in pregnancy.
Once acute severe has been controlled and seizure prophylaxis is underway, the definitive of preeclampsia is delivery of the placenta, the only cure. For term pregnancies (≥37 weeks), induction of labour is clearly beneficial. The HYPITAT trial showed that among women with gestational hypertension or mild preeclampsia at 36-41 weeks, induction reduced the composite poor maternal outcome from 44% to 31% (RR 0.71, 95% CI 0.59-0.86; NNT = 8) [63]A1b. This finding underpins ACOG’s recommendation to deliver at 37 weeks or beyond for those with preeclampsia without severe features [263]A1c. For women presenting at 34-36 weeks, the decision requires weighing maternal benefit against neonatal immaturity. The PHOENIX trial compared planned delivery versus expectant management in late preterm preeclampsia: planned delivery lowered the maternal composite from 75% to 65% (aRR 0.86, 0.79-0.94; NNT = 10) but increased neonatal unit admissions (42% vs 34%; RR 1.26, 1.08-1.47) [418]A1b. In low- and middle-income settings, the CRADLE-4 trial found that planned delivery from 34 weeks reduced (aRR 0.25, 0.07-0.87) with a non-significant effect on maternal mortality (aRR 0.91, 0.79-1.05) [419]A1b. Most guidelines, including ACOG, recommend delivery by 34 weeks for preeclampsia with severe features, balancing the trajectory of maternal organ dysfunction against the 2-3 weeks of additional fetal maturity [263]A1c.
Step 1: Antihypertensive Therapy Before Delivery
Severe hypertension (systolic ≥160 mm Hg or diastolic ≥110 mm Hg) must be treated within 30-60 minutes to reduce stroke risk [191]A1c. First-line agents are IV , IV , or immediate-release oral . The CHAP trial demonstrated that treating mild chronic hypertension to a target <140/90 mm Hg reduces adverse pregnancy outcomes (aRR 0.82, 0.74-0.92) without increasing small-for-gestational-age births (aRR 1.04, 0.82-1.31) [66]A1b. Among women with established preeclampsia, a network meta-analysis suggested that labetalol may be modestly favoured over nifedipine for reducing progression to preeclampsia (RR 0.50, 0.28-0.87) and preterm birth (RR 0.68, 0.52-0.90), though the evidence quality was low [161]A1a. A secondary analysis of CHAP found no difference in composite outcomes between labetalol and nifedipine (aRR 0.98, 0.82-1.18) [57]B2b. The choice of agent should be guided by clinician preference, maternal heart rate, and availability.
Table 1: Comparison of first-line oral antihypertensives for non-severe hypertension in pregnancy
| Agent | Key trial | Effect vs no treatment | -to-head evidence |
|---|---|---|---|
| CHAP (Sanusi 2024) | aRR 0.82 (0.72-0.94) for primary outcome [57]B2b | vs nifedipine: aRR 0.98 (0.82-1.18) [57]B2b | |
| CHAP (Sanusi 2024) | aRR 0.84 (0.71-0.99) [57]B2b | vs labetalol: no significant difference [57]B2b | |
| Network MA (Hup 2025) | Reduced severe hypertension: RR 0.44 (0.20-0.99) [161]A1a | Limited direct comparisons |
Step 2: Seizure Prophylaxis With Magnesium Sulfate
Magnesium sulfate is the drug of choice for preventing seizures in women with preeclampsia with severe features. The Cochrane review (15 trials, 11 444 women) reported that magnesium halved the risk of eclampsia (RR 0.41, 95% CI 0.29-0.58; NNT = 100) and reduced (RR 0.64, 0.50-0.83; NNT = 100) [117]A1a. The standard regimen is a 4-6 g intravenous loading dose followed by 1 g/hour for 24 hours. Maternal side effects (flushing, nausea) are common (24% vs 5%; NNTH = 6), but serious adverse effects are rare [117]A1a. ACOG recommends magnesium sulfate for all women with preeclampsia with severe features during labour and for 24 hours postpartum [263]A1c.
Step 3: Route of Delivery
The route of delivery should be determined by standard obstetric indications. No randomized trial has shown that cesarean section improves maternal outcomes in preeclampsia per se. The PHOENIX and HYPITAT trials allowed either mode, and cesarean rates were not significantly different between planned delivery and expectant management [63]A1b[418]A1b. For women with preeclampsia and a viable fetus, vaginal delivery is appropriate when the cervix is favourable and fetal status is reassuring. Cesarean is reserved for usual obstetric reasons (malpresentation, non-reassuring fetal status, failed induction).
Step 4: Postpartum Care
Blood pressure often peaks 3-6 days after delivery. Continue antihypertensive therapy as needed to keep BP <150/100 mm Hg (per ACOG). Magnesium is continued for 24 hours postpartum. For women who develop postpartum preeclampsia de novo, treat similarly. Long-term follow-up for cardiovascular risk is essential (discussed in the Prognosis section).
Table 2: Key trials informing definitive management
| Trial | Population | Intervention | Primary outcome | Effect size |
|---|---|---|---|---|
| HYPITAT 2009 [63]A1b | Mild hypertension at 36-41 wks | Induction vs expectant | Composite maternal morbidity | RR 0.71 (0.59-0.86); NNT 8 |
| PHOENIX 2019 [418]A1b | Late preterm preeclampsia (34-36 wks) | Planned delivery vs expectant | Maternal composite | aRR 0.86 (0.79-0.94) |
| CRADLE-4 2023 [419]A1b | Preterm preeclampsia in LMIC | Planned delivery vs expectant | Stillbirth reduction | aRR 0.25 (0.07-0.87) |
| CHAP 2022 [66]A1b | Mild chronic hypertension | Treat to <140/90 vs no treatment | Composite adverse outcome | aRR 0.82 (0.74-0.92) |
Controversies and Guideline Disagreement
| Question | Position A | Position B | Strength | Implication |
|---|---|---|---|---|
| Optimal first-line antihypertensive for non-severe hypertension | NICE/ACOG, labetalol, nifedipine, or methyldopa equally acceptable | Network meta-analysis [161]A1a, labetalar may be slightly better for preventing preeclampsia and preterm birth | Mild to moderate (low-quality evidence, not reflected in guidelines) [161]A1a[263]A1c | Clinicians can choose based on patient profile; no strong reason to prefer one agent |
| dose for preterm preeclampsia prevention | ASPRE trial [155]A1b, 150 mg daily from <16 wks reduces risk by 62% | Khander 2025 [58]A1b, 162 mg vs 81 mg: similar efficacy, but 162 mg association with more abruptions | Moderate (RCT evidence, but no guideline formally endorses 150 mg in US; ACOG recommends 81 mg) [58]A1b[263]A1c | US practice typically uses 81 mg; European guidelines use 150 mg; shared decision-making is warranted |
Pearl: For women with preeclampsia at term, immediate delivery improves maternal outcomes (HYPITAT NNT = 8); for late preterm disease, planned delivery reduces maternal morbidity but increases neonatal unit admissions (PHOENIX), the trade-off must be discussed with the patient. Magnesium sulfate halves eclampsia risk; labetalol and nifedipine are equally effective first-line antihypertensives.
Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy
- ▸Induction of labour at term (≥37 weeks) reduces poor maternal outcome by about 30% (RR 0.71) without increasing caesarean section or NICU admission (HYPITAT, PREVENT-PE) [63, 149].
- ▸For mild chronic hypertension, active treatment to target BP <140/90 mmHg with labetalol or nifedipine lowers adverse outcomes (CHAP trial, aRR 0.82) [66].
- ▸Magnesium sulfate halves eclampsia risk (RR 0.41, Cochrane) and is indicated for all severe pre-eclampsia [117].
From definitive medical and surgical staging, the central challenge shifts to the dual-patient calculus of when to deliver and how to prolong pregnancy safely. Decisions require balancing maternal risk of progression to eclampsia, end-organ injury, or against fetal risk of prematurity. The fullPIERS model can stratify near-term risk: gestational age, chest pain or dyspnoea, oxygen saturation, platelet count, creatinine, and aspartate transaminase predict adverse maternal outcome within 48 h (AUC 0.88) [389]B2b (2b). This risk estimate directly informs delivery timing.
Timing of Delivery
Term disease (≥37 weeks): Induction of labour improves maternal outcome without increasing neonatal morbidity. In the HYPITAT trial, women with gestational or mild pre-eclampsia beyond 37 weeks randomly assigned to induction had a lower rate of poor maternal outcome than those managed expectantly (31% vs 44%; RR 0.71, 95% CI 0.59-0.86; NNT ≈ 8) [63]A1b (1b). The PREVENT-PE trial extended this concept: risk stratification at 36 weeks using maternal factors plus angiogenic biomarkers identified high-risk women (risk ≥1 in 50); planned early-term birth (37-38 weeks) reduced the incidence of pre-eclampsia from 5.6% to 3.9% (aRR 0.70, 95% CI 0.58-0.86) without increasing emergency caesarean section or neonatal unit admission [149]A1b (1b).
Preterm disease (<37 weeks): Expectant may be attempted for stable women with late preterm (34-36 weeks) mild disease but must be balanced against maternal risk. For early-onset fetal growth restriction with abnormal umbilical artery Doppler, the DRIGITAT trial (nested RCT, n=40) suggested that immediate delivery at 34-36 weeks did not improve perinatal outcome and trended toward higher composite adverse outcome; authors concluded delivery should only be performed in trials [4]A1b (1b). In the TRUFFLE cohort of early-onset FGR (26-32 weeks, abnormal UA Doppler), the median time from diagnosis to delivery was 13 days without hypertension, 4 days with pre-eclampsia, and 3 days with HELLP syndrome; overall 70% survived without severe neonatal morbidity [267]B2b (2b). ACOG Practice Bulletin No. 222 recommends delivery by 37 weeks for mild disease and by 34 weeks for severe pre-eclampsia with features, with individualised timing for extreme prematurity (263) (1c).
In-Utero Pharmacotherapy
Antihypertensives: The CHAP trial (N=2408) randomly assigned women with mild chronic hypertension (BP 140-159/90-104 mmHg) before 20 weeks to active treatment (target <140/90 mmHg) or no treatment unless severe hypertension developed. Active treatment reduced the primary composite outcome (preeclampsia with severe features, preterm birth <35 weeks, abruption, or fetal/neonatal death) from 37.0% to 30.2% (aRR 0.82, 95% CI 0.74-0.92; NNT ≈ 15) with no increase in small-for-gestational age [66]A1b (1b). Both and appear equally effective; a secondary analysis of CHAP found no difference in outcomes between the two agents (aRR 0.98, 95% CI 0.82-1.18) [57]B2b (2b). ACOG recommends initiating oral labetalol or nifedipine as first-line when sustained BP ≥140/90 mmHg (263) (1c).
Magnesium sulfate for seizure prophylaxis: A Cochrane review of six trials (11,444 women) demonstrated that magnesium sulphate more than halves the risk of eclampsia (RR 0.41, 95% CI 0.29-0.58; NNT = 100) and reduces placental abruption (RR 0.64, 95% CI 0.50-0.83) [117]A1a (1a). Use is indicated for all women with severe pre-eclampsia during labour, delivery, and for 24 h postpartum (263) (1c).
Other agents with limited evidence: 40 mg daily did not lower plasma sFlt-1 levels or prolong pregnancy in early-onset pre-eclampsia (HR 0.84, 95% CI 0.50-1.40) in a small RCT [61]A1b (1b). may reduce pre-eclampsia risk in prevention trials (RR 0.52, 95% CI 0.35-0.78) but the evidence is low certainty due to bias [171]A1a (1a).
Intrapartum Management
- Blood pressure control: Maintain BP <160/105 mmHg during labour to reduce risk of cerebral haemorrhage. Intravenous or oral are first-line (263).
- Seizure prophylaxis: Magnesium sulfate infusion (loading then maintenance) for at least 24 h postpartum for women with severe features (263).
- Fluid management: Avoid volume overload; pulmonary oedema is a leading cause of ICU admission.
- Fetal monitoring: Continuous electronic fetal monitoring is recommended for all women with pre-eclampsia during labour.
Controversies and Guideline Disagreement
| Question | Position A | Position B | Strength | Implication for practice |
|---|---|---|---|---|
| Target BP in mild chronic hypertension | ACOG (2020): Treat to <140/90 mmHg (263) | Prior standard was not to treat unless >160/105 mmHg | Strong (paradigm shift after CHAP) [66]A1b[263]A1c | Active treatment from <20 weeks reduces adverse composite outcome without harming fetal growth [66]A1b |
| Universal first-trimester screening for pre-eclampsia | FMF algorithm: Recommend combined screening (maternal factors + MAP + UtA-PI + PlGF) with for high-risk (155, 71) | ACOG/NICE: Screen based on clinical risk factors only (263, 100) | Strong (different screening paradigms) | Combined screening detects ~75% of preterm PE vs ~40% with risk factors alone, enabling targeted aspirin use [100]D5[13]B2b |
Pearl: For term pre-eclampsia, offer induction of labour immediately to reduce maternal morbidity (HYPITAT, NNT 8); for preterm severe disease, individualise delivery timing using the fullPIERS model and angiogenic biomarkers to balance maternal safety against fetal prematurity [63]A1b[389]B2b.
| Drug | Key Trial | Population | Effect vs Comparator | NNT | Evidence Level |
|---|---|---|---|---|---|
| or | CHAP (N=2408) [66]A1b | Mild chronic HTN (BP 140-159/90-104) before 20 wk | aRR 0.82 (0.74-0.92) for composite outcome | ≈15 | 1b |
| Labetalol vs Nifedipine | CHAP secondary analysis (N=1137) [57]B2b | Same population | aRR 0.98 (0.82-1.18) | N/A (non-significant) | 2b |
| Magnesium Sulfate | Cochrane (6 RCTs, 11,444 women) [117]A1a | Pre-eclampsia (any severity) | RR 0.41 (0.29-0.58) for eclampsia | 100 | 1a |
History and Evolution of Treatment
- ▸Magnesium sulfate remains the only anticonvulsant proven to reduce eclampsia risk, displacing phenytoin, diazepam, and lytic cocktail (MAGPIE, Cochrane meta-analyses).
- ▸Low-dose aspirin initiated before 16 weeks reduces preterm preeclampsia by 62% and perinatal mortality (ASPRE, ASPIRIN trials), but benefit wanes if started after 16 weeks or at lower-than-150 mg doses.
- ▸Active antihypertensive treatment targeting BP <140/90 mm Hg in mild chronic hypertension reduces adverse outcomes without impairing fetal growth (CHAP trial).
Building on the evidence from trials of delivery timing, HYPITAT, PHOENIX, and CRADLE-4, the contemporary of preeclampsia rests on a foundation of landmark trials that established the role of magnesium sulfate, low-dose , and antihypertensive therapy, while discarding several previously promising strategies.
Magnesium sulfate: the only anticonvulsant that matters
The Magpie Trial (2002) randomized 10 141 women with preeclampsia to magnesium sulfate or placebo and demonstrated a 58% reduction in eclampsia (0.8% vs 1.9%;, 95% CI 0.29-0.60) and a probable reduction in maternal mortality (RR 0.55, 0.26-1.14) [459]A1b. Cochrane meta-analyses subsequently confirmed that magnesium sulfate is superior to (RR for recurrent seizures 0.34, 95% CI 0.24-0.49) and to lytic cocktail (RR 0.06, 95% CI 0.03-0.12 for further seizures) [292]A1a[296]A1a. The nimodipine trial (2003) was stopped early when magnesium sulfate proved significantly better at preventing seizures (0.8% vs 2.6%; RR 3.2, 95% CI 1.1-9.1) [464]A1b. These trials definitively established intravenous magnesium sulfate as the standard of care for eclampsia prophylaxis and treatment, displacing all other anticonvulsants.
Aspirin: from null result to first-trimester prevention
Early aspirin trials were disappointing. The CLASP trial (1994) randomized 9364 women to 60 mg aspirin or placebo and found only a non-significant 12% reduction in proteinuric preeclampsia [460]A1b. But a key observation emerged: the benefit was greatest for early-onset disease requiring preterm delivery. The PREDO trial (2012) confirmed that aspirin started before 16 weeks reduced preeclampsia (RR 0.6, 95% CI 0.4-0.8) and severe preeclampsia (RR 0.3, 95% CI 0.1-0.7) in a meta-analysis of high-risk women with abnormal uterine artery Doppler [456]A1a. The watershed ASPRE trial (2017) screened 26 941 singleton pregnancies using the FMF competing-risks model at 11-13 weeks and randomized high-risk women (risk >1:100) to 150 mg aspirin daily or placebo [155]A1b. Preterm preeclampsia occurred in 1.6% of the aspirin group vs 4.3% of the placebo group (OR 0.38, 95% CI 0.20-0.74; NNT = 37) [155]A1b. The ASPIRIN trial (2020) subsequently showed that 81 mg aspirin initiated before 14 weeks in nulliparous women in low-resource settings reduced preterm birth (vs; RR 0.89) with a trend toward reduced perinatal mortality [151]A1b. The ASPREO trial (2024) found no advantage of 162 mg over 81 mg in high-risk obese women (posterior RR 0.88, 95% credible interval 0.64-1.22) [383]A1b. These data underpin the USPSTF B recommendation for low-dose aspirin (81 mg/d) after 12 weeks in high-risk women [153]A1c.
Antihypertensive treatment: the CHAP trial settles the target
For decades, clinicians worried that treating mild chronic (BP <160/100) might impair fetal growth. The CHAP trial (2022) randomized 2408 women with mild chronic hypertension to active treatment targeting BP <140/90 or to no treatment unless severe hypertension developed [66]A1b. The primary composite outcome (preeclampsia with severe features, preterm birth <35 weeks, abruption, or fetal/neonatal death) occurred in 30.2% of the active-treatment group vs 37.0% in the control group (aRR 0.82, 95% CI 0.74-0.92; NNT = 15), with no increase in small-for-gestational-age infants [66]A1b. A secondary analysis confirmed that labetalol and nifedipine had similar efficacy [57]B2b. The POP-HT trial (2023) then showed that intensive postpartum blood pressure self-management reduced 24-hour diastolic BP by 5.8 mm Hg (95% CI 4.2-7.4) at 9 months, suggesting the window for cardiovascular risk modification extends into the puerperium [165]A1b.
Timing of delivery: earlier is better for maternal outcomes
The HYPITAT trial (2009) demonstrated that induction of labor after 37 weeks in women with gestational hypertension or mild preeclampsia reduced the composite poor maternal outcome from 44% to 31% (RR 0.71, 95% CI 0.59-0.86) [63]A1b. The PHOENIX trial (2019) extended this to late preterm preeclampsia (34 to <37 weeks): planned delivery reduced the maternal composite outcome from 75% to 65% (aRR 0.86, 95% CI 0.79-0.94) but increased neonatal unit admissions (42% vs 34%; aRR 1.26, 95% CI 1.08-1.47) [418]A1b. The CRADLE-4 trial (2023) confirmed non-inferior perinatal outcomes with planned delivery from 34 weeks in low-resource settings [419]A1b. The PREVENT-PE trial (2025) found that risk-stratified planned early-term birth at 36 weeks based on screening reduced term preeclampsia from 5.6% to 3.9% (aRR 0.70, 95% CI 0.58-0.86) without increasing serious adverse events [149]A1b.
Abandoned and investigational strategies
Several interventions failed to prevent preeclampsia in well-conducted trials. Supplementation with vitamins C and E showed no benefit (RR 1.20, 95% CI 0.82-1.75) [159]A1b. Calcium supplementation in healthy nulliparous women (2 g/day) did not reduce preeclampsia (RR 0.94, 95% CI 0.76-1.16) [462]A1b, although low-dose calcium (500 mg) may be noninferior to high-dose (1500 mg) in populations with low dietary intake [158]A1b[463]A1b. Pravastatin (20-40 mg daily) did not lower sFlt-1 levels or prolong pregnancy in early-onset preeclampsia [61]A1b[385]A1b. reduced weight gain and preeclampsia in obese women without diabetes (OR 0.24, 95% CI 0.10-0.61) [160]A1b, but a subsequent trial in women with type 2 diabetes or early gestational diabetes found no effect on preterm preeclampsia (aOR 1.04, 95% CI 0.70-1.56) [59]A1b. Low-molecular-weight added to aspirin reduced preeclampsia in women with a history of preeclampsia (RR 0.54, 95% CI 0.31-0.92) in a meta-analysis, but the evidence is limited and not yet guideline-recommended [182]A1a[356]A1a.
Controversies and Guideline Disagreement
| Question | ACOG (2020) | NICE (2019) | Strength | Implication |
|---|---|---|---|---|
| Aspirin dose for prevention | 81 mg daily | 75-150 mg daily | Low | Higher doses may confer more benefit but lack FDA approval in US [153]A1c[155]A1b |
| Aspirin discontinuation at 24-28 weeks if low sFlt-1/PlGF | Not addressed | Not addressed | Moderate | New evidence supports discontinuation in selected women [70]A1b |
| Blood pressure target in chronic hypertension | <140/90 mm Hg | <135/85 mm Hg | Low | Both targets yield similar outcomes; CHAP supports <140/90 [66]A1b |
These therapeutic milestones, magnesium sulfate for seizure prevention, low-dose aspirin for risk reduction, aggressive antihypertensive control, and planned delivery for late preterm disease, constitute the evidence-based pillars of management. As the next section details, failure to apply these measures increases the risk of serious maternal and fetal complications.
Pearl: The three interventions with the strongest evidence for improving outcomes in preeclampsia are magnesium sulfate for eclampsia prophylaxis (reduces seizures by 58%, NNT = 91), low-dose aspirin started before 16 weeks for high-risk women (reduces preterm preeclampsia by 62%, NNT = 37), and active treatment of blood pressure to <140/90 mm Hg (reduces adverse pregnancy outcomes by 18%, NNT = 15).
| Trial (Year) | Population | Intervention | Key Finding | NNT or Effect Size |
|---|---|---|---|---|
| MAGPIE (2002) | 10 141 women with preeclampsia | MgSO₄ vs placebo | 58% reduction in eclampsia (0.8% vs 1.9%) | NNT = 91 [459]A1b |
| CLASP (1994) | 9364 women at risk | Aspirin 60 mg vs placebo | Non-significant 12% reduction in proteinuric preeclampsia | , [460]A1b |
| ASPRE (2017) | 1620 high-risk women | Aspirin 150 mg vs placebo | Preterm PE: 1.6% vs 4.3% (OR 0.38) | NNT = 37 [155]A1b |
| CHAP (2022) | 2408 women with mild chronic HTN | Active BP treatment (<140/90) vs standard | Primary composite: 30.2% vs 37.0% (aRR 0.82) | NNT = 15 [66]A1b |
| HYPITAT (2009) | 756 women with mild HTN >37 wk | Induction vs expectant | Poor maternal outcome: 31% vs 44% (RR 0.71) | NNT = 8 [63]A1b |
| PHOENIX (2019) | 901 women, 34-37 wk preeclampsia | Planned delivery vs expectant | Maternal composite: 65% vs 75% (aRR 0.86) | NNT = 10 [418]A1b |
| PREVENT-PE (2025) | 8094 women, 36 wk screening | Risk-stratified planned early-term birth | Term PE: 3.9% vs 5.6% (aRR 0.70) | NNT = 59 [149]A1b |
Complications
- ▸Preeclampsia causes a spectrum of maternal complications including eclampsia, abruption, HELLP, and stroke, with frequencies dependent on severity and prophylaxis.
- ▸Fetal complications are driven by placental insufficiency leading to FGR, preterm birth, and stillbirth; aspirin prophylaxis reduces these risks.
- ▸Long-term maternal cardiovascular risk is significantly elevated, with atherosclerosis appearing a decade earlier.
Despite advances in antihypertensive therapy and timing of delivery, the multisystem nature of preeclampsia continues to generate a broad spectrum of complications affecting both mother and fetus. The frequency and severity of these complications are closely tied to gestational age at onset, severity of , and presence of end‑organ dysfunction [263]A1c[442]B3b.
Maternal Complications
Maternal complications arise from systemic endothelial dysfunction, vasospasm, and coagulopathy. Eclampsia occurs in 2% of women with severe features not receiving magnesium sulfate and in <0.6% of those who do [99]D5; magnesium sulfate reduces the risk by more than half (RR 0.41, 95% CI 0.29-0.58; NNT 100) [117]A1a. HELLP syndrome complicates 10-20% of severe preeclampsia and carries high risk of liver rupture, DIC, and acute kidney injury [281]D5. is more frequent with preeclampsia (OR 1.36 for postpartum preeclampsia) [77]B3b[91]D5. Pulmonary edema results from increased capillary permeability. Postpartum preeclampsia is associated with 6.48‑fold increased risk of severe maternal morbidity (RR 6.48) [77]B3b[96]D5. Cerebrovascular events (stroke, PRES) are leading causes of death, with disproportionate burden in Black women (2.5‑fold higher maternal mortality) [500]D5[99]D5. Long‑term, women develop atherosclerotic plaque 10 years earlier (pooled OR 1.57, 95% CI 1.39-1.78) [181]A1a.
Fetal and Neonatal Complications
Preeclampsia accounts for 6% of all preterm births and 19% of medically indicated preterm births in the US [153]A1c. Fetal growth restriction (FGR) is common; in the TRUFFLE cohort (early FGR at 26-32 weeks), perinatal death occurred in 8% and severe neonatal morbidity in 24% [267]B2b. risk is increased (OR 4.46 in term fetuses without SGA) [498]B2b. Neonatal complications include respiratory distress syndrome, bronchopulmonary dysplasia, , and neurological impairment, especially in extremely preterm deliveries [348]B2a. Low‑dose reduces preterm birth (RR 0.89) and perinatal mortality (RR 0.86) [151]A1b.
Surveillance and Supportive Care
Mechanism‑driven surveillance is key. Respiratory status monitoring for pulmonary edema, autonomic instability (labile hypertension, arrhythmias, ileus), and VTE prophylaxis with low‑molecular‑weight are warranted given the prothrombotic state. Pain should avoid NSAIDs if hypertension or renal impairment is present. Hospital‑acquired infections can be minimized by early mobilization, hand hygiene, and catheter avoidance.
| Complication | Frequency | Prevention | Management |
|---|---|---|---|
| Eclampsia | 2% without MgSO₄; <0.6% with MgSO₄ [99]D5 | Magnesium sulfate [117]A1a | MgSO₄, antihypertensives, delivery |
| HELLP syndrome | 10-20% of severe PE [281]D5 | Early diagnosis, delivery | Delivery, supportive care |
| Placental abruption | Higher with PE (OR 1.36) [77]B3b[91]D5 | Tight BP control | Delivery |
| Pulmonary edema | Variable | Fluid restriction | Diuresis, delivery |
| Preterm birth | 6% of all preterm births [153]A1c | Low‑dose aspirin [151]A1b | Antenatal corticosteroids, delivery timing |
| Fetal growth restriction | Common in early‑onset PE [267]B2b | Aspirin, surveillance | Serial US, Doppler, delivery |
| Stillbirth | OR 4.46 [498]B2b | Aspirin, surveillance | Prompt delivery |
| Postpartum PE | 0.3% of deliveries [77]B3b | Postpartum BP monitoring | Antihypertensives, MgSO₄ if severe [96]D5 |
Controversies and Guideline Disagreement
| Question | Position A | Position B | Strength | Implication |
|---|---|---|---|---|
| Aspirin timing for abruption risk | Start ≤16 weeks reduces abruption [427]A1a | Start >16 weeks shows trend toward increased abruption (RR 1.20, 95% CI 1.00-1.46) [427]A1a | Moderate | Initiate aspirin early; avoid late initiation if alternative strategies exist |
Pearl: The most critical intervention to reduce both maternal and fetal complications is timely delivery, guided by gestational age, severity, and fetal status, every day of expectant management must be weighed against the risk of stroke, abruption, or stillbirth.
Prognosis & Natural History
- ▸Without treatment, preeclampsia progresses to severe maternal complications in 5% within 48 hours; aspirin reduces preterm preeclampsia by 62%.
- ▸Recurrence rate in subsequent pregnancies is 40.6%; long-term cardiovascular risk is doubled.
- ▸The fullPIERS model (AUC 0.88) and sFlt-1/PlGF ratio improve short-term prognostication.
The complications described above underscore the importance of understanding the natural history of preeclampsia and the factors that modify its trajectory.
Untreated Course
Without intervention, preeclampsia follows a progressive course that can accelerate over days to weeks. The risk of eclampsia in women with severe features not receiving magnesium sulfate is 2%, rising to <0.6% with prophylaxis [99]D5. complicates 1% of all pregnancies, but the risk is substantially higher with preeclampsia [91]D5. The fullPIERS model, derived from 2023 women with preeclampsia, found that 5% experienced an adverse maternal outcome (death or serious morbidity) within 48 hours of admission [389]B2b. In the HYPITAT trial, expectant of mild hypertensive disease at term led to a 44% rate of poor maternal outcome, compared with 31% after induction of labour (RR 0.71, 95% CI 0.59-0.86) [63]A1b. The trajectory is worse with earlier onset: median time to delivery in the TRUFFLE cohort was 13 days without , 8 days with gestational hypertension, and only 3 days with HELLP syndrome [267]B2b.
Impact of Treatment on Prognosis
150 mg daily started before 16 weeks reduces preterm preeclampsia by 62% (OR 0.38, 95% CI 0.20-0.74) [155]A1b. In the CHAP trial, treating mild chronic hypertension to a target <140/90 mm Hg lowered the primary composite outcome from 37.0% to 30.2% (aRR 0.82, 95% CI 0.74-0.92) [66]A1b. Magnesium sulfate halves the risk of eclampsia (RR 0.41, 95% CI 0.29-0.58; NNT = 100) [117]A1a. For mild disease at term, induction of labour improves maternal outcome without increasing cesarean rates [63]A1b. Planned delivery at 39 weeks appears optimal for mild chronic hypertension, as early-term delivery (37-38 weeks) increases neonatal respiratory distress and hypoglycemia [265]B2b.
Recurrence in Subsequent Pregnancies
Recurrence of is common: a retrospective study of 2499 women found a 40.6% recurrence rate in the next pregnancy [381]B3b. Early pregnancy laboratory abnormalities (elevated platelet count, proteinuria, elevated liver enzymes) are associated with recurrence but have limited predictive value alone [381]B3b. Women with prior preeclampsia also have a doubled long-term risk of cardiovascular disease, and two-thirds die prematurely from CVD [479]D5. The POP-HT trial demonstrated that postpartum self-monitoring with physician-guided antihypertensive titration lowered 24-hour diastolic blood pressure by 5.8 mm Hg (95% CI -7.40 to -4.20) at 9 months, a strategy that may mitigate later cardiovascular risk [165]A1b.
Prognostic Markers
Several tools refine individual risk stratification. The fullPIERS model (gestational age, chest pain/dyspnea, oxygen saturation, platelet count, creatinine, AST) predicts adverse maternal outcomes within 48 hours with an AUC of 0.88 (95% CI 0.84-0.92) [389]B2b. The sFlt-1/PlGF ratio is FDA-approved to aid prediction of preeclampsia with severe features at 24-34 weeks [92]D5. The fibrinogen-to-albumin ratio (FAR) adds incremental prognostic value for composite adverse perinatal outcomes (AUC 0.888, continuous NRI 0.397) [140]B3b. First-trimester screening using the Fetal Medicine Foundation triple test (maternal factors, mean arterial pressure, uterine artery pulsatility index, placental growth factor) detects 75% of preterm preeclampsia at a 10% false-positive rate [100]D5.
Pearl: The recurrence risk of hypertensive disorders of pregnancy is approximately 40%; early pregnancy labs alone are insufficient to predict it, but the fullPIERS model and sFlt-1/PlGF ratio provide actionable short-term risk stratification that can guide triage and delivery timing.
Special Populations
- ▸Adolescent pregnancy is associated with a 12.9% prevalence of preeclampsia, though outcomes may approach those of adults with adequate care.
- ▸Lactation after preeclampsia is safe; bromocriptine should be avoided due to ischemic stroke and myocardial infarction risks.
- ▸Long-term cardiovascular monitoring is essential after preeclampsia, particularly early-onset, given evidence of increased intima-media thickness and elevated blood pressure in offspring.
While the natural history of preeclampsia is well-established, the disorder's presentation, diagnostic accuracy, and therapeutic margin shift in several host populations where standard obstetric pathways require deliberate adaptation. The evidence base for these groups remains limited; women who are pregnant or lactating have historically been excluded from drug research, and most medications are used off-label [510]D5.
Adolescents (Pediatrics)
Adolescent pregnancy confers a distinct risk profile. In the Eastern Mediterranean region, the prevalence of preeclampsia among adolescents is 12.9% (95% CI 7.3, 18.5) [523]B2a. However, a retrospective study comparing 1719 adolescents with 15,266 adults found no significant difference in preeclampsia rates (p=0.792) [525]B2b, suggesting that adequate antenatal care may mitigate risk. The adolescent uterus may exhibit partial progesterone resistance and incomplete decidualization, predisposing to defective deep placentation and, in the absence of cyclic menstrual preconditioning, an increased risk of preeclampsia in very young primigravidae [513]D5[515]D5. Among Syrian refugees, adolescent pregnancy is markedly more common (RR 3.78, 95% CI 3.06-4.88) [522]B2a. follows standard protocols, but emphasis on early booking, social support, and adherence to follow-up is critical.
Pregnancy (Special Considerations During Gestation and Lactation)
is safe and encouraged after preeclampsia. Among women with gestational , lactation for ≥6 months was associated with lower postpartum blood pressure, though this benefit was not observed in women who had preeclampsia [516]B2b.
Bromocriptine for lactation inhibition carries serious cardiovascular risks. In a pharmacovigilance survey, 105 serious adverse drug reactions were reported, including 18 ischemic strokes and 11 myocardial infarctions; 70.5% were cardiovascular, and many occurred in women with a history of hypertension or preeclampsia. The authors concluded bromocriptine should be used only when no alternative exists [518]C4.
Magnesium sulfate continuation postpartum, after a minimum 8-hour predelivery maintenance infusion, does not reduce eclampsia risk and prolongs time to ambulation (18.1 vs 11.8 hours) and time to lactation initiation (24.1 vs 17.1 hours) [507]A1b. Discontinuation immediately after delivery is safe.
Women exposed in utero to diethylstilbestrol carry a higher lifetime risk of preeclampsia (HR 1.42, 95% CI 1.07-1.89) [501]B2b, warranting heightened surveillance.
Elderly (Perimenopause and Long-Term Cardiovascular Risk)
Preeclampsia, particularly early-onset disease, is a marker of future cardiovascular risk. Women with early-onset preeclampsia have increased femoral artery intima-media thickness (0.63 vs 0.55 mm) compared with controls, a sign of early atherosclerosis [508]B3b. Offspring exposed to preeclampsia in utero also have higher blood pressure in childhood and young adulthood (SBP 2.0 mm Hg, 95% CI 1.2-2.8; DBP 1.4 mm Hg, 95% CI 0.9-1.9) [524]B2a. Postpartum counseling should include periodic , lifestyle modification, and blood pressure monitoring.
Immunocompromised
Direct evidence guiding preeclampsia management in immunocompromised women is sparse. The maternal-fetal interface relies on decidual natural killer cell function, and immune memory from prior pregnancies (pregnancy-trained NK cells) may improve placentation [512]D5. In women with immunosuppression (e.g., transplant recipients, autoimmune disease on biologics), these adaptive mechanisms may be altered; a low threshold for diagnostic testing and multidisciplinary care is prudent, though specific outcome data are lacking.
Pearl: In women with preeclampsia, discontinue magnesium sulfate immediately after delivery if a minimum 8-hour predelivery course has been completed, this shortens ambulation and lactation initiation time without increasing seizure risk [507]A1b; avoid bromocriptine for lactation suppression due to cardiovascular adverse effects [518]C4.
Prevention, Screening & Surveillance
- ▸Daily low-dose aspirin (81-150 mg) reduces preeclampsia risk by 15-62% depending on dose and initiation timing; optimal benefit requires start before 16 weeks' gestation.
- ▸First-trimester combined screening (FMF algorithm) detects 76.7% of preterm preeclampsia at 10% false-positive rate, far outperforming risk-factor-based screening (41% sensitivity).
- ▸Postpartum surveillance is critical: 36% of women with preeclampsia develop hypertension within 1 year, and atherosclerotic disease appears a decade earlier, justifying annual cardiovascular risk assessment.
Across all populations studied, including the special groups discussed above, the cornerstone of prevention remains early identification of at-risk women and initiation of low-dose . The approach must integrate screening selection, prophylaxis timing and dose, and postpartum surveillance for long-term cardiovascular risk.
Primary Prevention: Aspirin Prophylaxis
Low-dose aspirin reduces the incidence of preeclampsia, particularly preterm disease. The landmark ASPRE trial demonstrated that aspirin 150 mg daily initiated between 11 and 14 weeks and continued until 36 weeks in women identified by first-trimester combined screening reduced preterm preeclampsia by 62% (relative risk 0.38, 95% CI 0.20-0.74) [21]D5. A meta-analysis of individual patient data from 32,217 women showed a 10% reduction in preeclampsia risk (RR 0.90, 95% CI 0.84-0.97) across all doses [495]A1a. The USPSTF systematic review of 23 RCTs confirmed a pooled RR of 0.85 (95% CI 0.75-0.95) for preeclampsia, with corresponding reductions in perinatal mortality (RR 0.79), preterm birth (RR 0.80), and intrauterine growth restriction (RR 0.82) [178]A1a. No significant increase in (RR 1.03) or other bleeding harms was observed [178]A1a.
Dosing and timing. ACOG recommends low-dose aspirin 81 mg/day initiated between 12 and 28 weeks (optimally before 16 weeks) and continued daily until delivery [190]A1c. NICE guidelines advise 75-150 mg/day [100]D5. The ASPREO trial comparing 162 mg vs 81 mg in high-risk obese women found a posterior relative risk of 0.88 (95% CrI 0.64-1.22) for preeclampsia with severe features, a non-significant trend favoring the higher dose [383]A1b. In women with chronic , a meta-analysis of nine studies (2150 women) could not demonstrate a significant reduction in superimposed preeclampsia (OR 0.83) but did show a significant reduction in preterm birth (OR 0.63, 95% CI 0.45-0.89), justifying continued prophylaxis [529]A1a.
Aspirin effect by baseline risk. A secondary analysis of ASPRE trial participants with high compliance (≥90% of tablets) found that the benefit of 150 mg aspirin increased with first-trimester risk. Among women with initial Fetal Medicine Foundation (FMF) risk ≥1 in 20, aspirin reduced preterm preeclampsia risk by 76% (RR 0.24, 95% CI 0.09-0.63) and early preeclampsia (<34 weeks) by an estimated 94% (RR 0.06, 95% CI 0.01-0.96) [537]B2b. The number needed to screen with the FMF algorithm to prevent one case of preterm preeclampsia is 250 [100]D5.
Disparities in aspirin use. Prescription rates for eligible Black patients are similar to White patients, but adherence rates are lower (approximately 70% vs higher in White patients), contributing to persistent disparities in maternal outcomes. Barriers include inconsistent counseling, limited prenatal care access, and healthcare distrust [549]B2a. Culturally tailored education and adherence monitoring are needed.
Primary Prevention: Other Strategies
Weight . Counseling and behavioral interventions to limit gestational weight gain reduced the risk of gestational diabetes (RR 0.87, 95% CI 0.79-0.95) and macrosomia (RR 0.77), but no significant effect on preeclampsia was demonstrated in the USPSTF review (68 trials, 25,789 women) [179]A1a.
Periodontal treatment. Periodontal disease may increase preeclampsia risk; treatment in three controlled trials reduced preterm low birthweight by 57% (pooled RR 0.43, 95% CI 0.24-0.78), though specific preeclampsia data are limited [174]B2a.
Inorganic nitrate supplementation. A randomized trial protocol (NIT_CH) is evaluating whether inorganic nitrate capsules (starting at 16 weeks) can improve blood pressure control and reduce preeclampsia in women with chronic hypertension [545]D5. No results are yet available.
Secondary Prevention of Recurrence
Women with a prior pregnancy complicated by preeclampsia are at high risk for recurrence. A French nationwide cohort study of 2,829,274 women found that 14.7% of those with first-pregnancy preeclampsia developed preeclampsia again in their second pregnancy (incidence rate ratio 14.3, 95% CI 13.6-15.0) [531]B2b. The risk was higher with earlier onset and greater severity of the index pregnancy. Aspirin prophylaxis is recommended for all women with prior preeclampsia (a high-risk factor per ACOG) [190]A1c.
Screening Recommendations
The USPSTF recommends screening for preeclampsia with blood pressure measurements throughout pregnancy (Grade B recommendation) [154]A1c. No direct trial evidence compares screened versus unscreened populations, but adequate evidence shows that treatment reduces maternal and perinatal morbidity [79]B2a. Urine dipstick screening for proteinuria has poor test accuracy (sensitivity 22-100%, specificity 36-100%) and is not recommended as a stand-alone screening test in asymptomatic populations [79]B2a[24]D5.
Risk-factor-based screening. ACOG and NICE use lists of clinical risk factors to identify candidates for aspirin prophylaxis. However, this approach has low sensitivity: NICE criteria detect only 41% of preterm preeclampsia and 34% of term preeclampsia at a 10% false-positive rate; 2013 ACOG criteria detect only 5% and 2%, respectively [100]D5.
First-trimester combined screening. The FMF algorithm integrates maternal factors, mean arterial pressure, uterine artery pulsatility index (UtA-PI), and serum placental growth factor (PlGF). In the ASPRE screening cohort of 25,797 pregnancies, a risk cutoff of 1 in 100 detected 76.7% of preterm preeclampsia at a 10.5% screen-positive rate (false-positive rate 9.2%) [71]B2b. This performance is superior to risk-factor-based screening and is cost-effective: a decision analysis found seven fewer cases of preterm preeclampsia, cost savings of £9.06, and a QALY gain of 0.00006 per pregnancy screened compared with NICE screening [533]B3b. A cost-benefit analysis in Catalonia estimated healthcare savings of €3.38 million with the Gaussian algorithm without PlGF, and €3.29 million with PlGF (greater clinical benefit) [538]B2c. ACOG Committee Opinion No. 638 (2015) acknowledges that although these tests are marketed, taking a detailed medical history remains the currently recommended screening approach; evidence that first-trimester predictive tests improve outcomes is insufficient [536]A1c.
PlGF testing in suspected preeclampsia. The PARROT trial (stepped-wedge cluster-randomized, 1,035 women) showed that revealing PlGF results integrated with a clinical management algorithm reduced the time to diagnosis of preeclampsia compared with concealed testing, with no increase in adverse outcomes [64]A1b. This approach is being evaluated for chronic hypertension with suspected superimposed preeclampsia (B.I.P.E.S. trial protocol) [546]D5.
Postpartum Surveillance
The risk of long-term cardiovascular disease is substantially elevated after preeclampsia. A meta-analysis of 11 studies (13,217 participants) found that women with prior preeclampsia have atherosclerotic plaque approximately 10 years earlier than women without (pooled OR 1.57, 95% CI 1.39-1.78), with OR increasing to 2.00 in the 50-60 year age group [181]A1a. At one year postpartum, 36.4% of African women with preeclampsia had hypertension (≥140/90 mmHg) compared with 4.5% of controls (aIRR 1.26, 95% CI 1.16-1.36); increased aortic pulse wave velocity and left ventricular mass index were also observed [532]B2b. These data mandate structured postpartum follow-up: blood pressure check within 72 hours, at 1 week, and then annually for all women following a preeclamptic pregnancy, with aggressive management of modifiable cardiovascular risk factors.
Patient Education
Women should be counseled about preeclampsia symptoms (headache, visual changes, epigastric pain, shortness of breath) and the importance of prompt reporting. Adherence to low-dose aspirin is critical, rates average only 70% and are lower among Black patients [549]B2a. Postpartum, women must understand their heightened lifetime cardiovascular risk and the need for ongoing primary care follow-up.
Controversies and Guideline Disagreement
| Question | Position A | Position B | Strength | Implication |
|---|---|---|---|---|
| Universal vs risk-factor-based aspirin | Universal aspirin for all pregnant women reduces implementation failures and may prevent more cases at population level [534]D5 | Risk-factor-based screening (ACOG/NICE) targets those at highest risk, minimizing unnecessary medication exposure [190]A1c | Moderate; no -to-head RCT | Universal approach would increase population coverage but may face resistance from clinicians and patients regarding medicating all pregnancies |
| First-trimester screening algorithm vs simple risk-factor list | FMF algorithm detects 76.7% of preterm PE; cost-effective and superior [71]B2b[533]B3b | ACOG states insufficient evidence to recommend predictive tests over medical history [536]A1c | Strong evidence for algorithm performance; guideline disagreement on implementation | Algorithms require standardized biomarker measurement (MAP, UtA-PI, PlGF) and quality control; not universally available |
Pearl: The NNT with FMF-algorithm-guided aspirin prophylaxis to prevent one case of preterm preeclampsia is 250 women screened and treated; the effect is most pronounced in those with first-trimester risk >1 in 20, where aspirin reduces preterm preeclampsia by 76% (RR 0.24) [537]B2b[100]D5.
| Guideline | Daily dose | Initiation window | High-risk criteria |
|---|---|---|---|
| ACOG (2018) | 81 mg | 12 to 28 weeks (optimally before 16 weeks) | ≥1 high-risk factor or ≥2 moderate-risk factors [190]A1c |
| NICE (UK) | 75-150 mg | From 12 weeks until delivery | ≥1 high-risk factor or ≥2 moderate-risk factors [100]D5 |
| USPSTF (2021) | 81 mg (based on trials using 60-150 mg) | After 12 weeks (optimally before 16 weeks) | Same as ACOG [178]A1a |
| FMF/ASPRE | 150 mg nightly | 11-14 weeks until 36 weeks | First-trimester risk >1 in 100 by combined algorithm [21]D5 |
References
- [1]
. “Committee Opinion No. 573: Magnesium sulfate use in obstetrics.” Obstetrics and gynecology (2013). PMID: 23963425 ↗
L1GUIDELINECited in: Definition, Classification & Nomenclature - [2]
Scott G, Gillon TE, Pels A et al.. “Guidelines-similarities and dissimilarities: a systematic review of international clinical practice guidelines for pregnancy hypertension.” American journal of obstetrics and gynecology (2020). PMID: 32828743 ↗
L5GUIDELINECited in: Definition, Classification & Nomenclature, Clinical Presentation, Diagnosis & Workup, Acute Management - [3]
Chan JL, Legro RS, Eisenberg E et al.. “Correlation of Polycystic Ovarian Syndrome Phenotypes With Pregnancy and Neonatal Outcomes.” Obstetrics and gynecology (2024). PMID: 39173182 ↗
L3RCTCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, Clinical Presentation, Acute Management, History and Evolution of Treatment, Prognosis & Natural History - [4]
Marijnen MC, Kamphof HD, Damhuis SE et al.. “Doppler ultrasound of umbilical and middle cerebral artery in third trimester small-for-gestational age fetuses to decide on timing of delivery for suspected fetal growth restriction: A cohort with nested RCT (DRIGITAT).” BJOG : an international journal of obstetrics and gynaecology (2024). PMID: 38498267 ↗
L1RCTCited in: Definition, Classification & Nomenclature, Pathophysiology & Mechanism, Fetal Assessment, Antenatal Surveillance & Prenatal Diagnosis, Definitive Management: Medical, Operative & Surgical Staging, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, History and Evolution of Treatment - [5]
Magee LA, Singer J, Lee T et al.. “The impact of pre-eclampsia definitions on the identification of adverse outcome risk in hypertensive pregnancy - analyses from the CHIPS trial (Control of Hypertension in Pregnancy Study).” BJOG : an international journal of obstetrics and gynaecology (2021). PMID: 33230924 ↗
L2RCTCited in: Definition, Classification & Nomenclature, Clinical Presentation - [6]
Davidson KW, Barry MJ, Mangione CM et al.. “Screening for Gestational Diabetes: US Preventive Services Task Force Recommendation Statement.” JAMA (2021). PMID: 34374716 ↗
L1GUIDELINECited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, Definitive Management: Medical, Operative & Surgical Staging, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, History and Evolution of Treatment, Complications, Prevention, Screening & Surveillance - [7]
Panagiotopoulos M, Tseke P, Michala L. “Obstetric Complications in Women With Congenital Uterine Anomalies According to the 2013 European Society of Human Reproduction and Embryology and the European Society for Gynaecological Endoscopy Classification: A Systematic Review and Meta-analysis.” Obstetrics and gynecology (2022). PMID: 34856567 ↗
L1SR_OBSCited in: Definition, Classification & Nomenclature - [8]
Duffy J, Hirsch M, Pealing L et al.. “Inadequate safety reporting in pre-eclampsia trials: a systematic evaluation.” BJOG : an international journal of obstetrics and gynaecology (2017). PMID: 29030992 ↗
L1SR_OBSCited in: Definition, Classification & Nomenclature, Severity, Staging & Risk Stratification - [9]
Jeyaraman D, Walters B, Bramham K et al.. “Adverse pregnancy outcomes in pregnant women with chronic kidney disease: A systematic review and meta-analysis.” BJOG : an international journal of obstetrics and gynaecology (2024). PMID: 38488268 ↗
L1SR_OBSCited in: Definition, Classification & Nomenclature, Complications - [10]
Brunelli VB, Prefumo F. “Quality of first trimester risk prediction models for pre-eclampsia: a systematic review.” BJOG : an international journal of obstetrics and gynaecology (2015). PMID: 25761437 ↗
L5SR_OBSCited in: Definition, Classification & Nomenclature, Pathophysiology & Mechanism, Severity, Staging & Risk Stratification - [11]
Andolf E, Bladh M, Möller L et al.. “Prior placental bed disorders and later dementia: a retrospective Swedish register-based cohort study.” BJOG : an international journal of obstetrics and gynaecology (2020). PMID: 32145044 ↗
L3COHORTCited in: Definition, Classification & Nomenclature - [12]
Falco ML, Sivanathan J, Laoreti A et al.. “Placental histopathology associated with pre-eclampsia: systematic review and meta-analysis.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2017). PMID: 28436167 ↗
L1SR_OBSCited in: Definition, Classification & Nomenclature, Diagnosis & Workup, Severity, Staging & Risk Stratification - [13]
Cuenca-Gómez D, De Paco Matallana C, Rolle V et al.. “Comparison of different methods of first-trimester screening for preterm pre-eclampsia: cohort study.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2024). PMID: 38411276 ↗
L2COHORTCited in: Definition, Classification & Nomenclature, Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, Fetal Assessment, Antenatal Surveillance & Prenatal Diagnosis, Acute Management, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, History and Evolution of Treatment - [14]
Chatzakis C, Tsakmaki E, Psomiadou A et al.. “Different pregnancy outcomes according to the polycystic ovary syndrome diagnostic criteria: a systematic review and meta-analysis of 79 studies.” Fertility and sterility (2022). PMID: 35120743 ↗
L1SR_OBSCited in: Definition, Classification & Nomenclature - [15]
Lynch TA, Dexter SC. “Alcoholic Pancreatitis Masquerading as Preeclampsia.” Obstetrics and gynecology (2015). PMID: 26375717 ↗
L4CASE_REPORTCited in: Definition, Classification & Nomenclature - [16]
Keukens A, van Wely M, van der Meulen C et al.. “Pre-eclampsia in pregnancies resulting from oocyte donation, natural conception or IVF: a systematic review and meta-analysis.” Human reproduction (Oxford, England) (2022). PMID: 34931678 ↗
L1SR_OBSCited in: Definition, Classification & Nomenclature, Severity, Staging & Risk Stratification, Acute Management - [17]
Rittenhouse KJ, Kasaro MP, Spelke MB et al.. “Maternal Human Immunodeficiency Virus and Preeclampsia Among a Combined Cohort of Zambian Women.” Obstetrics and gynecology (2025). PMID: 40839874 ↗
L2OTHERCited in: Definition, Classification & Nomenclature, Severity, Staging & Risk Stratification - [18]
Rosenfeld EB, Brandt JS, Fields JC et al.. “Chronic Hypertension and the Risk of Readmission for Postpartum Cardiovascular Complications.” Obstetrics and gynecology (2023). PMID: 37917949 ↗
L3OTHERCited in: Definition, Classification & Nomenclature - [19]
Boller MJ, Xu F, Lee C et al.. “Perinatal Outcomes After Bariatric Surgery Compared With a Matched Control Group.” Obstetrics and gynecology (2023). PMID: 36735357 ↗
L3OTHERCited in: Definition, Classification & Nomenclature - [20]
Meeker JR, Canelón SP, Bai R et al.. “Individual-Level and Neighborhood-Level Risk Factors for Severe Maternal Morbidity.” Obstetrics and gynecology (2021). PMID: 33831923 ↗
L3OTHERCited in: Definition, Classification & Nomenclature - [21]
Rolnik DL, Nicolaides KH, Poon LC. “Prevention of preeclampsia with aspirin.” American journal of obstetrics and gynecology (2020). PMID: 32835720 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, Definitive Management: Medical, Operative & Surgical Staging, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, Complications, Prognosis & Natural History, Prevention, Screening & Surveillance - [22]
Erez O, Romero R, Jung E et al.. “Preeclampsia and eclampsia: the conceptual evolution of a syndrome.” American journal of obstetrics and gynecology (2022). PMID: 35177220 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Pathophysiology & Mechanism, Acute Management, Definitive Management: Medical, Operative & Surgical Staging, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, History and Evolution of Treatment, Complications - [23]
Horsch A, Garthus-Niegel S, Ayers S et al.. “Childbirth-related posttraumatic stress disorder: definition, risk factors, pathophysiology, diagnosis, prevention, and treatment.” American journal of obstetrics and gynecology (2024). PMID: 38233316 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Pathophysiology & Mechanism, Diagnosis & Workup, Definitive Management: Medical, Operative & Surgical Staging, History and Evolution of Treatment, Complications, Prevention, Screening & Surveillance - [24]
Fishel Bartal M, Lindheimer MD, Sibai BM. “Proteinuria during pregnancy: definition, pathophysiology, methodology, and clinical significance.” American journal of obstetrics and gynecology (2020). PMID: 32882208 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Pathophysiology & Mechanism, Diagnosis & Workup, Severity, Staging & Risk Stratification, Definitive Management: Medical, Operative & Surgical Staging, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, Complications, Prevention, Screening & Surveillance - [25]
Gyselaers W. “Hemodynamic pathways of gestational hypertension and preeclampsia.” American journal of obstetrics and gynecology (2022). PMID: 35177225 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Definitive Management: Medical, Operative & Surgical Staging, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy - [26]
Brosens I, Pijnenborg R, Vercruysse L et al.. “The "Great Obstetrical Syndromes" are associated with disorders of deep placentation.” American journal of obstetrics and gynecology (2010). PMID: 21094932 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature - [27]
Solt I, Cohen SM, Admati I et al.. “Placenta at single-cell resolution in early and late preeclampsia: insights and clinical implications.” American journal of obstetrics and gynecology (2025). PMID: 40253080 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature - [28]
Greer OYO, Anandanadesan R, Shah NM et al.. “Cardiogenic shock in pregnancy.” BJOG : an international journal of obstetrics and gynaecology (2023). PMID: 37794623 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Definitive Management: Medical, Operative & Surgical Staging, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy - [29]
Cerdeira AS, Agrawal S, Staff AC et al.. “Angiogenic factors: potential to change clinical practice in pre-eclampsia?” BJOG : an international journal of obstetrics and gynaecology (2017). PMID: 29193681 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Fetal Assessment, Antenatal Surveillance & Prenatal Diagnosis - [30]
Coomarasamy A, Sindhu KN, Gallos I et al.. “Postpartum haemorrhage: epidemiology, consequences, and missed opportunities.” Lancet (London, England) (2026). PMID: 42285119 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification & Nomenclature, Diagnosis & Workup, Prevention, Screening & Surveillance - [31]
Trejo-Domínguez A, Benitez L, Crovetto F et al.. “Ultraprocessed foods consumption and risk of preeclampsia: a secondary analysis of the improving mothers for a better prenatal care trial Barcelona (IMPACT BCN) randomized clinical trial.” The American journal of clinical nutrition (2026). PMID: 41780730 ↗
L2RCTCited in: Definition, Classification & Nomenclature - [32]
Youssef L, Crispi F, Paolucci S et al.. “Angiogenic factors alone or in combination with ultrasound Doppler criteria for risk classification among late-onset small fetuses with or without pre-eclampsia.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2025). PMID: 39888184 ↗
L2OTHERCited in: Definition, Classification & Nomenclature, Diagnosis & Workup - [33]
van de Meent M, Bel EW, Ganzevoort W et al.. “Perinatal risk assessment in pregnancies complicated by early-onset fetal growth restriction: development and internal validation of a prediction model for composite adverse perinatal outcome.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2025). PMID: 40623699 ↗
L2OTHERCited in: Definition, Classification & Nomenclature - [34]
Rolnik DL, Gil-Pugliese S, Syngelaki A et al.. “First-trimester prediction and prevention of preterm pre-eclampsia in women with chronic hypertension.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2026). PMID: 41903191 ↗
L2OTHERCited in: Definition, Classification & Nomenclature - [35]
Abdel Azim S, Wright A, Sapantzoglou I et al.. “Ophthalmic artery Doppler at 19-23 weeks' gestation in pregnancies that deliver small-for-gestational-age neonates.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2022). PMID: 35441758 ↗
L2OTHERCited in: Definition, Classification & Nomenclature - [36]
Palmrich P, Kalafat E, Pateisky P et al.. “Prognostic value of angiogenic markers in pregnancy with fetal growth restriction.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2024). PMID: 37774098 ↗
L3OTHERCited in: Definition, Classification & Nomenclature - [37]
Khan N, Andrade W, De Castro H et al.. “Impact of new definitions of pre-eclampsia on incidence and performance of first-trimester screening.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2020). PMID: 31503372 ↗
L3OTHERCited in: Definition, Classification & Nomenclature - [38]
Palacios C, Kostiuk LL, Cuthbert A et al.. “Vitamin D supplementation for women during pregnancy.” The Cochrane database of systematic reviews (2024). PMID: 39077939 ↗
L1SR_OBSCited in: Definition, Classification & Nomenclature, Acute Management, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, Prognosis & Natural History - [39]
Duley L, Meher S, Hunter KE et al.. “Antiplatelet agents for preventing pre-eclampsia and its complications.” The Cochrane database of systematic reviews (2019). PMID: 31684684 ↗
L1SR_OBSCited in: Definition, Classification & Nomenclature, Pathophysiology & Mechanism, Acute Management, Definitive Management: Medical, Operative & Surgical Staging, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, Complications, Prognosis & Natural History - [40]
Cluver CA, Rohwer C, Rohwer AC. “Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems.” The Cochrane database of systematic reviews (2025). PMID: 41330480 ↗
L1SR_OBSCited in: Definition, Classification & Nomenclature, Diagnosis & Workup, Acute Management, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, Complications, Prognosis & Natural History - [41]
Davidson SJ, Barrett HL, Price SA et al.. “Probiotics for preventing gestational diabetes.” The Cochrane database of systematic reviews (2021). PMID: 33870484 ↗
L1SR_OBSCited in: Definition, Classification & Nomenclature, Epidemiology, Etiology & Risk Factors, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, Complications - [42]
Bain E, Crane M, Tieu J et al.. “Diet and exercise interventions for preventing gestational diabetes mellitus.” The Cochrane database of systematic reviews (2015). PMID: 25864059 ↗
L1SR_OBSCited in: Definition, Classification & Nomenclature - [43]
Han S, Middleton P, Crowther CA. “Exercise for pregnant women for preventing gestational diabetes mellitus.” The Cochrane database of systematic reviews (2012). PMID: 22786521 ↗
L1SR_OBSCited in: Definition, Classification & Nomenclature - [44]
Hofmeyr GJ, Lawrie TA, Atallah AN et al.. “Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems.” The Cochrane database of systematic reviews (2014). PMID: 24960615 ↗
L1SR_OBSCited in: Definition, Classification & Nomenclature - [45]
Tieu J, Coat S, Hague W et al.. “Oral anti-diabetic agents for women with established diabetes/impaired glucose tolerance or previous gestational diabetes planning pregnancy, or pregnant women with pre-existing diabetes.” The Cochrane database of systematic reviews (2017). PMID: 29045765 ↗
L1SR_OBSCited in: Definition, Classification & Nomenclature - [46]
Wind M, Peters A, van den Akker-van Marle ME et al.. “Cost-effectiveness of the sFlt-1/PlGF ratio and telemonitoring in managing suspected pre-eclampsia: protocol for the PREPARE II randomised controlled trial.” BMJ open (2026). PMID: 42392637 ↗
L5TRIAL_NONRANDOMCited in: Definition, Classification & Nomenclature, Pathophysiology & Mechanism, Clinical Presentation, Diagnosis & Workup, Acute Management, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, Complications, Prognosis & Natural History - [47]
Chen I, Lalani S, Xie RH et al.. “Association between surgically diagnosed endometriosis and adverse pregnancy outcomes.” Fertility and sterility (2017). PMID: 29198848 ↗
L3OTHERCited in: Definition, Classification & Nomenclature, History and Evolution of Treatment - [48]
Wang C, Johansson ALV, Nyberg C et al.. “Prediction of pregnancy-related complications in women undergoing assisted reproduction, using machine learning methods.” Fertility and sterility (2024). PMID: 38373676 ↗
L2OTHERCited in: Definition, Classification & Nomenclature, Diagnosis & Workup, History and Evolution of Treatment - [49]
Pelland-Marcotte MC, Pérez Herrera NM, Boileau E et al.. “Factors Associated With Thromboembolism in Neonates: A Systematic Review and Meta-Analysis.” JAMA network open (2026). PMID: 42090153 ↗
L1SR_OBSCited in: Definition, Classification & Nomenclature, Severity, Staging & Risk Stratification, Definitive Management: Medical, Operative & Surgical Staging - [50]
Saad S, DeCesare J, Meadows R et al.. “Effect of COVID-19 infection on maternal and fetal outcomes of Pregnancy: A systematic review.” Pregnancy hypertension (2026). PMID: 41812517 ↗
L3SR_OBSCited in: Definition, Classification & Nomenclature - [51]
Patel S. “Intravenous magnesium administration errors, attributing factors and associated respiratory or cardiopulmonary arrest in obstetric and non-obstetric patients-A systematic review.” Anaesthesia, critical care & pain medicine (2025). PMID: 41033447 ↗
L4SR_OBSCited in: Definition, Classification & Nomenclature - [52]
Dayan N, Fell DB, Guo Y et al.. “Severe maternal morbidity in women with high BMI in IVF and unassisted singleton pregnancies.” Human reproduction (Oxford, England) (2018). PMID: 29982477 ↗
L2OTHERCited in: Definition, Classification & Nomenclature, Complications - [53]
Räisänen S, Randell K, Nielsen HS et al.. “Socioeconomic status affects the prevalence, but not the perinatal outcomes, of in vitro fertilization pregnancies.” Human reproduction (Oxford, England) (2013). PMID: 23892321 ↗
L2OTHERCited in: Definition, Classification & Nomenclature - [54]
Chen S, Zhao X, Xia L et al.. “Asymmetric U-shaped association between first-trimester maternal free thyroxine levels and the risk of preeclampsia: a large-scale cohort study.” Journal of hypertension (2026). PMID: 42101199 ↗
L2COHORTCited in: Definition, Classification & Nomenclature, Diagnosis & Workup - [55]
Wu J, Cheng H, Huang Y et al.. “Pregnancy adverse outcomes associated with change of blood pressure categories in early pregnancy among women with normotension: a retrospective cohort study.” BMC pregnancy and childbirth (2026). PMID: 42092811 ↗
L2COHORTCited in: Definition, Classification & Nomenclature - [56]
Espeche W, Minetto J, Cerri G et al.. “Does nocturnal hypertension reclassify maternal-fetal risk in women with white-coat hypertension? A cohort study in the second half of pregnancy.” Hypertension research : official journal of the Japanese Society of Hypertension (2026). PMID: 42032277 ↗
L2COHORTCited in: Definition, Classification & Nomenclature - [57]
Sanusi AA, Leach J, Boggess K et al.. “Pregnancy Outcomes of Nifedipine Compared With Labetalol for Oral Treatment of Mild Chronic Hypertension.” Obstetrics and gynecology (2024). PMID: 38949541 ↗
L2RCTCited in: Pathophysiology & Mechanism, Acute Management, Definitive Management: Medical, Operative & Surgical Staging, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, History and Evolution of Treatment, Prognosis & Natural History - [58]
Khander A, Thomas C, Matthews K et al.. “Comparison of 162 mg and 81 mg Aspirin for Prevention of Preeclampsia: A Randomized Controlled Trial.” Obstetrics and gynecology (2025). PMID: 41296512 ↗
L1RCTCited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, Definitive Management: Medical, Operative & Surgical Staging, Prognosis & Natural History - [59]
Patel M, Battarbee AN, Refuerzo JS et al.. “Association Between Metformin Use in Early Gestational or Type 2 Diabetes in Pregnancy and Preterm Preeclampsia.” Obstetrics and gynecology (2024). PMID: 39236318 ↗
L1RCTCited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Acute Management, History and Evolution of Treatment, Prognosis & Natural History - [60]
Rodger MA, Gris JC, de Vries JIP et al.. “Low-molecular-weight heparin and recurrent placenta-mediated pregnancy complications: a meta-analysis of individual patient data from randomised controlled trials.” Lancet (London, England) (2016). PMID: 27720497 ↗
L1SR_MA_RCTCited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, History and Evolution of Treatment, Complications - [61]
Ahmed A, Williams DJ, Cheed V et al.. “Pravastatin for early-onset pre-eclampsia: a randomised, blinded, placebo-controlled trial.” BJOG : an international journal of obstetrics and gynaecology (2019). PMID: 31715077 ↗
L1RCTCited in: Pathophysiology & Mechanism, Diagnosis & Workup, Acute Management, Definitive Management: Medical, Operative & Surgical Staging, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, History and Evolution of Treatment, Complications, Prognosis & Natural History - [62]
Papastefanou I, Chen Y, Nguyen-Hoang L et al.. “Impact of Aspirin on Timing of Birth in Pregnancies With Clinical Manifestations of Placental Dysfunction: Evidence From a Multicentre Randomised Clinical Trial.” BJOG : an international journal of obstetrics and gynaecology (2025). PMID: 40364747 ↗
L1RCTCited in: Pathophysiology & Mechanism - [63]
Koopmans CM, Bijlenga D, Groen H et al.. “Induction of labour versus expectant monitoring for gestational hypertension or mild pre-eclampsia after 36 weeks' gestation (HYPITAT): a multicentre, open-label randomised controlled trial.” Lancet (London, England) (2009). PMID: 19656558 ↗
L1RCTCited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, Acute Management, Definitive Management: Medical, Operative & Surgical Staging, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, History and Evolution of Treatment, Complications, Prognosis & Natural History - [64]
Duhig KE, Myers J, Seed PT et al.. “Placental growth factor testing to assess women with suspected pre-eclampsia: a multicentre, pragmatic, stepped-wedge cluster-randomised controlled trial.” Lancet (London, England) (2019). PMID: 30948284 ↗
L1RCTCited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Workup, Acute Management, Definitive Management: Medical, Operative & Surgical Staging, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, History and Evolution of Treatment, Complications, Prognosis & Natural History, Prevention, Screening & Surveillance - [65]
Hurrell A, Webster L, Sparkes J et al.. “Repeat placental growth factor-based testing in women with suspected preterm pre-eclampsia (PARROT-2): a multicentre, parallel-group, superiority, randomised controlled trial.” Lancet (London, England) (2024). PMID: 38342128 ↗
L1RCTCited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Acute Management, Definitive Management: Medical, Operative & Surgical Staging, History and Evolution of Treatment, Complications, Prognosis & Natural History - [66]
Tita AT, Szychowski JM, Boggess K et al.. “Treatment for Mild Chronic Hypertension during Pregnancy.” The New England journal of medicine (2022). PMID: 35363951 ↗
L1RCTCited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, Acute Management, Definitive Management: Medical, Operative & Surgical Staging, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, History and Evolution of Treatment, Complications, Prognosis & Natural History - [67]
Roberts JM, Myatt L, Spong CY et al.. “Vitamins C and E to prevent complications of pregnancy-associated hypertension.” The New England journal of medicine (2010). PMID: 20375405 ↗
L1RCTCited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, Acute Management, Definitive Management: Medical, Operative & Surgical Staging, Complications - [68]
Lim S, Li W, Kemper J et al.. “Biomarkers and the Prediction of Adverse Outcomes in Preeclampsia: A Systematic Review and Meta-analysis.” Obstetrics and gynecology (2021). PMID: 33278298 ↗
L2SR_OBSCited in: Pathophysiology & Mechanism, Diagnosis & Workup - [69]
Widmer M, Villar J, Benigni A et al.. “Mapping the theories of preeclampsia and the role of angiogenic factors: a systematic review.” Obstetrics and gynecology (2007). PMID: 17197602 ↗
L2SR_OBSCited in: Pathophysiology & Mechanism - [70]
Mendoza M, Bonacina E, Garcia-Manau P et al.. “Aspirin Discontinuation at 24 to 28 Weeks' Gestation in Pregnancies at High Risk of Preterm Preeclampsia: A Randomized Clinical Trial.” JAMA (2023). PMID: 36809321 ↗
L1RCTCited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, Acute Management, Definitive Management: Medical, Operative & Surgical Staging, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, History and Evolution of Treatment, Prognosis & Natural History - [71]
Rolnik DL, Wright D, Poon LCY et al.. “ASPRE trial: performance of screening for preterm pre-eclampsia.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2017). PMID: 28741785 ↗
L2RCTCited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, Acute Management, Definitive Management: Medical, Operative & Surgical Staging, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, History and Evolution of Treatment, Prevention, Screening & Surveillance - [72]
Aliasi M, Snoep MC, van Geloven N et al.. “Birthweight and isolated congenital heart defects - A systematic review and meta-analysis.” BJOG : an international journal of obstetrics and gynaecology (2022). PMID: 35352871 ↗
L2SR_OBSCited in: Pathophysiology & Mechanism - [73]
Conde-Agudelo A, Bird S, Kennedy SH et al.. “First- and second-trimester tests to predict stillbirth in unselected pregnant women: a systematic review and meta-analysis.” BJOG : an international journal of obstetrics and gynaecology (2014). PMID: 25236870 ↗
L2SR_OBSCited in: Pathophysiology & Mechanism, Fetal Assessment, Antenatal Surveillance & Prenatal Diagnosis - [74]
Yunas I, Islam MA, Sindhu KN et al.. “Causes of and risk factors for postpartum haemorrhage: a systematic review and meta-analysis.” Lancet (London, England) (2025). PMID: 40188841 ↗
L2SR_OBSCited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, Acute Management, Definitive Management: Medical, Operative & Surgical Staging, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, Prevention, Screening & Surveillance - [75]
Sovio U, Gaccioli F, Cook E et al.. “Association between adverse pregnancy outcome and placental biomarkers in the first trimester: A prospective cohort study.” BJOG : an international journal of obstetrics and gynaecology (2023). PMID: 37822261 ↗
L2COHORTCited in: Pathophysiology & Mechanism, Diagnosis & Workup, Acute Management - [76]
Zur RL, McLaughlin K, Aalto L et al.. “Phenotypes of maternal vascular malperfusion placental pathology and adverse pregnancy outcomes: A retrospective cohort study.” BJOG : an international journal of obstetrics and gynaecology (2024). PMID: 38725333 ↗
L3COHORTCited in: Pathophysiology & Mechanism, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy - [77]
Amar S, Potter BJ, Paradis G et al.. “Outcomes of Postpartum Preeclampsia: A Retrospective Cohort Study of 1.3 Million Pregnancies.” BJOG : an international journal of obstetrics and gynaecology (2024). PMID: 39623781 ↗
L3COHORTCited in: Pathophysiology & Mechanism, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, Complications - [78]
Fung GPG, Lam HS, Chan KYY et al.. “Angiogenic Biomarkers and Neonatal Outcomes in Suspected Preeclampsia: Retrospective Cohort Study.” BJOG : an international journal of obstetrics and gynaecology (2025). PMID: 41355705 ↗
L3COHORTCited in: Pathophysiology & Mechanism - [79]
Henderson JT, Thompson JH, Burda BU et al.. “Preeclampsia Screening: Evidence Report and Systematic Review for the US Preventive Services Task Force.” JAMA (2017). PMID: 28444285 ↗
L2SR_OBSCited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Acute Management, Prognosis & Natural History, Prevention, Screening & Surveillance - [80]
Townsend R, Khalil A, Premakumar Y et al.. “Prediction of pre-eclampsia: review of reviews.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2019). PMID: 30267475 ↗
L2SR_OBSCited in: Pathophysiology & Mechanism, Diagnosis & Workup, Acute Management, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, Prognosis & Natural History, Prevention, Screening & Surveillance - [81]
Velauthar L, Plana MN, Kalidindi M et al.. “First-trimester uterine artery Doppler and adverse pregnancy outcome: a meta-analysis involving 55,974 women.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2014). PMID: 24339044 ↗
L2SR_OBSCited in: Pathophysiology & Mechanism, Diagnosis & Workup, Fetal Assessment, Antenatal Surveillance & Prenatal Diagnosis, Definitive Management: Medical, Operative & Surgical Staging, Prognosis & Natural History, Prevention, Screening & Surveillance - [82]
Vercellini P, Viganò P, Bandini V et al.. “Association of endometriosis and adenomyosis with pregnancy and infertility.” Fertility and sterility (2023). PMID: 36948440 ↗
L5SR_OBSCited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, Acute Management, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, Complications, Prognosis & Natural History - [83]
Zullo F, Spagnolo E, Saccone G et al.. “Endometriosis and obstetrics complications: a systematic review and meta-analysis.” Fertility and sterility (2017). PMID: 28874260 ↗
L2SR_OBSCited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Definitive Management: Medical, Operative & Surgical Staging, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, Complications, Prognosis & Natural History - [84]
Lalani S, Choudhry AJ, Firth B et al.. “Endometriosis and adverse maternal, fetal and neonatal outcomes, a systematic review and meta-analysis.” Human reproduction (Oxford, England) (2018). PMID: 30239732 ↗
L2SR_OBSCited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Acute Management, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, Prognosis & Natural History - [85]
Groeneveld E, Lambers MJ, Lambalk CB et al.. “Preconceptional low-dose aspirin for the prevention of hypertensive pregnancy complications and preterm delivery after IVF: a meta-analysis with individual patient data.” Human reproduction (Oxford, England) (2013). PMID: 23528915 ↗
L1SR_OBSCited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, Acute Management, Definitive Management: Medical, Operative & Surgical Staging, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, Complications - [86]
Busnelli A, Schirripa I, Fedele F et al.. “Obstetric and perinatal outcomes following programmed compared to natural frozen-thawed embryo transfer cycles: a systematic review and meta-analysis.” Human reproduction (Oxford, England) (2022). PMID: 35553678 ↗
L2SR_OBSCited in: Pathophysiology & Mechanism, Severity, Staging & Risk Stratification, Acute Management, Definitive Management: Medical, Operative & Surgical Staging, Complications, Prognosis & Natural History - [87]
Khan GH, Galazis N, Docheva N et al.. “Overlap of proteomics biomarkers between women with pre-eclampsia and PCOS: a systematic review and biomarker database integration.” Human reproduction (Oxford, England) (2014). PMID: 25351721 ↗
L3SR_OBSCited in: Pathophysiology & Mechanism, Acute Management, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy - [88]
Vendittelli F, Barasinski C, Rivière O et al.. “Endometriosis and risk of adverse pregnancy outcomes: a retrospective multicenter cohort study.” Fertility and sterility (2024). PMID: 39089610 ↗
L3COHORTCited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, Acute Management, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, Prognosis & Natural History - [89]
Bourdon M, Santulli P, Beeker N et al.. “Impact of clomiphene citrate on multiple gestation births and perinatal outcomes: a nationwide cohort study.” Fertility and sterility (2025). PMID: 40222700 ↗
L3COHORTCited in: Pathophysiology & Mechanism, Definitive Management: Medical, Operative & Surgical Staging, History and Evolution of Treatment, Complications - [90]
Brännström M, Johannesson L, Bokström H et al.. “Livebirth after uterus transplantation.” Lancet (London, England) (2014). PMID: 25301505 ↗
L4CASE_REPORTCited in: Pathophysiology & Mechanism, Diagnosis & Workup, Fetal Assessment, Antenatal Surveillance & Prenatal Diagnosis, Definitive Management: Medical, Operative & Surgical Staging, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy - [91]
Oyelese Y, Ananth CV. “Placental abruption.” Obstetrics and gynecology (2006). PMID: 17012465 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Fetal Assessment, Antenatal Surveillance & Prenatal Diagnosis, Severity, Staging & Risk Stratification, Definitive Management: Medical, Operative & Surgical Staging, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, Complications, Prognosis & Natural History - [92]
Burwick RM, Rodriguez MH. “Angiogenic Biomarkers in Preeclampsia.” Obstetrics and gynecology (2024). PMID: 38350106 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, Complications, Prognosis & Natural History - [93]
Silver RM. “Fetal death.” Obstetrics and gynecology (2007). PMID: 17197601 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, Acute Management, Definitive Management: Medical, Operative & Surgical Staging, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, Complications, Prevention, Screening & Surveillance - [94]
Hui D, Hladunewich MA. “Chronic Kidney Disease and Pregnancy.” Obstetrics and gynecology (2019). PMID: 31135733 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Diagnosis & Workup, Severity, Staging & Risk Stratification - [95]
Smith GN, Louis JM, Saade GR. “Pregnancy and the Postpartum Period as an Opportunity for Cardiovascular Risk Identification and Management.” Obstetrics and gynecology (2019). PMID: 31503139 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Clinical Presentation - [96]
Hauspurg A, Jeyabalan A. “Postpartum preeclampsia or eclampsia: defining its place and management among the hypertensive disorders of pregnancy.” American journal of obstetrics and gynecology (2021). PMID: 35177218 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Workup, Acute Management, Definitive Management: Medical, Operative & Surgical Staging, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, History and Evolution of Treatment, Complications - [97]
Jung E, Romero R, Yeo L et al.. “The etiology of preeclampsia.” American journal of obstetrics and gynecology (2022). PMID: 35177222 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, Definitive Management: Medical, Operative & Surgical Staging, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy - [98]
Melchiorre K, Giorgione V, Thilaganathan B. “The placenta and preeclampsia: villain or victim?” American journal of obstetrics and gynecology (2021). PMID: 33771361 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, Clinical Presentation, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy - [99]
Fishel Bartal M, Sibai BM. “Eclampsia in the 21st century.” American journal of obstetrics and gynecology (2020). PMID: 32980358 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Acute Management, Definitive Management: Medical, Operative & Surgical Staging, History and Evolution of Treatment, Complications, Prognosis & Natural History - [100]
Chaemsaithong P, Sahota DS, Poon LC. “First trimester preeclampsia screening and prediction.” American journal of obstetrics and gynecology (2020). PMID: 32682859 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Definitive Management: Medical, Operative & Surgical Staging, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, Complications, Prognosis & Natural History, Prevention, Screening & Surveillance - [101]
Burton GJ, Jauniaux E. “Pathophysiology of placental-derived fetal growth restriction.” American journal of obstetrics and gynecology (2018). PMID: 29422210 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Fetal Assessment, Antenatal Surveillance & Prenatal Diagnosis - [102]
Powrie RO. “A 30-year-old woman with chronic hypertension trying to conceive.” JAMA (2007). PMID: 17911500 ↗
L5CASE_REPORTCited in: Pathophysiology & Mechanism, Definitive Management: Medical, Operative & Surgical Staging - [103]
Solnes Miltenburg A, Uwamahoro NS, Mwanga JR et al.. “Developing middle-range theories for the implementation of clinical practice guideline recommendations for pre-eclampsia prevention and management in eastern, central and southern Africa: a realist synthesis protocol.” BMJ open (2026). PMID: 42203303 ↗
L5GUIDELINECited in: Pathophysiology & Mechanism, Acute Management, Definitive Management: Medical, Operative & Surgical Staging, Complications, Prognosis & Natural History - [104]
Goldenberg RL, Culhane JF, Iams JD et al.. “Epidemiology and causes of preterm birth.” Lancet (London, England) (2008). PMID: 18177778 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Acute Management, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy - [105]
Chappell LC, Cluver CA, Kingdom J et al.. “Pre-eclampsia.” Lancet (London, England) (2021). PMID: 34051884 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, Complications - [106]
Steegers EA, von Dadelszen P, Duvekot JJ et al.. “Pre-eclampsia.” Lancet (London, England) (2010). PMID: 20598363 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Clinical Presentation, Definitive Management: Medical, Operative & Surgical Staging, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy - [107]
Ruiz-Irastorza G, Crowther M, Branch W et al.. “Antiphospholipid syndrome.” Lancet (London, England) (2010). PMID: 20822807 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Definitive Management: Medical, Operative & Surgical Staging - [108]
Zeisler H, Llurba E, Chantraine F et al.. “Predictive Value of the sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia.” The New England journal of medicine (2016). PMID: 26735990 ↗
L2OTHERCited in: Pathophysiology & Mechanism, Diagnosis & Workup, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy - [109]
Levine RJ, Lam C, Qian C et al.. “Soluble endoglin and other circulating antiangiogenic factors in preeclampsia.” The New England journal of medicine (2006). PMID: 16957146 ↗
L3OTHERCited in: Pathophysiology & Mechanism - [110]
Behrens I, Basit S, Lykke JA et al.. “Association Between Hypertensive Disorders of Pregnancy and Later Risk of Cardiomyopathy.” JAMA (2016). PMID: 26954411 ↗
L2OTHERCited in: Pathophysiology & Mechanism, Diagnosis & Workup - [111]
Stepan H, Galindo A, Hund M et al.. “Clinical utility of sFlt-1 and PlGF in screening, prediction, diagnosis and monitoring of pre-eclampsia and fetal growth restriction.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2023). PMID: 35816445 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Acute Management, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy - [112]
Tan MY, Syngelaki A, Poon LC et al.. “Screening for pre-eclampsia by maternal factors and biomarkers at 11-13 weeks' gestation.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2018). PMID: 29896812 ↗
L2OTHERCited in: Pathophysiology & Mechanism, Acute Management, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, Prognosis & Natural History - [113]
Sepúlveda-Martínez Á, Rodríguez-López M, Paz Y Miño F et al.. “Transgenerational transmission of small-for-gestational age.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2019). PMID: 30207012 ↗
L2OTHERCited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy - [114]
Nowacka U, Papastefanou I, Bouariu A et al.. “Second-trimester contingent screening for small-for-gestational-age neonate.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2022). PMID: 34214232 ↗
L2OTHERCited in: Pathophysiology & Mechanism, Fetal Assessment, Antenatal Surveillance & Prenatal Diagnosis, Severity, Staging & Risk Stratification - [115]
Moungmaithong S, Wang X, Lau CSL et al.. “Glycosylated fibronectin improves first-trimester prediction of pre-eclampsia.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2023). PMID: 37616523 ↗
L3OTHERCited in: Pathophysiology & Mechanism, Diagnosis & Workup - [116]
Yeung YK, Nguyen-Hoang L, Tse AW et al.. “Longitudinal fetal growth parameters in women at high risk for pre-eclampsia.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2025). PMID: 40776726 ↗
L3OTHERCited in: Pathophysiology & Mechanism, Definitive Management: Medical, Operative & Surgical Staging, Prevention, Screening & Surveillance - [117]
Duley L, Gülmezoglu AM, Henderson-Smart DJ et al.. “Magnesium sulphate and other anticonvulsants for women with pre-eclampsia.” The Cochrane database of systematic reviews (2010). PMID: 21069663 ↗
L1SR_OBSCited in: Pathophysiology & Mechanism, Acute Management, Definitive Management: Medical, Operative & Surgical Staging, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, Complications, Prognosis & Natural History - [118]
Earl R, Crowther CA, Middleton P. “Interventions for hyperthyroidism pre-pregnancy and during pregnancy.” The Cochrane database of systematic reviews (2013). PMID: 24249524 ↗
L1SR_OBSCited in: Pathophysiology & Mechanism, Definitive Management: Medical, Operative & Surgical Staging - [119]
Coyle ME, Smith C, Peat B. “Cephalic version by moxibustion for breech presentation.” The Cochrane database of systematic reviews (2023). PMID: 37158339 ↗
L1SR_OBSCited in: Pathophysiology & Mechanism, Clinical Presentation, Definitive Management: Medical, Operative & Surgical Staging, Complications - [120]
Rumbold A, Ota E, Hori H et al.. “Vitamin E supplementation in pregnancy.” The Cochrane database of systematic reviews (2015). PMID: 26343254 ↗
L1SR_OBSCited in: Pathophysiology & Mechanism - [121]
Rumbold A, Ota E, Nagata C et al.. “Vitamin C supplementation in pregnancy.” The Cochrane database of systematic reviews (2015). PMID: 26415762 ↗
L1SR_OBSCited in: Pathophysiology & Mechanism - [122]
Stampalija T, Gyte GM, Alfirevic Z. “Utero-placental Doppler ultrasound for improving pregnancy outcome.” The Cochrane database of systematic reviews (2010). PMID: 20824875 ↗
L1SR_OBSCited in: Pathophysiology & Mechanism, Fetal Assessment, Antenatal Surveillance & Prenatal Diagnosis - [123]
Haider BA, Bhutta ZA. “Multiple-micronutrient supplementation for women during pregnancy.” The Cochrane database of systematic reviews (2006). PMID: 17054223 ↗
L1SR_OBSCited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors - [124]
Haider BA, Bhutta ZA. “Multiple-micronutrient supplementation for women during pregnancy.” The Cochrane database of systematic reviews (2015). PMID: 26522344 ↗
L1SR_OBSCited in: Pathophysiology & Mechanism, Diagnosis & Workup - [125]
Earl R, Crowther CA, Middleton P. “Interventions for preventing and treating hyperthyroidism in pregnancy.” The Cochrane database of systematic reviews (2010). PMID: 20824882 ↗
L1SR_OBSCited in: Pathophysiology & Mechanism - [126]
Broughton DE, Moley KH. “Obesity and female infertility: potential mediators of obesity's impact.” Fertility and sterility (2017). PMID: 28292619 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Definitive Management: Medical, Operative & Surgical Staging, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, Prognosis & Natural History - [127]
Santamaria X, Taylor H. “MicroRNA and gynecological reproductive diseases.” Fertility and sterility (2014). PMID: 24882618 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy - [128]
Robertson SA, Sharkey DJ. “Seminal fluid and fertility in women.” Fertility and sterility (2016). PMID: 27485480 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, Definitive Management: Medical, Operative & Surgical Staging, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, History and Evolution of Treatment, Prognosis & Natural History - [129]
Tien-Lynn Lee I, Hoofnagle AN, Legro RS et al.. “Vitamin D binding protein and reproductive outcomes.” Fertility and sterility (2025). PMID: 41052748 ↗
L3OTHERCited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, Definitive Management: Medical, Operative & Surgical Staging, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, Complications, Prognosis & Natural History - [130]
Chouinard M, Mayrand MH, Ayoub A et al.. “Ectopic pregnancy and outcomes of future intrauterine pregnancy.” Fertility and sterility (2019). PMID: 31056305 ↗
L2OTHERCited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, Acute Management, Definitive Management: Medical, Operative & Surgical Staging, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, Prognosis & Natural History - [131]
Vigano P, Corti L, Berlanda N. “Beyond infertility: obstetrical and postpartum complications associated with endometriosis and adenomyosis.” Fertility and sterility (2015). PMID: 26348274 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, Clinical Presentation, Definitive Management: Medical, Operative & Surgical Staging - [132]
Moreira GM, Rodríguez-Guzmán R, Marciano NJS et al.. “The hypothalamic-neurohypophyseal system in preeclampsia: a systematic review with a subgroup meta-analysis of copeptin levels worldwide.” Frontiers in endocrinology (2026). PMID: 42375332 ↗
L2SR_OBSCited in: Pathophysiology & Mechanism, Clinical Presentation, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy - [133]
Shepherd J, Frampton G, Kearns B et al.. “Placental growth factor (PLGF)-based testing to help diagnose suspected pre-eclampsia: a systematic review and economic evaluation.” Health technology assessment (Winchester, England) (2026). PMID: 42366875 ↗
L2SR_OBSCited in: Pathophysiology & Mechanism, Clinical Presentation, Diagnosis & Workup, Acute Management, Definitive Management: Medical, Operative & Surgical Staging, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, Complications, Prognosis & Natural History - [134]
Philips EM, Trasande L, Kahn LG et al.. “Early pregnancy bisphenol and phthalate metabolite levels, maternal hemodynamics and gestational hypertensive disorders.” Human reproduction (Oxford, England) (2019). PMID: 30576447 ↗
L2OTHERCited in: Pathophysiology & Mechanism, Epidemiology, Etiology & Risk Factors, Acute Management, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy - [135]
Barjaktarovic M, Korevaar TI, Chaker L et al.. “The association of maternal thyroid function with placental hemodynamics.” Human reproduction (Oxford, England) (2017). PMID: 28130433 ↗
L2OTHERCited in: Pathophysiology & Mechanism - [136]
Koster MP, de Wilde MA, Veltman-Verhulst SM et al.. “Placental characteristics in women with polycystic ovary syndrome.” Human reproduction (Oxford, England) (2015). PMID: 26498178 ↗
L3OTHERCited in: Pathophysiology & Mechanism - [137]
Chen H, Zhang X, Cai S et al.. “Even high normal blood pressure affects live birth rate in women undergoing fresh embryo transfer.” Human reproduction (Oxford, England) (2022). PMID: 36125002 ↗
L3OTHERCited in: Pathophysiology & Mechanism, Diagnosis & Workup, Definitive Management: Medical, Operative & Surgical Staging - [138]
Brännström M, Racowsky C, Wiik J et al.. “Second report of registry of the International Society of Uterus Transplantation (ISUTx): international activities 2000-2024.” Human reproduction (Oxford, England) (2026). PMID: 41701557 ↗
L4OTHERCited in: Pathophysiology & Mechanism, Definitive Management: Medical, Operative & Surgical Staging, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy - [139]
James JL, Saghian R, Perwick R et al.. “Trophoblast plugs: impact on utero-placental haemodynamics and spiral artery remodelling.” Human reproduction (Oxford, England) (2018). PMID: 29955830 ↗
L5OTHERCited in: Pathophysiology & Mechanism - [140]
Chen X, Wang Z, Wang Y et al.. “Incremental prognostic value of the fibrinogen-to-albumin ratio for adverse perinatal outcomes in preeclampsia: a dual-center retrospective cohort study.” Frontiers in endocrinology (2026). PMID: 42290841 ↗
L3COHORTCited in: Pathophysiology & Mechanism, Diagnosis & Workup, Complications, Prognosis & Natural History - [141]
Jansen VLBI, Wiegers HMG, Salet DM et al.. “Heparin to prevent recurrent placenta-mediated pregnancy complications in women with antiphospholipid syndrome: a systematic review.” Research and practice in thrombosis and haemostasis (2026). PMID: 42339498 ↗
L2SR_OBSCited in: Pathophysiology & Mechanism, Acute Management, History and Evolution of Treatment - [142]
Godhamgaonkar A, Kasture V, Joshi S. “Trans fatty acids and pregnancy complications: A systematic review and meta-analysis.” Nutrition research (New York, N.Y.) (2026). PMID: 42190450 ↗
L2SR_OBSCited in: Pathophysiology & Mechanism - [143]
Odunvbun WO, Ukoba O, Isogun JK et al.. “A systematic review of pregnancy outcomes and management in polycystic ovary syndrome.” African journal of reproductive health (2026). PMID: 42202883 ↗
L2SR_OBSCited in: Pathophysiology & Mechanism - [144]
Zhang Z, Du J, Chen T et al.. “Extracellular Vesicle-Associated Non-Coding RNAs in Preeclampsia: Mechanistic Insights, Biomarker Discovery, and Emerging Nanomedicine Concepts.” International journal of nanomedicine (2026). PMID: 42403533 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism - [145]
Obeagu EI. “The Immuno-Cardiovascular Storm of Pre-Eclampsia: Cytokine-Mediated Endothelial Injury, Thrombosis, and Maternal Cardiovascular Instability.” Comprehensive Physiology (2026). PMID: 42381215 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology & Mechanism - [146]
. “Multifetal Gestations: Twin, Triplet, and Higher-Order Multifetal Pregnancies: ACOG Practice Bulletin, Number 231.” Obstetrics and gynecology (2021). PMID: 34011891 ↗
L1GUIDELINECited in: Epidemiology, Etiology & Risk Factors, Fetal Assessment, Antenatal Surveillance & Prenatal Diagnosis, Definitive Management: Medical, Operative & Surgical Staging, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, History and Evolution of Treatment, Complications, Prognosis & Natural History - [147]
Norton ME, Chauhan SP, Dashe JS. “Society for maternal-fetal medicine (SMFM) clinical guideline #7: nonimmune hydrops fetalis.” American journal of obstetrics and gynecology (2014). PMID: 25557883 ↗
L1GUIDELINECited in: Epidemiology, Etiology & Risk Factors, Fetal Assessment, Antenatal Surveillance & Prenatal Diagnosis, Severity, Staging & Risk Stratification, History and Evolution of Treatment, Prognosis & Natural History, Prevention, Screening & Surveillance - [148]
Rolnik DL, Poon LC, Syngelaki A et al.. “Aspirin, Birthweight, and Large-For-Gestational-Age Neonates: A Secondary Analysis of the ASPRE Trial.” BJOG : an international journal of obstetrics and gynaecology (2025). PMID: 40590060 ↗
L2RCTCited in: Epidemiology, Etiology & Risk Factors, Acute Management, Definitive Management: Medical, Operative & Surgical Staging, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, History and Evolution of Treatment, Prognosis & Natural History - [149]
Goadsby J, Syngelaki A, Magee LA et al.. “Scheduled birth at term for the prevention of pre-eclampsia (PREVENT-PE): an open-label randomised controlled trial.” Lancet (London, England) (2025). PMID: 41354041 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Fetal Assessment, Antenatal Surveillance & Prenatal Diagnosis, Severity, Staging & Risk Stratification, Acute Management, Definitive Management: Medical, Operative & Surgical Staging, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, History and Evolution of Treatment, Prognosis & Natural History - [150]
Wei D, Liu JY, Sun Y et al.. “Frozen versus fresh single blastocyst transfer in ovulatory women: a multicentre, randomised controlled trial.” Lancet (London, England) (2019). PMID: 30827784 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification, Acute Management, Definitive Management: Medical, Operative & Surgical Staging, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, History and Evolution of Treatment, Complications, Prognosis & Natural History - [151]
Hoffman MK, Goudar SS, Kodkany BS et al.. “Low-dose aspirin for the prevention of preterm delivery in nulliparous women with a singleton pregnancy (ASPIRIN): a randomised, double-blind, placebo-controlled trial.” Lancet (London, England) (2020). PMID: 31982074 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Acute Management, Definitive Management: Medical, Operative & Surgical Staging, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, History and Evolution of Treatment, Complications, Prognosis & Natural History - [152]
Hofmeyr GJ, Betrán AP, Singata-Madliki M et al.. “Prepregnancy and early pregnancy calcium supplementation among women at high risk of pre-eclampsia: a multicentre, double-blind, randomised, placebo-controlled trial.” Lancet (London, England) (2019). PMID: 30696573 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors - [153]
Davidson KW, Barry MJ, Mangione CM et al.. “Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality: US Preventive Services Task Force Recommendation Statement.” JAMA (2021). PMID: 34581729 ↗
L1GUIDELINECited in: Epidemiology, Etiology & Risk Factors, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, History and Evolution of Treatment, Complications - [154]
Bibbins-Domingo K, Grossman DC, Curry SJ et al.. “Screening for Preeclampsia: US Preventive Services Task Force Recommendation Statement.” JAMA (2017). PMID: 28444286 ↗
L1GUIDELINECited in: Epidemiology, Etiology & Risk Factors, Acute Management, Definitive Management: Medical, Operative & Surgical Staging, History and Evolution of Treatment, Complications, Prevention, Screening & Surveillance - [155]
Rolnik DL, Wright D, Poon LC et al.. “Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia.” The New England journal of medicine (2017). PMID: 28657417 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Acute Management, Definitive Management: Medical, Operative & Surgical Staging, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, History and Evolution of Treatment, Complications, Prognosis & Natural History - [156]
Simmons D, Immanuel J, Hague WM et al.. “Treatment of Gestational Diabetes Mellitus Diagnosed Early in Pregnancy.” The New England journal of medicine (2023). PMID: 37144983 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Acute Management, Definitive Management: Medical, Operative & Surgical Staging, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, History and Evolution of Treatment, Prognosis & Natural History - [157]
Hillier TA, Pedula KL, Ogasawara KK et al.. “A Pragmatic, Randomized Clinical Trial of Gestational Diabetes Screening.” The New England journal of medicine (2021). PMID: 33704936 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Acute Management, Definitive Management: Medical, Operative & Surgical Staging, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, History and Evolution of Treatment, Complications, Prognosis & Natural History, Prevention, Screening & Surveillance - [158]
Dwarkanath P, Muhihi A, Sudfeld CR et al.. “Two Randomized Trials of Low-Dose Calcium Supplementation in Pregnancy.” The New England journal of medicine (2024). PMID: 38197817 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Acute Management, Definitive Management: Medical, Operative & Surgical Staging, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, History and Evolution of Treatment, Prognosis & Natural History - [159]
Rumbold AR, Crowther CA, Haslam RR et al.. “Vitamins C and E and the risks of preeclampsia and perinatal complications.” The New England journal of medicine (2006). PMID: 16641396 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Acute Management, Definitive Management: Medical, Operative & Surgical Staging, History and Evolution of Treatment, Complications, Prognosis & Natural History - [160]
Syngelaki A, Nicolaides KH, Balani J et al.. “Metformin versus Placebo in Obese Pregnant Women without Diabetes Mellitus.” The New England journal of medicine (2016). PMID: 26840133 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Acute Management, Definitive Management: Medical, Operative & Surgical Staging, History and Evolution of Treatment, Prognosis & Natural History - [161]
Hup RJ, Damen JAA, Terstappen J et al.. “Oral antihypertensive treatment during pregnancy: a systematic review and network meta-analysis.” American journal of obstetrics and gynecology (2025). PMID: 40216176 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Definitive Management: Medical, Operative & Surgical Staging, Complications, Prognosis & Natural History - [162]
Yang J, Song Y, Gaskins AJ et al.. “Mediterranean diet and female reproductive health over lifespan: a systematic review and meta-analysis.” American journal of obstetrics and gynecology (2023). PMID: 37506751 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Definitive Management: Medical, Operative & Surgical Staging, Prognosis & Natural History, Special Populations - [163]
Al Khalaf S, Bodunde E, Maher GM et al.. “Chronic kidney disease and adverse pregnancy outcomes: a systematic review and meta-analysis.” American journal of obstetrics and gynecology (2021). PMID: 34736915 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, Complications, Prognosis & Natural History - [164]
Roberge S, Bujold E, Nicolaides KH. “Aspirin for the prevention of preterm and term preeclampsia: systematic review and metaanalysis.” American journal of obstetrics and gynecology (2017). PMID: 29138036 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Definitive Management: Medical, Operative & Surgical Staging - [165]
Kitt J, Fox R, Frost A et al.. “Long-Term Blood Pressure Control After Hypertensive Pregnancy Following Physician-Optimized Self-Management: The POP-HT Randomized Clinical Trial.” JAMA (2023). PMID: 37950919 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Acute Management, Definitive Management: Medical, Operative & Surgical Staging, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, History and Evolution of Treatment, Prognosis & Natural History - [166]
van der Wel AWT, Frank CMC, Bout-Rebel R et al.. “Myo-inositol Supplementation to Prevent Pregnancy Complications in Polycystic Ovary Syndrome: A Randomized Clinical Trial.” JAMA (2025). PMID: 40920401 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Acute Management, Definitive Management: Medical, Operative & Surgical Staging, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, History and Evolution of Treatment, Complications, Prognosis & Natural History - [167]
Crovetto F, Crispi F, Casas R et al.. “Effects of Mediterranean Diet or Mindfulness-Based Stress Reduction on Prevention of Small-for-Gestational Age Birth Weights in Newborns Born to At-Risk Pregnant Individuals: The IMPACT BCN Randomized Clinical Trial.” JAMA (2021). PMID: 34874420 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors, Acute Management, Definitive Management: Medical, Operative & Surgical Staging, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, History and Evolution of Treatment, Complications, Prognosis & Natural History - [168]
Santos S, Voerman E, Amiano P et al.. “Impact of maternal body mass index and gestational weight gain on pregnancy complications: an individual participant data meta-analysis of European, North American and Australian cohorts.” BJOG : an international journal of obstetrics and gynaecology (2019). PMID: 30786138 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Acute Management, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, Complications, Prognosis & Natural History - [169]
Arechvo A, Voicu D, Gil MM et al.. “Maternal race and pre-eclampsia: Cohort study and systematic review with meta-analysis.” BJOG : an international journal of obstetrics and gynaecology (2022). PMID: 35620879 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Acute Management, History and Evolution of Treatment - [170]
Jaskolka D, Retnakaran R, Zinman B et al.. “Fetal sex and maternal risk of pre-eclampsia/eclampsia: a systematic review and meta-analysis.” BJOG : an international journal of obstetrics and gynaecology (2016). PMID: 27315789 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, Prognosis & Natural History - [171]
Makama M, McDougall ARA, Cao J et al.. “L-Arginine and L-Citrulline for Prevention and Treatment of Pre-Eclampsia: A Systematic Review and Meta-Analysis.” BJOG : an international journal of obstetrics and gynaecology (2025). PMID: 39800868 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Acute Management, Definitive Management: Medical, Operative & Surgical Staging, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, Prognosis & Natural History - [172]
Lipworth H, Barrett J, Murphy KE et al.. “Gestational weight gain in twin gestations and pregnancy outcomes: a systematic review and meta-analysis.” BJOG : an international journal of obstetrics and gynaecology (2021). PMID: 34775675 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Complications, Prognosis & Natural History - [173]
van der Slink LL, Scholten I, van Etten-Jamaludin FS et al.. “Pregnancy in women with liver cirrhosis is associated with increased risk for complications: A systematic review and meta-analysis of the literature.” BJOG : an international journal of obstetrics and gynaecology (2022). PMID: 35319158 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors - [174]
Xiong X, Buekens P, Fraser WD et al.. “Periodontal disease and adverse pregnancy outcomes: a systematic review.” BJOG : an international journal of obstetrics and gynaecology (2006). PMID: 16411989 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Definitive Management: Medical, Operative & Surgical Staging, Prevention, Screening & Surveillance - [175]
Pittara T, Vyrides A, Lamnisos D et al.. “Pre-eclampsia and long-term health outcomes for mother and infant: an umbrella review.” BJOG : an international journal of obstetrics and gynaecology (2021). PMID: 33638891 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Acute Management - [176]
Singh M, Wambua S, Lee SI et al.. “Autoimmune diseases and adverse pregnancy outcomes: an umbrella review.” Lancet (London, England) (2023). PMID: 37997130 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Acute Management, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, Prognosis & Natural History - [177]
Campbell M, Koegl J, Bone JN et al.. “Differences in Risk Factors for Severe Preeclampsia and HELLP Syndrome in Singleton Versus Twin Pregnancies: A Population-Based Cohort Study.” BJOG : an international journal of obstetrics and gynaecology (2025). PMID: 40887753 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors, History and Evolution of Treatment - [178]
Henderson JT, Vesco KK, Senger CA et al.. “Aspirin Use to Prevent Preeclampsia and Related Morbidity and Mortality: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.” JAMA (2021). PMID: 34581730 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Acute Management, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, Complications, Prognosis & Natural History, Prevention, Screening & Surveillance - [179]
Cantor AG, Jungbauer RM, McDonagh M et al.. “Counseling and Behavioral Interventions for Healthy Weight and Weight Gain in Pregnancy: Evidence Report and Systematic Review for the US Preventive Services Task Force.” JAMA (2021). PMID: 34032824 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Acute Management, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, Complications, Prognosis & Natural History, Prevention, Screening & Surveillance - [180]
D'antonio F, Prasad S, Masciullo L et al.. “Selective fetal growth restriction in dichorionic diamniotic twin pregnancy: systematic review and meta-analysis of pregnancy and perinatal outcomes.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2024). PMID: 37519089 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Acute Management, Definitive Management: Medical, Operative & Surgical Staging, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, Complications, Prognosis & Natural History - [181]
Jansen G, de Rooy A, Janssen E et al.. “Atherosclerosis after pre-eclampsia: systematic review and meta-analysis.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2025). PMID: 40886380 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Acute Management, Definitive Management: Medical, Operative & Surgical Staging, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, Complications, Prevention, Screening & Surveillance - [182]
Roberge S, Demers S, Nicolaides KH et al.. “Prevention of pre-eclampsia by low-molecular-weight heparin in addition to aspirin: a meta-analysis.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2016). PMID: 26481090 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Definitive Management: Medical, Operative & Surgical Staging, History and Evolution of Treatment, Prognosis & Natural History - [183]
Huang M, Xie W, Kang L et al.. “Development and validation of prediction model for pre-eclampsia-related maternal adverse outcome: retrospective cohort study.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2025). PMID: 40878350 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Workup, Severity, Staging & Risk Stratification, Complications - [184]
Mills G, Badeghiesh A, Suarthana E et al.. “Polycystic ovary syndrome as an independent risk factor for gestational diabetes and hypertensive disorders of pregnancy: a population-based study on 9.1 million pregnancies.” Human reproduction (Oxford, England) (2020). PMID: 32535629 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy - [185]
Glavind MT, Forman A, Arendt LH et al.. “Endometriosis and pregnancy complications: a Danish cohort study.” Fertility and sterility (2016). PMID: 27743699 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Acute Management, Definitive Management: Medical, Operative & Surgical Staging - [186]
Wei SQ, Bilodeau-Bertrand M, Auger N. “Association of PCOS with offspring morbidity: a longitudinal cohort study.” Human reproduction (Oxford, England) (2022). PMID: 35830879 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Acute Management, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, Complications, Prognosis & Natural History - [187]
Chen X, Gissler M, Lavebratt C. “Association of maternal polycystic ovary syndrome and diabetes with preterm birth and offspring birth size: a population-based cohort study.” Human reproduction (Oxford, England) (2022). PMID: 35348682 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Diagnosis & Workup - [188]
Sigelko AD, Strek ME, Wolfe KS. “Asthma in Pregnancy.” Obstetrics and gynecology (2025). PMID: 40472372 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Definitive Management: Medical, Operative & Surgical Staging, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, History and Evolution of Treatment, Complications, Prognosis & Natural History - [189]
Do SC, Leonard SA, Kan P et al.. “Postpartum Readmission for Hypertension After Discharge on Labetalol or Nifedipine.” Obstetrics and gynecology (2022). PMID: 36075068 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Severity, Staging & Risk Stratification, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy - [190]
. “ACOG Committee Opinion No. 743: Low-Dose Aspirin Use During Pregnancy.” Obstetrics and gynecology (2018). PMID: 29939940 ↗
L1OTHERCited in: Epidemiology, Etiology & Risk Factors, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, Prevention, Screening & Surveillance - [191]
. “ACOG Committee Opinion No. 767: Emergent Therapy for Acute-Onset, Severe Hypertension During Pregnancy and the Postpartum Period.” Obstetrics and gynecology (2019). PMID: 30575639 ↗
L1OTHERCited in: Epidemiology, Etiology & Risk Factors, Acute Management, Definitive Management: Medical, Operative & Surgical Staging - [192]
Erez O, Besser L, Schwartz AD et al.. “DIC in pregnancy: lessons from an international registry of the International Society for Thrombosis and Hemostasis: Communication from the SSC of the ISTH.” Journal of thrombosis and haemostasis : JTH (2026). PMID: 42362026 ↗
L5GUIDELINECited in: Epidemiology, Etiology & Risk Factors, History and Evolution of Treatment - [193]
Vikse BE, Irgens LM, Leivestad T et al.. “Preeclampsia and the risk of end-stage renal disease.” The New England journal of medicine (2008). PMID: 18716297 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup - [194]
Garg AX, Nevis IF, McArthur E et al.. “Gestational hypertension and preeclampsia in living kidney donors.” The New England journal of medicine (2014). PMID: 25397608 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup - [195]
Zou L, Li H, Shi Y et al.. “The hemodynamic effects of bolus norepinephrine and phenylephrine in the treatment of hypotensive events in preeclamptic women with severe features following spinal anesthesia during cesarean section: a randomized controlled trial.” Frontiers in pharmacology (2026). PMID: 42428501 ↗
L1RCTCited in: Epidemiology, Etiology & Risk Factors - [196]
Hooijschuur MCE, Ghossein-Doha C, Kroon AA et al.. “Metabolic syndrome and pre-eclampsia.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2019). PMID: 30246464 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Acute Management, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, History and Evolution of Treatment - [197]
Arechvo A, Wright A, Syngelaki A et al.. “Incidence of pre-eclampsia: effect of deprivation.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2023). PMID: 36178775 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, History and Evolution of Treatment, Prognosis & Natural History - [198]
Middleton P, Gomersall JC, Gould JF et al.. “Omega-3 fatty acid addition during pregnancy.” The Cochrane database of systematic reviews (2018). PMID: 30480773 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Acute Management, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, Complications, Prognosis & Natural History - [199]
Brown J, Alwan NA, West J et al.. “Lifestyle interventions for the treatment of women with gestational diabetes.” The Cochrane database of systematic reviews (2017). PMID: 28472859 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Acute Management, Definitive Management: Medical, Operative & Surgical Staging, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, Complications, Prognosis & Natural History - [200]
Rumbold A, Duley L, Crowther CA et al.. “Antioxidants for preventing pre-eclampsia.” The Cochrane database of systematic reviews (2008). PMID: 18254042 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Definitive Management: Medical, Operative & Surgical Staging, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy - [201]
Churchill D, Beevers GD, Meher S et al.. “Diuretics for preventing pre-eclampsia.” The Cochrane database of systematic reviews (2007). PMID: 17253507 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors - [202]
Kramer MS. “WITHDRAWN: Nutritional advice in pregnancy.” The Cochrane database of systematic reviews (2007). PMID: 17636602 ↗
L5SR_OBSCited in: Epidemiology, Etiology & Risk Factors, History and Evolution of Treatment - [203]
Reid SM, Middleton P, Cossich MC et al.. “Interventions for clinical and subclinical hypothyroidism pre-pregnancy and during pregnancy.” The Cochrane database of systematic reviews (2013). PMID: 23728666 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors - [204]
Meher S, Duley L. “Garlic for preventing pre-eclampsia and its complications.” The Cochrane database of systematic reviews (2006). PMID: 16856110 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors - [205]
Salam RA, Zuberi NF, Bhutta ZA. “Pyridoxine (vitamin B6) supplementation during pregnancy or labour for maternal and neonatal outcomes.” The Cochrane database of systematic reviews (2015). PMID: 26039815 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors - [206]
Sites CK, Wilson D, Barsky M et al.. “Embryo cryopreservation and preeclampsia risk.” Fertility and sterility (2017). PMID: 28974308 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, Prognosis & Natural History, Prevention, Screening & Surveillance - [207]
Calanchini M, Aye CYL, Orchard E et al.. “Fertility issues and pregnancy outcomes in Turner syndrome.” Fertility and sterility (2020). PMID: 32622407 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Definitive Management: Medical, Operative & Surgical Staging - [208]
Li L, Du X. “Association between blood lipid levels and preeclampsia: a meta-analysis.” Frontiers in medicine (2026). PMID: 42328555 ↗
L2SR_OBSCited in: Epidemiology, Etiology & Risk Factors - [209]
Vinogradov R, Holden E, Patel M et al.. “Model Development on Adherence to Aspirin in Pregnancy: A Co-Produced Qualitative Systematic Review and Meta-Ethnography.” Health expectations : an international journal of public participation in health care and health policy (2026). PMID: 42283318 ↗
L5SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Acute Management, Definitive Management: Medical, Operative & Surgical Staging - [210]
Bernard V, Donadille B, Zenaty D et al.. “Spontaneous fertility and pregnancy outcomes amongst 480 women with Turner syndrome.” Human reproduction (Oxford, England) (2016). PMID: 26874361 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors - [211]
Li J, Eriksson M, Czene K et al.. “Common diseases as determinants of menopausal age.” Human reproduction (Oxford, England) (2016). PMID: 27798047 ↗
L4OTHERCited in: Epidemiology, Etiology & Risk Factors, Diagnosis & Workup, Definitive Management: Medical, Operative & Surgical Staging, Special Populations - [212]
Stephansson O, Kieler H, Granath F et al.. “Endometriosis, assisted reproduction technology, and risk of adverse pregnancy outcome.” Human reproduction (Oxford, England) (2009). PMID: 19439428 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, Complications, Prognosis & Natural History - [213]
van Hooff MHA, Caanen MR, Peters HE et al.. “Adolescent menstrual cycle pattern, body mass index, endocrine and ovarian ultrasound characteristics of PCOS and future fertility, cardiovascular-, and metabolic health: a 25-year longitudinal follow-up study.” Human reproduction (Oxford, England) (2025). PMID: 39656822 ↗
L2OTHERCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Severity, Staging & Risk Stratification, Acute Management, Definitive Management: Medical, Operative & Surgical Staging, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, History and Evolution of Treatment, Special Populations - [214]
Chen Y, Zhan Z, Wan S et al.. “Preoperative risk score for invasive uterus-sparing hemostasis at cesarean delivery: a retrospective cohort study.” BMC pregnancy and childbirth (2026). PMID: 42410551 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors - [215]
Tavares ALT, Pasa VD, de Jesus Fernandes Martins Lima JF et al.. “Protocol for the ECLIPSE-BRAZIL: a prospective cohort study on biomarkers and risk stratification for Preeclampsia.” BMC pregnancy and childbirth (2026). PMID: 42393560 ↗
L5COHORTCited in: Epidemiology, Etiology & Risk Factors, Clinical Presentation, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy - [216]
Katholm KK, Eriksen LK, Lycke KD et al.. “Active surveillance of cervical intraepithelial neoplasia and adverse pregnancy outcomes: A register-based cohort study.” Acta obstetricia et gynecologica Scandinavica (2026). PMID: 42383805 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy - [217]
Zhu Y, Yu Y, Jin Z et al.. “Adverse pregnancy outcomes and risk factors in women with primary Sjögren's syndrome: data from a prospective study.” Frontiers in reproductive health (2026). PMID: 42293234 ↗
L2COHORTCited in: Epidemiology, Etiology & Risk Factors - [218]
Wang C, You C, Zhang Y. “Nutritional supplements for preventing preeclampsia: A network meta-analysis.” The Indian journal of medical research (2026). PMID: 42397815 ↗
L1SR_OBSCited in: Epidemiology, Etiology & Risk Factors, Acute Management, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy - [219]
Germar MJCV, Palileo-Villanueva LM, Suplido SAL et al.. “Philippine Clinical Practice Guidelines for Periodic Health Examination: Screening for Prenatal Disorders.” Acta medica Philippina (2026). PMID: 42382932 ↗
L1GUIDELINECited in: Epidemiology, Etiology & Risk Factors - [220]
McCance DR, Holmes VA, Maresh MJ et al.. “Vitamins C and E for prevention of pre-eclampsia in women with type 1 diabetes (DAPIT): a randomised placebo-controlled trial.” Lancet (London, England) (2010). PMID: 20580423 ↗
L1RCTCited in: Clinical Presentation - [221]
Gupta M, Govindappagari S, Burwick RM. “Pregnancy-Associated Atypical Hemolytic Uremic Syndrome: A Systematic Review.” Obstetrics and gynecology (2020). PMID: 31809447 ↗
L4SR_OBSCited in: Clinical Presentation, Diagnosis & Workup, Acute Management - [222]
Elharram M, Dayan N, Kaur A et al.. “Long-Term Cognitive Impairment After Preeclampsia: A Systematic Review and Meta-analysis.” Obstetrics and gynecology (2018). PMID: 29995746 ↗
L2SR_OBSCited in: Clinical Presentation, Diagnosis & Workup, History and Evolution of Treatment - [223]
DeNicola N, Grossman D, Marko K et al.. “Telehealth Interventions to Improve Obstetric and Gynecologic Health Outcomes: A Systematic Review.” Obstetrics and gynecology (2020). PMID: 31977782 ↗
L2SR_OBSCited in: Clinical Presentation - [224]
Conde-Agudelo A, Romero R. “SARS-CoV-2 infection during pregnancy and risk of preeclampsia: a systematic review and meta-analysis.” American journal of obstetrics and gynecology (2021). PMID: 34302772 ↗
L2SR_OBSCited in: Clinical Presentation - [225]
Pamidi S, Pinto LM, Marc I et al.. “Maternal sleep-disordered breathing and adverse pregnancy outcomes: a systematic review and metaanalysis.” American journal of obstetrics and gynecology (2013). PMID: 23911687 ↗
L2SR_OBSCited in: Clinical Presentation - [226]
Nguyen PY, Sanderson B, Makama M et al.. “Polyphenols for the Prevention or Management of Preeclampsia: A Systematic Review and Meta-Analysis.” BJOG : an international journal of obstetrics and gynaecology (2025). PMID: 40025969 ↗
L1SR_OBSCited in: Clinical Presentation, Definitive Management: Medical, Operative & Surgical Staging, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, Prognosis & Natural History - [227]
Langton K, Tufton N, Akker S et al.. “Pregnancy and phaeochromocytoma/paraganglioma: clinical clues affecting diagnosis and outcome - a systematic review.” BJOG : an international journal of obstetrics and gynaecology (2021). PMID: 33342020 ↗
L4SR_OBSCited in: Clinical Presentation, Diagnosis & Workup, Fetal Assessment, Antenatal Surveillance & Prenatal Diagnosis, Acute Management, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, History and Evolution of Treatment, Complications, Prognosis & Natural History - [228]
Cheung KW, Tan LN, Meher S. “Clinical algorithms for the management of intrapartum maternal urine abnormalities.” BJOG : an international journal of obstetrics and gynaecology (2022). PMID: 35415941 ↗
L5SR_OBSCited in: Clinical Presentation, Definitive Management: Medical, Operative & Surgical Staging, History and Evolution of Treatment - [229]
Forrest M, Matossian M, Papacostas Quintanilla H et al.. “Anxiety and Arterial Stiffness in High-Risk Pregnancies: A Secondary Analysis of a Prospective Cohort Study.” BJOG : an international journal of obstetrics and gynaecology (2025). PMID: 40776677 ↗
L2COHORTCited in: Clinical Presentation, Diagnosis & Workup, Severity, Staging & Risk Stratification, History and Evolution of Treatment - [230]
Hayes-Ryan D, Meaney S, Fitzgerald AP et al.. “A prospective study of placental growth factor in twin pregnancy and development of a dichorionic twin pregnancy specific reference range.” BJOG : an international journal of obstetrics and gynaecology (2020). PMID: 32946654 ↗
L2COHORTCited in: Clinical Presentation - [231]
Tuovinen S, Räikkönen K, Kajantie E et al.. “Depressive symptoms in adulthood and intrauterine exposure to pre-eclampsia: the Helsinki Birth Cohort Study.” BJOG : an international journal of obstetrics and gynaecology (2010). PMID: 20560943 ↗
L3COHORTCited in: Clinical Presentation - [232]
Salmeri N, Pizzetti A, Grassi E et al.. “Multiple pregnancy with complete hydatidiform mole and coexisting normal fetus: systematic review and meta-analysis of clinical outcomes from non-randomized studies.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2025). PMID: 41066778 ↗
L2SR_OBSCited in: Clinical Presentation, Diagnosis & Workup, Fetal Assessment, Antenatal Surveillance & Prenatal Diagnosis, Severity, Staging & Risk Stratification - [233]
Ni X, Su X, Shi Y et al.. “Association between adenomyosis volume and adverse perinatal outcomes: multicenter cohort study.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2024). PMID: 39482801 ↗
L3COHORTCited in: Clinical Presentation, Severity, Staging & Risk Stratification, Complications - [234]
Dawoud SA, Silverman JIM, Chung SM. “Postpartum Recovery From Meningioma-Related Oculomotor Palsy.” Obstetrics and gynecology (2021). PMID: 33706360 ↗
L4CASE_REPORTCited in: Clinical Presentation, Fetal Assessment, Antenatal Surveillance & Prenatal Diagnosis - [235]
Scime NV, Velez MP, Choi MY et al.. “Association between infertility and incident onset of systemic autoimmune rheumatic disease after childbirth: a population-based cohort study.” Human reproduction (Oxford, England) (2025). PMID: 39656875 ↗
L2COHORTCited in: Clinical Presentation, Diagnosis & Workup - [236]
Dombrowski MP. “Asthma and pregnancy.” Obstetrics and gynecology (2006). PMID: 16946229 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Severity, Staging & Risk Stratification, Definitive Management: Medical, Operative & Surgical Staging - [237]
Cunningham FG, Twickler DM. “Neurocysticercosis Complicating Pregnancy.” Obstetrics and gynecology (2022). PMID: 35852272 ↗
L4OTHERCited in: Clinical Presentation - [238]
Rana S, Burke SD, Karumanchi SA. “Imbalances in circulating angiogenic factors in the pathophysiology of preeclampsia and related disorders.” American journal of obstetrics and gynecology (2020). PMID: 33096092 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Diagnosis & Workup, Severity, Staging & Risk Stratification - [239]
Cagino K, Prabhu M, Sibai B. “Is magnesium sulfate therapy warranted in all cases of late postpartum severe hypertension? A suggested approach to a clinical conundrum.” American journal of obstetrics and gynecology (2023). PMID: 37467840 ↗
L5OTHERCited in: Clinical Presentation, Acute Management - [240]
Sibai BM, Stella CL. “Diagnosis and management of atypical preeclampsia-eclampsia.” American journal of obstetrics and gynecology (2008). PMID: 19019323 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation - [241]
Aukes AM, De Groot JC, Wiegman MJ et al.. “Long-term cerebral imaging after pre-eclampsia.” BJOG : an international journal of obstetrics and gynaecology (2012). PMID: 22703533 ↗
L2OTHERCited in: Clinical Presentation - [242]
Akhtar MA, Saravelos SH, Li TC et al.. “Reproductive Implications and Management of Congenital Uterine Anomalies: Scientific Impact Paper No. 62 November 2019.” BJOG : an international journal of obstetrics and gynaecology (2019). PMID: 31749334 ↗
L1REVIEW_NARRATIVECited in: Clinical Presentation - [243]
Mol BWJ, Roberts CT, Thangaratinam S et al.. “Pre-eclampsia.” Lancet (London, England) (2015). PMID: 26342729 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation, Definitive Management: Medical, Operative & Surgical Staging - [244]
McCarthy F, Doyle A, Khashan A et al.. “Assessment of glycogen phosphorylase isoenzyme BB as a biomarker for pre-eclampsia and small for gestational age.” Lancet (London, England) (2015). PMID: 26312889 ↗
L3OTHERCited in: Clinical Presentation - [245]
Grgic O, Radakovic B, Barisic D. “Hyperreactio luteinalis could be a risk factor for development of HELLP syndrome: case report.” Fertility and sterility (2008). PMID: 18829007 ↗
L4CASE_REPORTCited in: Clinical Presentation, Fetal Assessment, Antenatal Surveillance & Prenatal Diagnosis - [246]
Soto-Torres E, Hernandez-Andrade E, Huntley E et al.. “Ultrasound and Doppler findings in pregnant women with SARS-CoV-2 infection.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2021). PMID: 33794060 ↗
L3OTHERCited in: Clinical Presentation - [247]
Gyselaers W, Mullens W, Tomsin K et al.. “Role of dysfunctional maternal venous hemodynamics in the pathophysiology of pre-eclampsia: a review.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2011). PMID: 21611996 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation - [248]
Ling HZ, Jara PG, Nicolaides KH et al.. “Impact of maternal height, weight at presentation and gestational weight gain on cardiac adaptation in pregnancy.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2022). PMID: 35020246 ↗
L2OTHERCited in: Clinical Presentation - [249]
Company Calabuig AM, Nunez E, Georgiopoulos G et al.. “Three-dimensional echocardiography and strain cardiac imaging in women with pre-eclampsia with follow-up to 6 months postpartum.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2023). PMID: 37550920 ↗
L2OTHERCited in: Clinical Presentation - [250]
de Sonnaville CMW, Hukkelhoven CW, Vlemmix F et al.. “Impact of Hypertension and Preeclampsia Intervention Trial At Near Term-I (HYPITAT-I) on obstetric management and outcome in The Netherlands.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2019). PMID: 31486156 ↗
L2OTHERCited in: Clinical Presentation - [251]
Sokratous N, Bednorz M, Wright A et al.. “Prediction using serum glycosylated fibronectin of imminent pre-eclampsia in women with new-onset hypertension.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2023). PMID: 37606310 ↗
L2OTHERCited in: Clinical Presentation - [252]
Zhang J, Wu TX, Liu GJ. “Chinese herbal medicine for the treatment of pre-eclampsia.” The Cochrane database of systematic reviews (2006). PMID: 16625625 ↗
L1SR_OBSCited in: Clinical Presentation - [253]
Xu Z, Zhao F, Lin F et al.. “Preeclampsia is associated with a deficiency of lipoxin A4, an endogenous anti-inflammatory mediator.” Fertility and sterility (2014). PMID: 24796762 ↗
L5OTHERCited in: Clinical Presentation - [254]
Beneventi F, Locatelli E, Alpini C et al.. “Association between previously unknown connective tissue disease and subclinical hypothyroidism diagnosed during first trimester of pregnancy.” Fertility and sterility (2015). PMID: 26297901 ↗
L3OTHERCited in: Clinical Presentation - [255]
Engels Calvo V, Cruz Melguizo S, Abascal-Saiz A et al.. “Perinatal outcomes of pregnancies resulting from assisted reproduction technology in SARS-CoV-2-infected women: a prospective observational study.” Fertility and sterility (2021). PMID: 33972083 ↗
L2OTHERCited in: Clinical Presentation - [256]
Krieg SA, Henne MB, Westphal LM. “Obstetric outcomes in donor oocyte pregnancies compared with advanced maternal age in in vitro fertilization pregnancies.” Fertility and sterility (2007). PMID: 17727845 ↗
L3OTHERCited in: Clinical Presentation - [257]
Yi C, Cheng P, Peng N et al.. “Association between maternal depressive symptoms during pregnancy and the risk of preeclampsia: a meta-analysis.” Frontiers in psychiatry (2026). PMID: 41918587 ↗
L1SR_OBSCited in: Clinical Presentation - [258]
Hermans SP, Arreguin AN, Ma J et al.. “Racial Disparities in U.S. Peripartum Cardiomyopathy: Systematic Review and Meta-Analysis of Risk Factors and Outcomes.” JACC. Advances (2026). PMID: 41844488 ↗
L1SR_OBSCited in: Clinical Presentation - [259]
Dai Y, Diao Z, Sun H et al.. “MicroRNA-155 is involved in the remodelling of human-trophoblast-derived HTR-8/SVneo cells induced by lipopolysaccharides.” Human reproduction (Oxford, England) (2011). PMID: 21515911 ↗
L5OTHERCited in: Clinical Presentation - [260]
Saignes H, Romain-Scelle N, Labrune E et al.. “Live birth after oocyte donation in women with Turner syndrome compared with other causes of premature ovarian insufficiency: a retrospective cohort study.” Journal of assisted reproduction and genetics (2026). PMID: 42183950 ↗
L3COHORTCited in: Clinical Presentation - [261]
Hastie R, Ahmed F, Mehdipour P et al.. “Identifying novel prodromal symptoms of eclampsia: A two-country, case-control study.” PLoS medicine (2026). PMID: 42048280 ↗
L3CASE_CONTROLCited in: Clinical Presentation, Definitive Management: Medical, Operative & Surgical Staging - [262]
Keryakos HKH, Youssuf AM, El-Ela MA et al.. “Urinary transcription factor 21 (TCF21) as a non-invasive biomarker of podocyte injury in preeclampsia: diagnostic performance and translational insights from a case-control study.” BMC pregnancy and childbirth (2026). PMID: 41998596 ↗
L3CASE_CONTROLCited in: Clinical Presentation - [263]
. “Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin, Number 222.” Obstetrics and gynecology (2020). PMID: 32443079 ↗
L1GUIDELINECited in: Diagnosis & Workup, Fetal Assessment, Antenatal Surveillance & Prenatal Diagnosis, Definitive Management: Medical, Operative & Surgical Staging, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, History and Evolution of Treatment, Complications - [264]
. “ACOG Practice Bulletin No. 202: Gestational Hypertension and Preeclampsia.” Obstetrics and gynecology (2019). PMID: 30575675 ↗
L1GUIDELINECited in: Diagnosis & Workup, Fetal Assessment, Antenatal Surveillance & Prenatal Diagnosis, Definitive Management: Medical, Operative & Surgical Staging, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, History and Evolution of Treatment, Complications - [265]
Metz TD, Kuo HC, Harper L et al.. “Optimal Timing of Delivery for Pregnant Individuals With Mild Chronic Hypertension.” Obstetrics and gynecology (2024). PMID: 39013178 ↗
L2RCTCited in: Diagnosis & Workup, Acute Management, Definitive Management: Medical, Operative & Surgical Staging, History and Evolution of Treatment, Prognosis & Natural History - [266]
Tucker KL, Mort S, Yu LM et al.. “Effect of Self-monitoring of Blood Pressure on Diagnosis of Hypertension During Higher-Risk Pregnancy: The BUMP 1 Randomized Clinical Trial.” JAMA (2022). PMID: 35503346 ↗
L1RCTCited in: Diagnosis & Workup, Acute Management, Definitive Management: Medical, Operative & Surgical Staging - [267]
Lees C, Marlow N, Arabin B et al.. “Perinatal morbidity and mortality in early-onset fetal growth restriction: cohort outcomes of the trial of randomized umbilical and fetal flow in Europe (TRUFFLE).” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2013). PMID: 24078432 ↗
L2RCTCited in: Diagnosis & Workup, Fetal Assessment, Antenatal Surveillance & Prenatal Diagnosis, Severity, Staging & Risk Stratification, Acute Management, Definitive Management: Medical, Operative & Surgical Staging, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, History and Evolution of Treatment, Complications, Prognosis & Natural History - [268]
Wright D, Wright A, Magee LA et al.. “Calcium supplementation for the prevention of pre-eclampsia: Challenging the evidence from meta-analyses.” BJOG : an international journal of obstetrics and gynaecology (2024). PMID: 38302677 ↗
L1SR_OBSCited in: Diagnosis & Workup, Acute Management, Definitive Management: Medical, Operative & Surgical Staging, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, Prognosis & Natural History - [269]
Cnossen JS, Leeflang MM, de Haan EE et al.. “Accuracy of body mass index in predicting pre-eclampsia: bivariate meta-analysis.” BJOG : an international journal of obstetrics and gynaecology (2007). PMID: 17903233 ↗
L1SR_OBSCited in: Diagnosis & Workup, Severity, Staging & Risk Stratification - [270]
Elbarbary N, Pritsini F, Kazi A et al.. “Point-of-Care Tests for Preeclampsia: Systematic Review and Meta-Analysis of Diagnostic Test Accuracy Studies.” BJOG : an international journal of obstetrics and gynaecology (2024). PMID: 39663778 ↗
L1SR_OBSCited in: Diagnosis & Workup - [271]
Piccoli GB, Daidola G, Attini R et al.. “Kidney biopsy in pregnancy: evidence for counselling? A systematic narrative review.” BJOG : an international journal of obstetrics and gynaecology (2013). PMID: 23320849 ↗
L2SR_OBSCited in: Diagnosis & Workup, Fetal Assessment, Antenatal Surveillance & Prenatal Diagnosis - [272]
Giorgione V, Ridder A, Kalafat E et al.. “Incidence of postpartum hypertension within 2 years of a pregnancy complicated by pre-eclampsia: a systematic review and meta-analysis.” BJOG : an international journal of obstetrics and gynaecology (2020). PMID: 32981216 ↗
L1SR_OBSCited in: Diagnosis & Workup - [273]
Elenis E, Joelsson LS, Stavreus-Evers A et al.. “Perinatal outcomes of progesterone in natural frozen-thawed embryo transfer pregnancies: insights from 2 randomized controlled trials.” Fertility and sterility (2024). PMID: 39722356 ↗
L1RCTCited in: Diagnosis & Workup, Acute Management, History and Evolution of Treatment - [274]
Zhang B, Wei D, Legro RS et al.. “Obstetric complications after frozen versus fresh embryo transfer in women with polycystic ovary syndrome: results from a randomized trial.” Fertility and sterility (2018). PMID: 29338857 ↗
L2RCTCited in: Diagnosis & Workup, History and Evolution of Treatment - [275]
Holowko N, Roos N, Pasternak B et al.. “Glycaemic Control in Women With Type 1 Diabetes and Preeclampsia Risk: A Nationwide Cohort Study.” BJOG : an international journal of obstetrics and gynaecology (2025). PMID: 40856153 ↗
L2COHORTCited in: Diagnosis & Workup - [276]
Ayyash M, Wen T, Purisch S et al.. “Hypertensive Disorders at Delivery and Postpartum Cardiovascular Morbidity: A Retrospective Cohort Study.” BJOG : an international journal of obstetrics and gynaecology (2025). PMID: 41121451 ↗
L2COHORTCited in: Diagnosis & Workup - [277]
Løvvik TS, Wikström AK, Neovius M et al.. “Pregnancy and perinatal outcomes in women with polycystic ovary syndrome and twin births: a population-based cohort study.” BJOG : an international journal of obstetrics and gynaecology (2015). PMID: 25761516 ↗
L2COHORTCited in: Diagnosis & Workup - [278]
Kitmiridou D, Mitrogiannis I, Charakida M et al.. “Retinal imaging in pre-eclamptic pregnancy: systematic review.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2026). PMID: 41531381 ↗
L2SR_OBSCited in: Diagnosis & Workup - [279]
Kalafat E, Laoreti A, Khalil A et al.. “Ophthalmic artery Doppler for prediction of pre-eclampsia: systematic review and meta-analysis.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2018). PMID: 29330892 ↗
L1SR_OBSCited in: Diagnosis & Workup, Fetal Assessment, Antenatal Surveillance & Prenatal Diagnosis - [280]
. “Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin Summary, Number 222.” Obstetrics and gynecology (2020). PMID: 32443077 ↗
L1REVIEW_NARRATIVECited in: Diagnosis & Workup, Fetal Assessment, Antenatal Surveillance & Prenatal Diagnosis, Definitive Management: Medical, Operative & Surgical Staging, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, Complications - [281]
Sibai BM. “Imitators of severe preeclampsia.” Obstetrics and gynecology (2007). PMID: 17400860 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup, Definitive Management: Medical, Operative & Surgical Staging, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, Complications - [282]
Burwick RM, Velásquez JA, Valencia CM et al.. “Terminal Complement Activation in Preeclampsia.” Obstetrics and gynecology (2018). PMID: 30399106 ↗
L3OTHERCited in: Diagnosis & Workup - [283]
Nicolaides KH, Sarno M, Wright A. “Ophthalmic artery Doppler in the prediction of preeclampsia.” American journal of obstetrics and gynecology (2021). PMID: 34292158 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy - [284]
Kametas NA, Nzelu D, Nicolaides KH. “Chronic hypertension and superimposed preeclampsia: screening and diagnosis.” American journal of obstetrics and gynecology (2021). PMID: 35177217 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup, Severity, Staging & Risk Stratification, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy - [285]
Weitzner O, Barrett J, Murphy KE et al.. “National and international guidelines on the management of twin pregnancies: a comparative review.” American journal of obstetrics and gynecology (2023). PMID: 37244456 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup, Prevention, Screening & Surveillance - [286]
Redline RW, Roberts DJ, Parast MM et al.. “Placental pathology is necessary to understand common pregnancy complications and achieve an improved taxonomy of obstetrical disease.” American journal of obstetrics and gynecology (2022). PMID: 35973475 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup - [287]
Silver R, Craigo S, Porter F et al.. “Society for Maternal-Fetal Medicine Consult Series #64: Systemic lupus erythematosus in pregnancy.” American journal of obstetrics and gynecology (2022). PMID: 36084704 ↗
L1OTHERCited in: Diagnosis & Workup - [288]
Battarbee AN, Sinkey RG, Harper LM et al.. “Chronic hypertension in pregnancy.” American journal of obstetrics and gynecology (2019). PMID: 31715148 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup - [289]
Barrett HL, Dekker Nitert M, Conwell LS et al.. “Probiotics for preventing gestational diabetes.” The Cochrane database of systematic reviews (2014). PMID: 24574258 ↗
L1SR_OBSCited in: Diagnosis & Workup, Acute Management, Definitive Management: Medical, Operative & Surgical Staging, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy - [290]
Shepherd E, Salam RA, Middleton P et al.. “Antenatal and intrapartum interventions for preventing cerebral palsy: an overview of Cochrane systematic reviews.” The Cochrane database of systematic reviews (2017). PMID: 28786098 ↗
L1SR_OBSCited in: Diagnosis & Workup, Fetal Assessment, Antenatal Surveillance & Prenatal Diagnosis - [291]
Muktabhant B, Lawrie TA, Lumbiganon P et al.. “Diet or exercise, or both, for preventing excessive weight gain in pregnancy.” The Cochrane database of systematic reviews (2015). PMID: 26068707 ↗
L1SR_OBSCited in: Diagnosis & Workup - [292]
Duley L, Henderson-Smart DJ, Chou D. “Magnesium sulphate versus phenytoin for eclampsia.” The Cochrane database of systematic reviews (2010). PMID: 20927719 ↗
L1SR_OBSCited in: Diagnosis & Workup, History and Evolution of Treatment - [293]
de Jong PG, Kaandorp S, Di Nisio M et al.. “Aspirin and/or heparin for women with unexplained recurrent miscarriage with or without inherited thrombophilia.” The Cochrane database of systematic reviews (2014). PMID: 24995856 ↗
L1SR_OBSCited in: Diagnosis & Workup, History and Evolution of Treatment - [294]
Duley L, Henderson-Smart DJ, Walker GJ et al.. “Magnesium sulphate versus diazepam for eclampsia.” The Cochrane database of systematic reviews (2010). PMID: 21154341 ↗
L1SR_OBSCited in: Diagnosis & Workup - [295]
Haider BA, Bhutta ZA. “Multiple-micronutrient supplementation for women during pregnancy.” The Cochrane database of systematic reviews (2017). PMID: 28407219 ↗
L1SR_OBSCited in: Diagnosis & Workup - [296]
Duley L, Gülmezoglu AM, Chou D. “Magnesium sulphate versus lytic cocktail for eclampsia.” The Cochrane database of systematic reviews (2010). PMID: 20824833 ↗
L1SR_OBSCited in: Diagnosis & Workup, History and Evolution of Treatment - [297]
Shepherd E, Gomersall JC, Tieu J et al.. “Combined diet and exercise interventions for preventing gestational diabetes mellitus.” The Cochrane database of systematic reviews (2017). PMID: 29129039 ↗
L1SR_OBSCited in: Diagnosis & Workup - [298]
Ashworth DC, Maule SP, Stewart F et al.. “Setting and techniques for monitoring blood pressure during pregnancy.” The Cochrane database of systematic reviews (2020). PMID: 32748394 ↗
L1SR_OBSCited in: Diagnosis & Workup - [299]
Palomba S, Costanzi F, Cannarella R et al.. “Persistence of hypertension after pregnancy-related hypertensive disorders in women with polycystic ovary syndrome.” Fertility and sterility (2025). PMID: 40280223 ↗
L2OTHERCited in: Diagnosis & Workup, Definitive Management: Medical, Operative & Surgical Staging, History and Evolution of Treatment, Prevention, Screening & Surveillance - [300]
Ganer Herman H, Volodarsky-Perel A, Ton Nu TN et al.. “Diminished ovarian reserve is a risk factor for preeclampsia and placental malperfusion lesions.” Fertility and sterility (2023). PMID: 36702344 ↗
L2OTHERCited in: Diagnosis & Workup - [301]
Stern JE, Liu CL, Cui X et al.. “Assisted reproductive technology treatment increases obstetric and neonatal risks over that of the underlying infertility diagnosis.” Fertility and sterility (2022). PMID: 35397876 ↗
L2OTHERCited in: Diagnosis & Workup, History and Evolution of Treatment - [302]
Chiu YH, Yland JJ, Rinaudo P et al.. “Effectiveness and safety of intrauterine insemination vs. assisted reproductive technology: emulating a target trial using an observational database of administrative claims.” Fertility and sterility (2022). PMID: 35305813 ↗
L2OTHERCited in: Diagnosis & Workup, History and Evolution of Treatment - [303]
Canini S, Prefumo F, Pastorino D et al.. “Association between birth weight and first-trimester free beta-human chorionic gonadotropin and pregnancy-associated plasma protein A.” Fertility and sterility (2007). PMID: 17509577 ↗
L2OTHERCited in: Diagnosis & Workup - [304]
Dayan N, Lanes A, Walker MC et al.. “Effect of chronic hypertension on assisted pregnancy outcomes: a population-based study in Ontario, Canada.” Fertility and sterility (2015). PMID: 26690007 ↗
L2OTHERCited in: Diagnosis & Workup - [305]
Torloni MR, Cormick G, Atallah AN. “Trial trustworthiness assessment: commentary on the Cochrane 2025 systematic review on calcium supplementation during pregnancy.” Reproductive health (2026). PMID: 42374462 ↗
L5SR_OBSCited in: Diagnosis & Workup, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, Complications, Prognosis & Natural History - [306]
Spinillo A, Dominoni M, Pano MR et al.. “Antenatal, pregnancy and delivery risk factors for infant cerebral palsy: an umbrella review of meta-analyses and systematic reviews.” American journal of obstetrics & gynecology MFM (2026). PMID: 42128358 ↗
L2SR_OBSCited in: Diagnosis & Workup, Prevention, Screening & Surveillance - [307]
Nazri HM, Greaves E, Quenby S et al.. “The role of small extracellular vesicle-miRNAs in endometriosis.” Human reproduction (Oxford, England) (2023). PMID: 37877421 ↗
L5REVIEW_NARRATIVECited in: Diagnosis & Workup, Prognosis & Natural History - [308]
Petersen SH, Åsvold BO, Lawlor DA et al.. “Preterm birth in assisted reproduction: the mediating role of hypertensive disorders in pregnancy.” Human reproduction (Oxford, England) (2025). PMID: 39656847 ↗
L2OTHERCited in: Diagnosis & Workup, Definitive Management: Medical, Operative & Surgical Staging - [309]
Brosens IA, De Sutter P, Hamerlynck T et al.. “Endometriosis is associated with a decreased risk of pre-eclampsia.” Human reproduction (Oxford, England) (2007). PMID: 17452394 ↗
L3OTHERCited in: Diagnosis & Workup, Definitive Management: Medical, Operative & Surgical Staging - [310]
Farland LV, Stern JE, Liu CL et al.. “Polycystic ovary syndrome and risk of adverse pregnancy outcomes: a registry linkage study from Massachusetts.” Human reproduction (Oxford, England) (2022). PMID: 36149255 ↗
L2OTHERCited in: Diagnosis & Workup, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, History and Evolution of Treatment, Complications, Prognosis & Natural History - [311]
Hadfield RM, Lain SJ, Raynes-Greenow CH et al.. “Is there an association between endometriosis and the risk of pre-eclampsia? A population based study.” Human reproduction (Oxford, England) (2009). PMID: 19443457 ↗
L2OTHERCited in: Diagnosis & Workup, History and Evolution of Treatment - [312]
de Vos ES, Koning AHJ, Steegers-Theunissen RPM et al.. “Assessment of first-trimester utero-placental vascular morphology by 3D power Doppler ultrasound image analysis using a skeletonization algorithm: the Rotterdam Periconception Cohort.” Human reproduction (Oxford, England) (2022). PMID: 36125007 ↗
L2OTHERCited in: Diagnosis & Workup, Fetal Assessment, Antenatal Surveillance & Prenatal Diagnosis - [313]
Loh WW, Ananth CV. “Contributions of preeclampsia to preterm delivery: a hypothetical interventional cohort study using incremental propensity scores.” International journal of epidemiology (2026). PMID: 42427224 ↗
L2COHORTCited in: Diagnosis & Workup, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy - [314]
Joseph KS, Mehrabadi A, Boutin A et al.. “Temporal trends in risk of acute kidney injury among patients with preeclampsia in Canada: a retrospective cohort study.” CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne (2026). PMID: 42185002 ↗
L2COHORTCited in: Diagnosis & Workup, Severity, Staging & Risk Stratification, Definitive Management: Medical, Operative & Surgical Staging - [315]
Antovic A, Nguyen NV, Gunnarsson I et al.. “Second delivery rates and recurrence of adverse pregnancy outcomes in women with systemic lupus erythematosus: a nationwide population-based cohort study.” Rheumatology (Oxford, England) (2026). PMID: 42096876 ↗
L2COHORTCited in: Diagnosis & Workup - [316]
Geng H, Li Y, Chen Y et al.. “Early decrease in circulating miR-21 correlates with preeclampsia occurrence and Outcomes: A retrospective study.” Pregnancy hypertension (2026). PMID: 42085912 ↗
L3COHORTCited in: Diagnosis & Workup, Severity, Staging & Risk Stratification, Definitive Management: Medical, Operative & Surgical Staging - [317]
Suryawan AZ, Handono B, Siddiq A et al.. “Early adaptation of Fetomaternal Foundation algorithm screening in Indonesia - A 2 years cohort study in West Java.” Pregnancy hypertension (2026). PMID: 42000523 ↗
L2COHORTCited in: Diagnosis & Workup, Fetal Assessment, Antenatal Surveillance & Prenatal Diagnosis - [318]
Zipursky JS, Vigod SN, Babujee A et al.. “Maternal attention deficit hyperactivity disorder and adverse obstetrical and perinatal outcomes: A population-based cohort study in Ontario, Canada.” American journal of obstetrics & gynecology MFM (2026). PMID: 41990995 ↗
L2COHORTCited in: Diagnosis & Workup - [319]
. “ACOG Practice Bulletin No. 202 Summary: Gestational Hypertension and Preeclampsia.” Obstetrics and gynecology (2019). PMID: 30575668 ↗
L1GUIDELINECited in: Fetal Assessment, Antenatal Surveillance & Prenatal Diagnosis, History and Evolution of Treatment - [320]
González A, Peguero A, Meler E et al.. “Treatment of early-onset fetal growth restriction with low molecular weight heparin does not prolong gestation: a randomized clinical trial.” American journal of obstetrics and gynecology (2024). PMID: 39521297 ↗
L1RCTCited in: Fetal Assessment, Antenatal Surveillance & Prenatal Diagnosis - [321]
Thangaratinam S, Ismail KM, Sharp S et al.. “Accuracy of serum uric acid in predicting complications of pre-eclampsia: a systematic review.” BJOG : an international journal of obstetrics and gynaecology (2006). PMID: 16553648 ↗
L2SR_OBSCited in: Fetal Assessment, Antenatal Surveillance & Prenatal Diagnosis - [322]
Duffy J, Hirsch M, Ziebland S et al.. “Methodological decisions influence the identification of potential core outcomes in studies related to pre-eclampsia: an analysis informing the development of recommendations for future core outcome set developers.” BJOG : an international journal of obstetrics and gynaecology (2019). PMID: 31359560 ↗
L2SR_OBSCited in: Fetal Assessment, Antenatal Surveillance & Prenatal Diagnosis - [323]
Meroni A, Mascherpa M, Minopoli M et al.. “Is mid-gestational uterine artery Doppler still useful in a setting with routine first-trimester pre-eclampsia screening? A cohort study.” BJOG : an international journal of obstetrics and gynaecology (2023). PMID: 36852521 ↗
L2COHORTCited in: Fetal Assessment, Antenatal Surveillance & Prenatal Diagnosis - [324]
Chan N, Smet ME, Sandow R et al.. “Implications of failure to achieve a result from prenatal maternal serum cell-free DNA testing: a historical cohort study.” BJOG : an international journal of obstetrics and gynaecology (2017). PMID: 29090507 ↗
L2COHORTCited in: Fetal Assessment, Antenatal Surveillance & Prenatal Diagnosis - [325]
Sapantzoglou I, Antsaklis P, Pergialiotis V et al.. “Added value of ophthalmic artery Doppler in prediction of pre-eclampsia: systematic review and meta-analysis.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2025). PMID: 40829118 ↗
L2SR_OBSCited in: Fetal Assessment, Antenatal Surveillance & Prenatal Diagnosis, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy - [326]
Cheng Y, Leung TY, Law LW et al.. “First trimester screening for pre-eclampsia in Chinese pregnancies: case-control study.” BJOG : an international journal of obstetrics and gynaecology (2018). PMID: 29032578 ↗
L3CASE_CONTROLCited in: Fetal Assessment, Antenatal Surveillance & Prenatal Diagnosis - [327]
Hong J, Crawford K, Cavanagh E et al.. “Placental biomarker and fetoplacental Doppler abnormalities are strongly associated with placental pathology in pregnancies with small-for-gestational-age fetus: prospective study.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2025). PMID: 40329845 ↗
L2COHORTCited in: Fetal Assessment, Antenatal Surveillance & Prenatal Diagnosis - [328]
Wax JR, Pinette MG, Cartin A et al.. “Pyruvate kinase deficiency complicating pregnancy.” Obstetrics and gynecology (2007). PMID: 17267892 ↗
L4CASE_REPORTCited in: Fetal Assessment, Antenatal Surveillance & Prenatal Diagnosis - [329]
Matsuo K, Tudor EL, Baschat AA. “Alport syndrome and pregnancy.” Obstetrics and gynecology (2007). PMID: 17267885 ↗
L4CASE_REPORTCited in: Fetal Assessment, Antenatal Surveillance & Prenatal Diagnosis - [330]
Barton JR, Sibai BM. “Prediction and prevention of recurrent preeclampsia.” Obstetrics and gynecology (2008). PMID: 18669736 ↗
L5REVIEW_NARRATIVECited in: Fetal Assessment, Antenatal Surveillance & Prenatal Diagnosis, Severity, Staging & Risk Stratification, History and Evolution of Treatment - [331]
Greenberg M, Zhu Y, Shan J et al.. “Gestational and Pregestational Diabetes Screening Changes in Early Pregnancy and Perinatal Outcomes.” Obstetrics and gynecology (2025). PMID: 41100860 ↗
L2OTHERCited in: Fetal Assessment, Antenatal Surveillance & Prenatal Diagnosis, Prevention, Screening & Surveillance - [332]
Usman S, Hanidu A, Kovalenko M et al.. “The sonopartogram.” American journal of obstetrics and gynecology (2023). PMID: 37164504 ↗
L5REVIEW_NARRATIVECited in: Fetal Assessment, Antenatal Surveillance & Prenatal Diagnosis, Acute Management - [333]
Kingdom JC, Audette MC, Hobson SR et al.. “A placenta clinic approach to the diagnosis and management of fetal growth restriction.” American journal of obstetrics and gynecology (2017). PMID: 29254754 ↗
L5REVIEW_NARRATIVECited in: Fetal Assessment, Antenatal Surveillance & Prenatal Diagnosis - [334]
Donno V, Prats P, Rodriguez I et al.. “First-trimester uterine artery pulsatility index and preeclampsia risk in pregnancies after artificial frozen embryo transfer: analysis of over 27,000 pregnancies.” American journal of obstetrics and gynecology (2024). PMID: 39477051 ↗
L2OTHERCited in: Fetal Assessment, Antenatal Surveillance & Prenatal Diagnosis - [335]
Norton ME, MacPherson C, Demko Z et al.. “Obstetrical, perinatal, and genetic outcomes associated with nonreportable prenatal cell-free DNA screening results.” American journal of obstetrics and gynecology (2023). PMID: 36965866 ↗
L2OTHERCited in: Fetal Assessment, Antenatal Surveillance & Prenatal Diagnosis - [336]
Yan Q, Zhang Y, Blue NR et al.. “Genetic associations with placental and pregnancy proteins in maternal serum identify biomarkers for hypertension in pregnancy.” American journal of obstetrics and gynecology (2025). PMID: 41183724 ↗
L2OTHERCited in: Fetal Assessment, Antenatal Surveillance & Prenatal Diagnosis - [337]
Tay J, Masini G, McEniery CM et al.. “Uterine and fetal placental Doppler indices are associated with maternal cardiovascular function.” American journal of obstetrics and gynecology (2018). PMID: 30243605 ↗
L3OTHERCited in: Fetal Assessment, Antenatal Surveillance & Prenatal Diagnosis - [338]
Mateus J, Newman RB, Zhang C et al.. “Fetal growth patterns in pregnancy-associated hypertensive disorders: NICHD Fetal Growth Studies.” American journal of obstetrics and gynecology (2019). PMID: 31226296 ↗
L2OTHERCited in: Fetal Assessment, Antenatal Surveillance & Prenatal Diagnosis - [339]
Zhu J, Zhang J, Wu Y et al.. “Intertwin growth discordance throughout gestation and hypertensive disorders of pregnancy.” American journal of obstetrics and gynecology (2022). PMID: 36403860 ↗
L2OTHERCited in: Fetal Assessment, Antenatal Surveillance & Prenatal Diagnosis - [340]
Khaw A, Kametas NA, Turan OM et al.. “Maternal cardiac function and uterine artery Doppler at 11-14 weeks in the prediction of pre-eclampsia in nulliparous women.” BJOG : an international journal of obstetrics and gynaecology (2008). PMID: 18190374 ↗
L2OTHERCited in: Fetal Assessment, Antenatal Surveillance & Prenatal Diagnosis - [341]
Bonacina E, Armengol-Alsina M, Casellas A et al.. “Angiogenic factors and fetal Doppler for predicting adverse pregnancy outcome in early-onset small fetuses with and without pre-eclampsia.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2026). PMID: 41723869 ↗
L2OTHERCited in: Fetal Assessment, Antenatal Surveillance & Prenatal Diagnosis, Acute Management - [342]
Wright D, Gallo DM, Gil Pugliese S et al.. “Contingent screening for preterm pre-eclampsia.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2016). PMID: 26643929 ↗
L2OTHERCited in: Fetal Assessment, Antenatal Surveillance & Prenatal Diagnosis - [343]
Kamphof HD, Marijnen MC, Damhuis SE et al.. “Predictive value of fetal Doppler velocimetry, fetal growth trajectory and maternal serum biomarkers for short-term adverse perinatal outcome: secondary analysis of DRIGITAT study.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2025). PMID: 40641303 ↗
L2OTHERCited in: Fetal Assessment, Antenatal Surveillance & Prenatal Diagnosis - [344]
Gibbone E, Sapantzoglou I, Nuñez-Cerrato ME et al.. “Relationship between ophthalmic artery Doppler and maternal cardiovascular function.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2021). PMID: 33524212 ↗
L2OTHERCited in: Fetal Assessment, Antenatal Surveillance & Prenatal Diagnosis - [345]
Bond DM, Gordon A, Hyett J et al.. “Planned early delivery versus expectant management of the term suspected compromised baby for improving outcomes.” The Cochrane database of systematic reviews (2015). PMID: 26599471 ↗
L1SR_OBSCited in: Fetal Assessment, Antenatal Surveillance & Prenatal Diagnosis - [346]
de Klerk ND, Berben PBQ, de Vries IR et al.. “Continuous non-invasive electrophysiological monitoring in high-risk pregnancies: study protocol of a cohort intervention random sampling study in a tertiary obstetrical care centre in the Netherlands (NIEM-O study).” BMJ open (2025). PMID: 41224309 ↗
L5TRIAL_NONRANDOMCited in: Fetal Assessment, Antenatal Surveillance & Prenatal Diagnosis - [347]
Zambella E, Inversetti A, Pivato CA et al.. “Ultrasound evaluation of placental volume and placental vascular indices in women developing hypertensive disorders in pregnancy compared to controls: a systematic review and meta-analysis.” European heart journal. Quality of care & clinical outcomes (2026). PMID: 41672727 ↗
L3SR_OBSCited in: Fetal Assessment, Antenatal Surveillance & Prenatal Diagnosis - [348]
Piergianni M, Della Valle L, Khalil A et al.. “Perinatal and maternal outcomes of extremely early-onset fetal growth restriction (≤ 26 weeks): systematic review and meta-analysis.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2025). PMID: 41235926 ↗
L2SR_OBSCited in: Fetal Assessment, Antenatal Surveillance & Prenatal Diagnosis, Complications - [349]
Anand-Ivell R, Ivell R, Driscoll D et al.. “Insulin-like factor 3 levels in amniotic fluid of human male fetuses.” Human reproduction (Oxford, England) (2008). PMID: 18310050 ↗
L4OTHERCited in: Fetal Assessment, Antenatal Surveillance & Prenatal Diagnosis - [350]
Papageorghiou AT, Prefumo F, Leslie K et al.. “Defective endovascular trophoblast invasion in the first trimester is associated with increased maternal serum ischemia-modified albumin.” Human reproduction (Oxford, England) (2008). PMID: 18281685 ↗
L2OTHERCited in: Fetal Assessment, Antenatal Surveillance & Prenatal Diagnosis - [351]
Stark T, Kruit H, Rahkonen L. “Home telemonitoring in high-risk pregnancies: A Finnish retrospective cohort study.” Acta obstetricia et gynecologica Scandinavica (2026). PMID: 42272129 ↗
L3COHORTCited in: Fetal Assessment, Antenatal Surveillance & Prenatal Diagnosis - [352]
Eroğlu C, Eroğlu ÖO, Çağlar AT. “Comparative Predictive Value of First-Trimester Crown-Rump Length and Nuchal Translucency Discordance for Fetal Growth Restriction in Twin Pregnancies: A Retrospective Cohort Study.” Journal of clinical medicine (2026). PMID: 42074930 ↗
L3COHORTCited in: Fetal Assessment, Antenatal Surveillance & Prenatal Diagnosis - [353]
Gibson SMP, Medley N, Belmar N et al.. “Umbilical‑artery‑based Doppler versus multimodal surveillance for fetal growth restriction secondary to pre‑eclampsia: a retrospective cohort study in a low‑resource setting.” Pregnancy hypertension (2026). PMID: 41887042 ↗
L3COHORTCited in: Fetal Assessment, Antenatal Surveillance & Prenatal Diagnosis - [354]
Hansen S, Petersen OB, Vogel I et al.. “Discrepancy in menstrual and ultrasound-based gestational age is associated with chromosomal aberrations and adverse pregnancy outcomes-Results from a nationwide cohort study.” Acta obstetricia et gynecologica Scandinavica (2026). PMID: 41725333 ↗
L3COHORTCited in: Fetal Assessment, Antenatal Surveillance & Prenatal Diagnosis - [355]
Bütün Z, Kayapınar M, Şenol G et al.. “Fetal ventricular contractility and birth outcomes: a prospective cohort study.” BMC pregnancy and childbirth (2026). PMID: 41664012 ↗
L2COHORTCited in: Fetal Assessment, Antenatal Surveillance & Prenatal Diagnosis - [356]
Cruz-Lemini M, Vázquez JC, Ullmo J et al.. “Low-molecular-weight heparin for prevention of preeclampsia and other placenta-mediated complications: a systematic review and meta-analysis.” American journal of obstetrics and gynecology (2021). PMID: 34301348 ↗
L1SR_OBSCited in: Severity, Staging & Risk Stratification, History and Evolution of Treatment - [357]
Peris M, Crompton K, Shepherd DA et al.. “The association between human chorionic gonadotropin and adverse pregnancy outcomes: a systematic review and meta-analysis.” American journal of obstetrics and gynecology (2023). PMID: 37572838 ↗
L2SR_OBSCited in: Severity, Staging & Risk Stratification - [358]
van Eekhout JCA, Becking EC, Scheffer PG et al.. “First-Trimester Prediction Models Based on Maternal Characteristics for Adverse Pregnancy Outcomes: A Systematic Review and Meta-Analysis.” BJOG : an international journal of obstetrics and gynaecology (2024). PMID: 39449094 ↗
L2SR_OBSCited in: Severity, Staging & Risk Stratification - [359]
O'Brien LM, Bullough AS, Chames MC et al.. “Hypertension, snoring, and obstructive sleep apnoea during pregnancy: a cohort study.” BJOG : an international journal of obstetrics and gynaecology (2014). PMID: 24888772 ↗
L2COHORTCited in: Severity, Staging & Risk Stratification - [360]
Borthen I, Eide MG, Daltveit AK et al.. “Obstetric outcome in women with epilepsy: a hospital-based, retrospective study.” BJOG : an international journal of obstetrics and gynaecology (2011). PMID: 21557799 ↗
L3COHORTCited in: Severity, Staging & Risk Stratification - [361]
Choi ES, Jung SH, Jung YM et al.. “Polygenic Risk for Pre-Eclampsia and the Long-Term Risk of Incident Hypertension and Cardiovascular Disease: A Population-Based Cohort Study.” BJOG : an international journal of obstetrics and gynaecology (2025). PMID: 41236086 ↗
L2COHORTCited in: Severity, Staging & Risk Stratification - [362]
Johansson K, Bodnar LM, Stephansson O et al.. “Safety of low weight gain or weight loss in pregnancies with class 1, 2, and 3 obesity: a population-based cohort study.” Lancet (London, England) (2024). PMID: 38555927 ↗
L3COHORTCited in: Severity, Staging & Risk Stratification, Acute Management, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, Complications - [363]
Kalafat E, Sukur YE, Abdi A et al.. “Metformin for prevention of hypertensive disorders of pregnancy in women with gestational diabetes or obesity: systematic review and meta-analysis of randomized trials.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2018). PMID: 29749110 ↗
L1SR_OBSCited in: Severity, Staging & Risk Stratification, Definitive Management: Medical, Operative & Surgical Staging - [364]
Bellos I, Pergialiotis V, Antsaklis A et al.. “Safety of non-steroidal anti-inflammatory drugs in postpartum period in women with hypertensive disorders of pregnancy: systematic review and meta-analysis.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2020). PMID: 32068930 ↗
L2SR_OBSCited in: Severity, Staging & Risk Stratification - [365]
Gray KJ, Kovacheva VP, Mirzakhani H et al.. “Risk of pre-eclampsia in patients with a maternal genetic predisposition to common medical conditions: a case-control study.” BJOG : an international journal of obstetrics and gynaecology (2020). PMID: 32741103 ↗
L3CASE_CONTROLCited in: Severity, Staging & Risk Stratification - [366]
Auger N, Fraser WD, Paradis G et al.. “Preeclampsia and Long-term Risk of Maternal Retinal Disorders.” Obstetrics and gynecology (2017). PMID: 27926640 ↗
L3OTHERCited in: Severity, Staging & Risk Stratification - [367]
Shih YH, Yang CY, Lung CC. “Pregnancy-Induced Hypertension and Association With Future Autoimmune Diseases.” Obstetrics and gynecology (2025). PMID: 40014856 ↗
L3OTHERCited in: Severity, Staging & Risk Stratification - [368]
Smith C, Teng F, Branch E et al.. “Maternal and Perinatal Morbidity and Mortality Associated With Anemia in Pregnancy.” Obstetrics and gynecology (2019). PMID: 31764734 ↗
L3OTHERCited in: Severity, Staging & Risk Stratification - [369]
Jamieson DJ, Rasmussen SA. “An update on COVID-19 and pregnancy.” American journal of obstetrics and gynecology (2021). PMID: 34534497 ↗
L5REVIEW_NARRATIVECited in: Severity, Staging & Risk Stratification - [370]
Tanner MS, Davey MA, Mol BW et al.. “The evolution of the diagnostic criteria of preeclampsia-eclampsia.” American journal of obstetrics and gynecology (2022). PMID: 35177221 ↗
L5REVIEW_NARRATIVECited in: Severity, Staging & Risk Stratification, History and Evolution of Treatment - [371]
Gallos ID, Sindhu KN, Yunas I et al.. “Prevention of postpartum haemorrhage: from evidence to implementation at scale.” Lancet (London, England) (2026). PMID: 42285117 ↗
L5REVIEW_NARRATIVECited in: Severity, Staging & Risk Stratification, Special Populations, Prevention, Screening & Surveillance - [372]
Souza JP, Gülmezoglu AM, Vogel J et al.. “Moving beyond essential interventions for reduction of maternal mortality (the WHO Multicountry Survey on Maternal and Newborn Health): a cross-sectional study.” Lancet (London, England) (2013). PMID: 23683641 ↗
L4OTHERCited in: Severity, Staging & Risk Stratification - [373]
Tse KY, Yu NYF, Leung KY et al.. “Dichorionic twin pregnancy with selective fetal growth restriction: prognosis, complications and implications of Doppler abnormalities.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2025). PMID: 40542552 ↗
L3OTHERCited in: Severity, Staging & Risk Stratification, Definitive Management: Medical, Operative & Surgical Staging - [374]
Brown J, Grzeskowiak L, Williamson K et al.. “Insulin for the treatment of women with gestational diabetes.” The Cochrane database of systematic reviews (2017). PMID: 29103210 ↗
L1SR_OBSCited in: Severity, Staging & Risk Stratification - [375]
Bastek JA, Elovitz MA. “The role and challenges of biomarkers in spontaneous preterm birth and preeclampsia.” Fertility and sterility (2013). PMID: 23394778 ↗
L5REVIEW_NARRATIVECited in: Severity, Staging & Risk Stratification, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy - [376]
Reyes-Muñoz E, Castellanos-Barroso G, Ramírez-Eugenio BY et al.. “The risk of gestational diabetes mellitus among Mexican women with a history of infertility and polycystic ovary syndrome.” Fertility and sterility (2012). PMID: 22503417 ↗
L3OTHERCited in: Severity, Staging & Risk Stratification - [377]
Nørreslet LB, Agner T, Mortz CG. “Pregnancy in Women with Atopic Dermatitis: A Systematic Review of Concerns and Challenges.” Acta dermato-venereologica (2026). PMID: 42153313 ↗
L2SR_OBSCited in: Severity, Staging & Risk Stratification, Prognosis & Natural History - [378]
de Kanter E, Vernooij RWM, Huis In 't Veld L et al.. “The inclusion and intended use of prediction models in clinical guidelines: a systematic review of five clinical domains in four countries.” Journal of clinical epidemiology (2026). PMID: 42025974 ↗
L2SR_OBSCited in: Severity, Staging & Risk Stratification - [379]
Zhang J, Chen Y, Huang G et al.. “Association between maternal thyroid function and adverse outcomes of pregnant women and offspring: evidence from an umbrella review.” BMC pregnancy and childbirth (2026). PMID: 41963840 ↗
L2SR_OBSCited in: Severity, Staging & Risk Stratification - [380]
Katsukunya JN, Davidson B, Mnika K et al.. “Preeclampsia Genomic Susceptibility Factors in Populations of African Ancestry: A Systematic Review and Meta-Analysis.” International journal of molecular sciences (2026). PMID: 41898457 ↗
L1SR_OBSCited in: Severity, Staging & Risk Stratification - [381]
Salameh MA, Li Y, Jordan D et al.. “Predictive value of early pregnancy laboratory markers for recurrence of hypertensive disorders of pregnancy: A retrospective study.” Pregnancy hypertension (2026). PMID: 42190619 ↗
L3COHORTCited in: Severity, Staging & Risk Stratification, History and Evolution of Treatment, Complications, Prognosis & Natural History - [382]
Bai X, Zhu Q, Wang H et al.. “Atherogenic index of plasma and risk of hypertensive disorders of pregnancy in women with gestational diabetes mellitus: a two-center cohort study.” Hypertension research : official journal of the Japanese Society of Hypertension (2026). PMID: 42156525 ↗
L3COHORTCited in: Severity, Staging & Risk Stratification, Complications - [383]
Amro FH, Blackwell SC, Pedroza C et al.. “Aspirin 162 mg vs 81 mg for preeclampsia prophylaxis in high-risk obese individuals: a comparative effectiveness open-label randomized trial (ASPREO).” American journal of obstetrics and gynecology (2024). PMID: 38977068 ↗
L1RCTCited in: Acute Management, History and Evolution of Treatment, Prevention, Screening & Surveillance - [384]
Lin L, Huai J, Li B et al.. “A randomized controlled trial of low-dose aspirin for the prevention of preeclampsia in women at high risk in China.” American journal of obstetrics and gynecology (2021). PMID: 34389292 ↗
L1RCTCited in: Acute Management, History and Evolution of Treatment - [385]
Costantine MM, West H, Wisner KL et al.. “A randomized pilot clinical trial of pravastatin versus placebo in pregnant patients at high risk of preeclampsia.” American journal of obstetrics and gynecology (2021). PMID: 34033812 ↗
L1RCTCited in: Acute Management, History and Evolution of Treatment - [386]
Chen ZJ, Shi Y, Sun Y et al.. “Fresh versus Frozen Embryos for Infertility in the Polycystic Ovary Syndrome.” The New England journal of medicine (2016). PMID: 27509101 ↗
L1RCTCited in: Acute Management, Definitive Management: Medical, Operative & Surgical Staging, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, History and Evolution of Treatment, Complications, Prognosis & Natural History - [387]
Landon MB, Spong CY, Thom E et al.. “A multicenter, randomized trial of treatment for mild gestational diabetes.” The New England journal of medicine (2009). PMID: 19797280 ↗
L1RCTCited in: Acute Management, Definitive Management: Medical, Operative & Surgical Staging, History and Evolution of Treatment, Complications, Prognosis & Natural History - [388]
Okonkwo M, Nash CM. “Duration of Postpartum Magnesium Sulphate for the Prevention of Eclampsia: A Systematic Review and Meta-analysis.” Obstetrics and gynecology (2022). PMID: 35271534 ↗
L1SR_OBSCited in: Acute Management - [389]
von Dadelszen P, Payne B, Li J et al.. “Prediction of adverse maternal outcomes in pre-eclampsia: development and validation of the fullPIERS model.” Lancet (London, England) (2010). PMID: 21185591 ↗
L2TRIAL_NONRANDOMCited in: Acute Management, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, Complications, Prognosis & Natural History - [390]
Woo Kinshella ML, Sarr C, Sandhu A et al.. “Calcium for pre-eclampsia prevention: A systematic review and network meta-analysis to guide personalised antenatal care.” BJOG : an international journal of obstetrics and gynaecology (2022). PMID: 35596262 ↗
L1SR_OBSCited in: Acute Management, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy - [391]
Brouwers L, van der Meiden-van Roest AJ, Savelkoul C et al.. “Recurrence of pre-eclampsia and the risk of future hypertension and cardiovascular disease: a systematic review and meta-analysis.” BJOG : an international journal of obstetrics and gynaecology (2018). PMID: 29978553 ↗
L1SR_OBSCited in: Acute Management, History and Evolution of Treatment - [392]
Alijotas-Reig J, Palacio-Garcia C, Llurba E et al.. “Cell-derived microparticles and vascular pregnancy complications: a systematic and comprehensive review.” Fertility and sterility (2012). PMID: 23122952 ↗
L2SR_OBSCited in: Acute Management, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, Complications, Prognosis & Natural History - [393]
McCaulley JA, Pates JA. “Postpartum cerebral venous thrombosis.” Obstetrics and gynecology (2011). PMID: 21768841 ↗
L4CASE_REPORTCited in: Acute Management, Prevention, Screening & Surveillance - [394]
Chu J, Gallos I, Tobias A et al.. “Vitamin D and assisted reproductive treatment outcome: a systematic review and meta-analysis.” Human reproduction (Oxford, England) (2018). PMID: 29149263 ↗
L1SR_OBSCited in: Acute Management, Definitive Management: Medical, Operative & Surgical Staging, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, Complications, Prognosis & Natural History - [395]
Zhang J, Liu X, Rao L et al.. “Adverse obstetric and perinatal outcomes of patients with history of recurrent miscarriage: a retrospective cohort study.” Fertility and sterility (2023). PMID: 37121567 ↗
L3COHORTCited in: Acute Management, History and Evolution of Treatment, Complications - [396]
Wise LA, Mikkelsen EM, Sørensen HT et al.. “Prospective study of time to pregnancy and adverse birth outcomes.” Fertility and sterility (2015). PMID: 25707334 ↗
L2COHORTCited in: Acute Management, Definitive Management: Medical, Operative & Surgical Staging - [397]
Asvold BO, Vatten LJ, Tanbo TG et al.. “Concentrations of human chorionic gonadotrophin in very early pregnancy and subsequent pre-eclampsia: a cohort study.” Human reproduction (Oxford, England) (2014). PMID: 24722241 ↗
L2COHORTCited in: Acute Management - [398]
Pryde PG, Mittendorf R. “Contemporary usage of obstetric magnesium sulfate: indication, contraindication, and relevance of dose.” Obstetrics and gynecology (2009). PMID: 19701048 ↗
L5REVIEW_NARRATIVECited in: Acute Management - [399]
Lafleur N, Wei SQ, Bilodeau-Bertrand M et al.. “Association of Endometriosis and Severe Maternal Morbidity.” Obstetrics and gynecology (2022). PMID: 36357981 ↗
L3OTHERCited in: Acute Management - [400]
Watkins VY, O'Donnell CM, Perez M et al.. “The impact of physical activity during pregnancy on labor and delivery.” American journal of obstetrics and gynecology (2021). PMID: 34081895 ↗
L2OTHERCited in: Acute Management - [401]
Getahun D, Fassett MJ, Jacobsen SJ et al.. “Perinatal outcomes after bariatric surgery.” American journal of obstetrics and gynecology (2021). PMID: 34216568 ↗
L2OTHERCited in: Acute Management - [402]
Rademaker D, de Wit L, Duijnhoven RG et al.. “Oral Glucose-Lowering Agents vs Insulin for Gestational Diabetes: A Randomized Clinical Trial.” JAMA (2025). PMID: 39761054 ↗
L1OTHERCited in: Acute Management, Definitive Management: Medical, Operative & Surgical Staging, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, History and Evolution of Treatment - [403]
Auger N, Fraser WD, Healy-Profitós J et al.. “Association Between Preeclampsia and Congenital Heart Defects.” JAMA (2015). PMID: 26501535 ↗
L2OTHERCited in: Acute Management - [404]
Rode L, Wright A, Wright D et al.. “Screening for pre-eclampsia using pregnancy-associated plasma protein-A or placental growth factor measurements in blood samples collected at 8-14 weeks' gestation.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2025). PMID: 40127386 ↗
L2OTHERCited in: Acute Management - [405]
Hofmeyr GJ, Lawrie TA, Atallah ÁN et al.. “Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems.” The Cochrane database of systematic reviews (2018). PMID: 30277579 ↗
L1SR_OBSCited in: Acute Management, Definitive Management: Medical, Operative & Surgical Staging, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, Complications, Prognosis & Natural History - [406]
Hamulyák EN, Scheres LJ, Marijnen MC et al.. “Aspirin or heparin or both for improving pregnancy outcomes in women with persistent antiphospholipid antibodies and recurrent pregnancy loss.” The Cochrane database of systematic reviews (2020). PMID: 32358837 ↗
L1SR_OBSCited in: Acute Management, Definitive Management: Medical, Operative & Surgical Staging, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, Complications, Prognosis & Natural History - [407]
Abalos E, Duley L, Steyn DW et al.. “Antihypertensive drug therapy for mild to moderate hypertension during pregnancy.” The Cochrane database of systematic reviews (2018). PMID: 30277556 ↗
L1SR_OBSCited in: Acute Management, Definitive Management: Medical, Operative & Surgical Staging, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, Prognosis & Natural History - [408]
Makrides M, Crosby DD, Bain E et al.. “Magnesium supplementation in pregnancy.” The Cochrane database of systematic reviews (2014). PMID: 24696187 ↗
L1SR_OBSCited in: Acute Management, Definitive Management: Medical, Operative & Surgical Staging, Complications - [409]
Legro RS. “Preconception weight loss in the obese patient: overhyped or underutilized?” Fertility and sterility (2022). PMID: 36116797 ↗
L5REVIEW_NARRATIVECited in: Acute Management, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, Complications - [410]
Zhang WY, von Versen-Höynck F, Kapphahn KI et al.. “Maternal and neonatal outcomes associated with trophectoderm biopsy.” Fertility and sterility (2019). PMID: 31103283 ↗
L2OTHERCited in: Acute Management - [411]
Ginod P, Badeghiesh A, Baghlaf H et al.. “Pregnancy and delivery outcomes after abdominal vs. laparoscopic myomectomy: an evaluation of an American population database.” Fertility and sterility (2024). PMID: 39128671 ↗
L2OTHERCited in: Acute Management, Definitive Management: Medical, Operative & Surgical Staging - [412]
Lunddorf LLH, Brix N, Ernst A et al.. “Hypertensive disorders in pregnancy and timing of pubertal development in daughters and sons.” Human reproduction (Oxford, England) (2020). PMID: 32766758 ↗
L2OTHERCited in: Acute Management, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, Prognosis & Natural History - [413]
Phillips K, Singh M, Lee SI et al.. “Migraine and risk of adverse obstetric outcomes: a matched cohort study of English linked electronic health records.” BMC medicine (2026). PMID: 42415054 ↗
L2COHORTCited in: Acute Management, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy - [414]
Singh M, Subramanian A, Wambua S et al.. “Autoimmune diseases and risk of adverse pregnancy outcomes: a population-based cohort study of five million pregnancies in the UK.” BMC medicine (2026). PMID: 42169116 ↗
L2COHORTCited in: Acute Management - [415]
Gu L, Shen J. “Maternal and neonatal outcomes of intrahepatic cholestasis of pregnancy in twin pregnancies: a systematic review and meta-analysis.” The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians (2026). PMID: 42392869 ↗
L2SR_OBSCited in: Acute Management, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, Complications - [416]
Liu D, Chen Y, Liu F. “The influence of hydroxychloroquine on the risk of pre-eclampsia, hypertension, and premature delivery in patients with systemic lupus erythematosus during pregnancy: a meta-analysis.” European journal of clinical pharmacology (2026). PMID: 42168466 ↗
L2SR_OBSCited in: Acute Management - [417]
Zhang Y, Peng K, Wang L et al.. “Gestational weight gain and preeclampsia in twin pregnancies: a retrospective cohort study.” The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians (2026). PMID: 42342556 ↗
L2COHORTCited in: Acute Management - [418]
Chappell LC, Brocklehurst P, Green ME et al.. “Planned early delivery or expectant management for late preterm pre-eclampsia (PHOENIX): a randomised controlled trial.” Lancet (London, England) (2019). PMID: 31472930 ↗
L1RCTCited in: Definitive Management: Medical, Operative & Surgical Staging, History and Evolution of Treatment - [419]
Beardmore-Gray A, Vousden N, Seed PT et al.. “Planned delivery or expectant management for late preterm pre-eclampsia in low-income and middle-income countries (CRADLE-4): a multicentre, open-label, randomised controlled trial.” Lancet (London, England) (2023). PMID: 37393919 ↗
L1RCTCited in: Definitive Management: Medical, Operative & Surgical Staging, History and Evolution of Treatment - [420]
Curry SJ, Krist AH, Owens DK et al.. “Screening for Elevated Blood Lead Levels in Children and Pregnant Women: US Preventive Services Task Force Recommendation Statement.” JAMA (2019). PMID: 30990556 ↗
L1GUIDELINECited in: Definitive Management: Medical, Operative & Surgical Staging, History and Evolution of Treatment, Complications, Prevention, Screening & Surveillance - [421]
Murphy VE, Namazy JA, Powell H et al.. “A meta-analysis of adverse perinatal outcomes in women with asthma.” BJOG : an international journal of obstetrics and gynaecology (2011). PMID: 21749633 ↗
L2SR_OBSCited in: Definitive Management: Medical, Operative & Surgical Staging, Complications - [422]
McCauley H, Lowe K, Furtado N et al.. “What are the essential components of antenatal care? A systematic review of the literature and development of signal functions to guide monitoring and evaluation.” BJOG : an international journal of obstetrics and gynaecology (2021). PMID: 34839568 ↗
L2SR_OBSCited in: Definitive Management: Medical, Operative & Surgical Staging - [423]
Sorrenti S, Prasad S, Elbarbary N et al.. “Interventions to Address Disparities in Perinatal Outcomes by Ethnicity: A Systematic Review.” BJOG : an international journal of obstetrics and gynaecology (2025). PMID: 40988125 ↗
L2SR_OBSCited in: Definitive Management: Medical, Operative & Surgical Staging, Complications, Prevention, Screening & Surveillance - [424]
Haapsamo M, Martikainen H, Tinkanen H et al.. “Low-dose aspirin therapy and hypertensive pregnancy complications in unselected IVF and ICSI patients: a randomized, placebo-controlled, double-blind study.” Human reproduction (Oxford, England) (2010). PMID: 20943705 ↗
L1RCTCited in: Definitive Management: Medical, Operative & Surgical Staging, History and Evolution of Treatment - [425]
Maheshwari A, Bell JL, Bhide P et al.. “Elective freezing of embryos versus fresh embryo transfer in IVF: a multicentre randomized controlled trial in the UK (E-Freeze).” Human reproduction (Oxford, England) (2022). PMID: 34999830 ↗
L1RCTCited in: Definitive Management: Medical, Operative & Surgical Staging, History and Evolution of Treatment - [426]
Maggard MA, Yermilov I, Li Z et al.. “Pregnancy and fertility following bariatric surgery: a systematic review.” JAMA (2008). PMID: 19017915 ↗
L2SR_OBSCited in: Definitive Management: Medical, Operative & Surgical Staging, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, Complications, Prognosis & Natural History - [427]
Turner JM, Robertson NT, Hartel G et al.. “Impact of low-dose aspirin on adverse perinatal outcome: meta-analysis and meta-regression.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2020). PMID: 31479546 ↗
L1SR_OBSCited in: Definitive Management: Medical, Operative & Surgical Staging, Complications - [428]
Bernardes TP, Zwertbroek EF, Broekhuijsen K et al.. “Delivery or expectant management for prevention of adverse maternal and neonatal outcomes in hypertensive disorders of pregnancy: an individual participant data meta-analysis.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2019). PMID: 30697855 ↗
L1SR_OBSCited in: Definitive Management: Medical, Operative & Surgical Staging - [429]
Dall'Asta A, D'Antonio F, Saccone G et al.. “Cardiovascular events following pregnancy complicated by pre-eclampsia with emphasis on comparison between early- and late-onset forms: systematic review and meta-analysis.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2021). PMID: 32484256 ↗
L2SR_OBSCited in: Definitive Management: Medical, Operative & Surgical Staging - [430]
Masini G, Foo LF, Tay J et al.. “Preeclampsia has two phenotypes which require different treatment strategies.” American journal of obstetrics and gynecology (2021). PMID: 34774281 ↗
L5REVIEW_NARRATIVECited in: Definitive Management: Medical, Operative & Surgical Staging, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, Complications - [431]
Vikström J, Josefsson A, Hammar M et al.. “Risk of postpartum psychosis after IVF treatment: a nationwide case-control study.” Human reproduction (Oxford, England) (2016). PMID: 27927846 ↗
L3CASE_CONTROLCited in: Definitive Management: Medical, Operative & Surgical Staging, History and Evolution of Treatment - [432]
Atallah A, Khelfa D, Dorel G et al.. “Post-partum follow-up after hypertensive disorders during pregnancy: Review of national and international clinical practice guidelines.” Pregnancy hypertension (2026). PMID: 42105507 ↗
L5GUIDELINECited in: Definitive Management: Medical, Operative & Surgical Staging - [433]
Yu CK, Teoh TG, Robinson S. “Obesity in pregnancy.” BJOG : an international journal of obstetrics and gynaecology (2006). PMID: 16903839 ↗
L5REVIEW_NARRATIVECited in: Definitive Management: Medical, Operative & Surgical Staging - [434]
Ali NB, Sudfeld CR, Muhihi A et al.. “Effect of calcium supplementation in pregnancy on maternal anemia and iron status: secondary analyses of two randomized trials in India and Tanzania.” The American journal of clinical nutrition (2026). PMID: 42067065 ↗
L1RCTCited in: Definitive Management: Medical, Operative & Surgical Staging, History and Evolution of Treatment - [435]
Alexopoulos AS, Blair R, Peters AL. “Management of Preexisting Diabetes in Pregnancy: A Review.” JAMA (2019). PMID: 31087027 ↗
L5REVIEW_NARRATIVECited in: Definitive Management: Medical, Operative & Surgical Staging, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, History and Evolution of Treatment - [436]
Basso O, Rasmussen S, Weinberg CR et al.. “Trends in fetal and infant survival following preeclampsia.” JAMA (2006). PMID: 16985227 ↗
L2OTHERCited in: Definitive Management: Medical, Operative & Surgical Staging - [437]
Pan X, Peng J, Chen Y et al.. “sFlt-1/PlGF ratio thresholds for diagnosing pre-eclampsia in pregnant women with high blood pressure.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2025). PMID: 40992360 ↗
L2OTHERCited in: Definitive Management: Medical, Operative & Surgical Staging - [438]
Nguyen TM, Crowther CA, Wilkinson D et al.. “Magnesium sulphate for women at term for neuroprotection of the fetus.” The Cochrane database of systematic reviews (2013). PMID: 23450601 ↗
L1SR_OBSCited in: Definitive Management: Medical, Operative & Surgical Staging - [439]
Alwan N, Tuffnell DJ, West J. “Treatments for gestational diabetes.” The Cochrane database of systematic reviews (2009). PMID: 19588341 ↗
L1SR_OBSCited in: Definitive Management: Medical, Operative & Surgical Staging, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy - [440]
Luke B. “Adverse effects of female obesity and interaction with race on reproductive potential.” Fertility and sterility (2017). PMID: 28366413 ↗
L5REVIEW_NARRATIVECited in: Definitive Management: Medical, Operative & Surgical Staging, Complications - [441]
Polyzos NP. “Endometrial preparation protocols for frozen embryo transfer: risk assessment and individualized management.” Human reproduction (Oxford, England) (2025). PMID: 40796314 ↗
L5OTHERCited in: Definitive Management: Medical, Operative & Surgical Staging, Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, Complications, Prognosis & Natural History, Prevention, Screening & Surveillance - [442]
Chen L, Shi H, Wei Y et al.. “Prevalence, trends, and subtype-specific outcomes of hypertensive disorders in pregnancy in China: data from 18 million pregnant women in a hospitalization-based retrospective study.” Hypertension research : official journal of the Japanese Society of Hypertension (2026). PMID: 42203888 ↗
L3COHORTCited in: Definitive Management: Medical, Operative & Surgical Staging, Complications, Prognosis & Natural History - [443]
Kantomaa T, Gissler M, Ryynänen M et al.. “Cardiovascular morbidity and mortality after preeclampsia: A nationwide case-cohort study.” Pregnancy hypertension (2026). PMID: 42097111 ↗
L3COHORTCited in: Definitive Management: Medical, Operative & Surgical Staging, History and Evolution of Treatment - [444]
Li T, Li T, Yu X et al.. “Pregnancy outcomes and risk factors analysis in patients with chronic kidney disease: a nested case-control study.” BMC pregnancy and childbirth (2026). PMID: 42098645 ↗
L3CASE_CONTROLCited in: Definitive Management: Medical, Operative & Surgical Staging - [445]
Erbey B, Atalay CR, Erbey S. “Etiological Spectrum and Maternal Peripartum Hematologic Outcomes of Thrombocytopenia in Pregnancy: A Retrospective Cohort Study.” Medicina (Kaunas, Lithuania) (2026). PMID: 42075642 ↗
L3COHORTCited in: Definitive Management: Medical, Operative & Surgical Staging - [446]
Voerman E, Santos S, Inskip H et al.. “Association of Gestational Weight Gain With Adverse Maternal and Infant Outcomes.” JAMA (2019). PMID: 31063572 ↗
L2SR_OBSCited in: Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, Complications, Prognosis & Natural History - [447]
Jones Pullins M, Boggess K, Porter TF. “Aspirin in Pregnancy.” Obstetrics and gynecology (2023). PMID: 37917941 ↗
L5REVIEW_NARRATIVECited in: Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy - [448]
Bakrania BA, George EM, Granger JP. “Animal models of preeclampsia: investigating pathophysiology and therapeutic targets.” American journal of obstetrics and gynecology (2021). PMID: 33722383 ↗
L5REVIEW_NARRATIVECited in: Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy - [449]
Metzger BE, Lowe LP, Dyer AR et al.. “Hyperglycemia and adverse pregnancy outcomes.” The New England journal of medicine (2008). PMID: 18463375 ↗
L2OTHERCited in: Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy - [450]
Perak AM, Lancki N, Kuang A et al.. “Associations of Maternal Cardiovascular Health in Pregnancy With Offspring Cardiovascular Health in Early Adolescence.” JAMA (2021). PMID: 33591345 ↗
L2OTHERCited in: Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, Special Populations - [451]
Canjels LPW, Alers RJ, van de Ven V et al.. “Cerebral volume is unaffected after pre-eclampsia.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2023). PMID: 36730173 ↗
L3OTHERCited in: Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, History and Evolution of Treatment - [452]
Magnus MC, Skåra KH, Carlsen EØ et al.. “Use of assisted reproductive technologies for male and female infertility and perinatal outcomes.” Fertility and sterility (2025). PMID: 39954979 ↗
L2OTHERCited in: Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, Complications - [453]
Uc C, Uc P, Karaman E et al.. “Impact of Surgery-to-Conception Interval on Maternal and Perinatal Outcomes Following Laparoscopic Sleeve Gastrectomy: A Retrospective Cohort Study.” Obesity surgery (2026). PMID: 42432394 ↗
L2COHORTCited in: Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy, History and Evolution of Treatment - [454]
Mumbanza F, Mariet AS, Auger N et al.. “Industrial emissions and risks of preterm and small-for-gestational-age birth: A population-based cohort study in Quebec, Canada.” Environmental epidemiology (Philadelphia, Pa.) (2026). PMID: 42416175 ↗
L2COHORTCited in: Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy - [455]
Adilan A, Zhan H, Hu Y et al.. “The economic burden of preeclampsia: a systematic review.” Hypertension in pregnancy (2026). PMID: 42387820 ↗
L5SR_OBSCited in: Maternal-Fetal Management: Timing of Delivery & In-Utero Therapy - [456]
Villa PM, Kajantie E, Räikkönen K et al.. “Aspirin in the prevention of pre-eclampsia in high-risk women: a randomised placebo-controlled PREDO Trial and a meta-analysis of randomised trials.” BJOG : an international journal of obstetrics and gynaecology (2012). PMID: 23126307 ↗
L1SR_MA_RCTCited in: History and Evolution of Treatment - [457]
Al-Rubaie Z, Askie LM, Ray JG et al.. “The performance of risk prediction models for pre-eclampsia using routinely collected maternal characteristics and comparison with models that include specialised tests and with clinical guideline decision rules: a systematic review.” BJOG : an international journal of obstetrics and gynaecology (2016). PMID: 27225348 ↗
L2SR_OBSCited in: History and Evolution of Treatment, Prevention, Screening & Surveillance - [458]
Blondon M, Claver M, Celetta E et al.. “Preventing Postpartum Venous Thromboembolism With Low-Molecular-Weight Heparin: The PP-HEP Pilot Randomised Controlled Trial.” BJOG : an international journal of obstetrics and gynaecology (2024). PMID: 39238110 ↗
L2RCTCited in: History and Evolution of Treatment - [459]
Altman D, Carroli G, Duley L et al.. “Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial.” Lancet (London, England) (2002). PMID: 12057549 ↗
L1RCTCited in: History and Evolution of Treatment - [460]
. “CLASP: a randomised trial of low-dose aspirin for the prevention and treatment of pre-eclampsia among 9364 pregnant women. CLASP (Collaborative Low-dose Aspirin Study in Pregnancy) Collaborative Group.” Lancet (London, England) (1994). PMID: 7906809 ↗
L1RCTCited in: History and Evolution of Treatment - [461]
Steyn DW, Odendaal HJ. “Randomised controlled trial of ketanserin and aspirin in prevention of pre-eclampsia.” Lancet (London, England) (1997). PMID: 9357405 ↗
L1RCTCited in: History and Evolution of Treatment - [462]
Levine RJ, Hauth JC, Curet LB et al.. “Trial of calcium to prevent preeclampsia.” The New England journal of medicine (1997). PMID: 9211675 ↗
L1RCTCited in: History and Evolution of Treatment - [463]
Belizán JM, Villar J, Gonzalez L et al.. “Calcium supplementation to prevent hypertensive disorders of pregnancy.” The New England journal of medicine (1991). PMID: 1922250 ↗
L1RCTCited in: History and Evolution of Treatment - [464]
Belfort MA, Anthony J, Saade GR et al.. “A comparison of magnesium sulfate and nimodipine for the prevention of eclampsia.” The New England journal of medicine (2003). PMID: 12540643 ↗
L1RCTCited in: History and Evolution of Treatment - [465]
Tiruneh SA, Vu TTT, Moran LJ et al.. “Externally validated prediction models for pre-eclampsia: systematic review and meta-analysis.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2024). PMID: 37724649 ↗
L2SR_OBSCited in: History and Evolution of Treatment, Prognosis & Natural History - [466]
Leung HHY, Papastefanou I, Chen Y et al.. “Aspirin delays preterm birth in pregnancies at high risk for preterm pre-eclampsia: evidence from randomized clinical trial in Asia.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2025). PMID: 40454801 ↗
L1RCTCited in: History and Evolution of Treatment - [467]
Liu X, Zhang C, Lin Z et al.. “Association of maternal mild hypothyroidism in the first and third trimesters with obstetric and perinatal outcomes: a prospective cohort study.” American journal of obstetrics and gynecology (2024). PMID: 39218287 ↗
L2COHORTCited in: History and Evolution of Treatment - [468]
Dolitzky M, Inbal A, Segal Y et al.. “A randomized study of thromboprophylaxis in women with unexplained consecutive recurrent miscarriages.” Fertility and sterility (2006). PMID: 16769056 ↗
L1RCTCited in: History and Evolution of Treatment - [469]
Chesley LC. “Diagnosis of preeclampsia.” Obstetrics and gynecology (1985). PMID: 3883267 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment - [470]
Mørch NF, Nøhr B, Kirk M et al.. “Early pregnancy concentrations of pregnancy-associated plasma protein-A (PAPP-A) and insulin-like growth factor-1 (IGF-1) following frozen embryo transfer: secondary analyses from a randomized controlled trial.” Human reproduction (Oxford, England) (2026). PMID: 41875321 ↗
L1RCTCited in: History and Evolution of Treatment - [471]
Wright D, Wright A, Nicolaides KH. “The competing risk approach for prediction of preeclampsia.” American journal of obstetrics and gynecology (2019). PMID: 31733203 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment - [472]
Carbone IF, Cruz JJ, Sarquis R et al.. “Assisted conception and placental perfusion assessed by uterine artery Doppler at 11-13 weeks' gestation.” Human reproduction (Oxford, England) (2011). PMID: 21489976 ↗
L2TRIAL_NONRANDOMCited in: History and Evolution of Treatment - [473]
Shub A, Walker SP. “Planned early delivery versus expectant management for monoamniotic twins.” The Cochrane database of systematic reviews (2015). PMID: 25906204 ↗
L1SR_OBSCited in: History and Evolution of Treatment - [474]
Matchaba PT, Moodley J. “WITHDRAWN: Corticosteroids for HELLP syndrome in pregnancy.” The Cochrane database of systematic reviews (2009). PMID: 19588331 ↗
L1SR_OBSCited in: History and Evolution of Treatment - [475]
Duley L, Gulmezoglu AM. “Magnesium sulphate versus lytic cocktail for eclampsia.” The Cochrane database of systematic reviews (2001). PMID: 11279786 ↗
L1SR_OBSCited in: History and Evolution of Treatment - [476]
Knight M, Duley L, Henderson-Smart DJ et al.. “WITHDRAWN: Antiplatelet agents for preventing and treating pre-eclampsia.” The Cochrane database of systematic reviews (2007). PMID: 17636639 ↗
L1SR_OBSCited in: History and Evolution of Treatment - [477]
Kramer MS. “WITHDRAWN: Energy/protein restriction for high weight-for-height or weight gain during pregnancy.” The Cochrane database of systematic reviews (2007). PMID: 17636585 ↗
L1SR_OBSCited in: History and Evolution of Treatment - [478]
Kennedy AL, Stern CJ, Tong S et al.. “The incidence of hypertensive disorders of pregnancy following sperm donation in IVF: an Australian state-wide retrospective cohort study.” Human reproduction (Oxford, England) (2019). PMID: 31863120 ↗
L2COHORTCited in: History and Evolution of Treatment - [479]
Hodges V, Mitchell C, Chew-Graham C et al.. “Addressing cardiovascular risk after adverse pregnancy outcomes: a health equity-focused qualitative review.” The British journal of general practice : the journal of the Royal College of General Practitioners (2026). PMID: 42134966 ↗
L5SR_OBSCited in: History and Evolution of Treatment, Prognosis & Natural History - [480]
Carvajal JA, Carvajal SA, Araujo K et al.. “Early maternal DHA supplementation fails to modify clinical phenotypes associated with impaired placentation: A randomized, double-blind, placebo-controlled trial (DEEPER trial).” Placenta (2026). PMID: 42025271 ↗
L1RCTCited in: History and Evolution of Treatment - [481]
Sederholm Lawesson S, Swahn E, Pihlsgård M et al.. “Association Between History of Adverse Pregnancy Outcomes and Coronary Artery Disease Assessed by Coronary Computed Tomography Angiography.” JAMA (2023). PMID: 36749333 ↗
L2OTHERCited in: History and Evolution of Treatment - [482]
Klonoff-Cohen HS, Savitz DA, Cefalo RC et al.. “An epidemiologic study of contraception and preeclampsia.” JAMA (1989). PMID: 2810672 ↗
L3OTHERCited in: History and Evolution of Treatment - [483]
Arechvo A, Demertzidou E, Adjahou S et al.. “Routine 36-week scan: prediction of prolonged neonatal intensive care unit admission.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2025). PMID: 40542571 ↗
L2OTHERCited in: History and Evolution of Treatment - [484]
Riishede I, Rode L, Sperling L et al.. “Pre-eclampsia screening in Denmark (PRESIDE): national validation study.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2023). PMID: 36840981 ↗
L2OTHERCited in: History and Evolution of Treatment - [485]
Charakida M, Chatzakis C, Magee LA et al.. “Association of maternal body mass index with hemodynamic and vascular alterations at 35-37 weeks' gestation.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2025). PMID: 39815418 ↗
L2OTHERCited in: History and Evolution of Treatment - [486]
Koerts JJ, Voskamp LW, Rousian M et al.. “Impact of corpus luteum number on maternal pregnancy and birth outcomes: the Rotterdam Periconception Cohort.” Fertility and sterility (2024). PMID: 39644989 ↗
L2OTHERCited in: History and Evolution of Treatment - [487]
Gao D, Juan J, Wang X et al.. “Long-term mortality in women with a history of hypertensive disorders of pregnancy: a systematic review and meta-analysis.” EClinicalMedicine (2026). PMID: 42180401 ↗
L1SR_OBSCited in: History and Evolution of Treatment - [488]
von Versen-Höynck F, Griesinger G. “Should any use of artificial cycle regimen for frozen-thawed embryo transfer in women capable of ovulation be abandoned: yes, but what's next for FET cycle practice and research?” Human reproduction (Oxford, England) (2022). PMID: 35640158 ↗
L5OTHERCited in: History and Evolution of Treatment - [489]
Schaaf JM, Bruinse HW, van der Leeuw-Harmsen L et al.. “Reproductive outcome after early-onset pre-eclampsia.” Human reproduction (Oxford, England) (2010). PMID: 21134949 ↗
L2OTHERCited in: History and Evolution of Treatment, Complications - [490]
Yang X, Zhang J, Wu J et al.. “Association between the number of oocytes retrieved and neonatal outcomes after freeze-all IVF cycles.” Human reproduction (Oxford, England) (2019). PMID: 31621863 ↗
L2OTHERCited in: History and Evolution of Treatment - [491]
Lozoya-Angulo ME, Cañizares-Hernández FG, Requena-López S et al.. “First-trimester lipoprotein(a) and longitudinal renal biomarker trajectories preceding preeclampsia: a pilot cohort study.” Archives of gynecology and obstetrics (2026). PMID: 42390652 ↗
L2COHORTCited in: History and Evolution of Treatment - [492]
Yoshida Y, Iriyama T, Ariyoshi Y et al.. “Effect of prophylactic subcutaneous unfractionated heparin on the maternal sFlt-1/PlGF ratio: a retrospective cohort study.” BMC pregnancy and childbirth (2026). PMID: 42174451 ↗
L2COHORTCited in: History and Evolution of Treatment - [493]
Jain S, Mor S, Jain M et al.. “Feto-maternal outcomes in hypertensive disorders of pregnancy: a prospective community-based cohort study in rural central India.” Pregnancy hypertension (2026). PMID: 42105508 ↗
L2COHORTCited in: History and Evolution of Treatment - [494]
Duffy J, Hirsch M, Kawsar A et al.. “Outcome reporting across randomised controlled trials evaluating therapeutic interventions for pre-eclampsia.” BJOG : an international journal of obstetrics and gynaecology (2017). PMID: 28432737 ↗
L1SR_MA_RCTCited in: Complications - [495]
Askie LM, Duley L, Henderson-Smart DJ et al.. “Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data.” Lancet (London, England) (2007). PMID: 17512048 ↗
L1SR_OBSCited in: Complications, Prognosis & Natural History, Prevention, Screening & Surveillance - [496]
Carr H, Johansson K, Snowden JM et al.. “Maternal and Interpregnancy Factors and Risks of First-Time Preeclampsia in Second Pregnancy: A Swedish National Cohort Study.” BJOG : an international journal of obstetrics and gynaecology (2025). PMID: 40888026 ↗
L2COHORTCited in: Complications - [497]
Roberge S, Nicolaides KH, Demers S et al.. “Prevention of perinatal death and adverse perinatal outcome using low-dose aspirin: a meta-analysis.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2013). PMID: 23362106 ↗
L1SR_OBSCited in: Complications - [498]
D'Alberti E, Dockree S, Garbagnati M et al.. “Risk factors for mortality and severe morbidity in fetuses with normal late third-trimester scan: population-based cohort study.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2025). PMID: 40519155 ↗
L2COHORTCited in: Complications, Prevention, Screening & Surveillance - [499]
Panaitescu AM, Syngelaki A, Prodan N et al.. “Chronic hypertension and adverse pregnancy outcome: a cohort study.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2017). PMID: 28436175 ↗
L2COHORTCited in: Complications, Prognosis & Natural History - [500]
Joseph KS, Boutin A, Lisonkova S et al.. “Maternal Mortality in the United States: Recent Trends, Current Status, and Future Considerations.” Obstetrics and gynecology (2021). PMID: 33831914 ↗
L5OTHERCited in: Complications, Prevention, Screening & Surveillance - [501]
Hoover RN, Hyer M, Pfeiffer RM et al.. “Adverse health outcomes in women exposed in utero to diethylstilbestrol.” The New England journal of medicine (2011). PMID: 21991952 ↗
L2OTHERCited in: Complications, Special Populations - [502]
Singh B, Reschke L, Segars J et al.. “Frozen-thawed embryo transfer: the potential importance of the corpus luteum in preventing obstetrical complications.” Fertility and sterility (2020). PMID: 32106972 ↗
L5REVIEW_NARRATIVECited in: Complications - [503]
Norrman E, Bergh C, Wennerholm UB. “Pregnancy outcome and long-term follow-up after in vitro fertilization in women with renal transplantation.” Human reproduction (Oxford, England) (2014). PMID: 25376456 ↗
L4OTHERCited in: Complications - [504]
Yu P, Chen S, Li Q et al.. “Association between in vitro fertilization and preeclampsia: a multicenter cohort study with subgroup analysis by maternal age, BMI, and parity.” Frontiers in endocrinology (2026). PMID: 42222076 ↗
L2COHORTCited in: Complications - [505]
Roberge S, Nicolaides K, Demers S et al.. “The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta-analysis.” American journal of obstetrics and gynecology (2016). PMID: 27640943 ↗
L1SR_OBSCited in: Prognosis & Natural History - [506]
Cai C, Vandermeer B, Khurana R et al.. “The impact of occupational shift work and working hours during pregnancy on health outcomes: a systematic review and meta-analysis.” American journal of obstetrics and gynecology (2019). PMID: 31276631 ↗
L2SR_OBSCited in: Prognosis & Natural History - [507]
Vigil-DeGracia P, Ludmir J, Ng J et al.. “Is there benefit to continue magnesium sulphate postpartum in women receiving magnesium sulphate before delivery? A randomised controlled study.” BJOG : an international journal of obstetrics and gynaecology (2018). PMID: 29878650 ↗
L1RCTCited in: Special Populations - [508]
Blaauw J, van Pampus MG, Van Doormaal JJ et al.. “Increased intima-media thickness after early-onset preeclampsia.” Obstetrics and gynecology (2006). PMID: 16738162 ↗
L3OTHERCited in: Special Populations - [509]
Schiff MA, Doody DR, Crane DA et al.. “Pregnancy Outcomes Among Deaf Women in Washington State, 1987-2012.” Obstetrics and gynecology (2017). PMID: 29016488 ↗
L2OTHERCited in: Special Populations - [510]
Ren Z, Bremer AA, Pawlyk AC. “Drug development research in pregnant and lactating women.” American journal of obstetrics and gynecology (2021). PMID: 33887238 ↗
L5REVIEW_NARRATIVECited in: Special Populations - [511]
Hurrell A, Webster L, Chappell LC et al.. “The assessment of blood pressure in pregnant women: pitfalls and novel approaches.” American journal of obstetrics and gynecology (2021). PMID: 33514455 ↗
L5REVIEW_NARRATIVECited in: Special Populations - [512]
Goldman-Wohl D, Gamliel M, Mandelboim O et al.. “Learning from experience: cellular and molecular bases for improved outcome in subsequent pregnancies.” American journal of obstetrics and gynecology (2019). PMID: 30802436 ↗
L5REVIEW_NARRATIVECited in: Special Populations - [513]
Brosens I, Benagiano G. “Menstrual preconditioning for the prevention of major obstetrical syndromes in polycystic ovary syndrome.” American journal of obstetrics and gynecology (2015). PMID: 26212182 ↗
L5REVIEW_NARRATIVECited in: Special Populations - [514]
Mulligan ML, Felton SK, Riek AE et al.. “Implications of vitamin D deficiency in pregnancy and lactation.” American journal of obstetrics and gynecology (2009). PMID: 19846050 ↗
L5OTHERCited in: Special Populations - [515]
Brosens I, Benagiano G, Brosens JJ. “The potential perinatal origin of placentation disorders in the young primigravida.” American journal of obstetrics and gynecology (2015). PMID: 25582103 ↗
L5REVIEW_NARRATIVECited in: Special Populations - [516]
Countouris ME, Schwarz EB, Rossiter BC et al.. “Effects of lactation on postpartum blood pressure among women with gestational hypertension and preeclampsia.” American journal of obstetrics and gynecology (2016). PMID: 26945604 ↗
L2OTHERCited in: Special Populations - [517]
Demay MB, Pittas AG, Bikle DD et al.. “Vitamin D for the Prevention of Disease: An Endocrine Society Clinical Practice Guideline.” The Journal of clinical endocrinology and metabolism (2024). PMID: 38828931 ↗
L1GUIDELINECited in: Special Populations - [518]
Bernard N, Jantzem H, Becker M et al.. “Severe adverse effects of bromocriptine in lactation inhibition: a pharmacovigilance survey.” BJOG : an international journal of obstetrics and gynaecology (2015). PMID: 25761676 ↗
L4OTHERCited in: Special Populations - [519]
Alemu BK, Wu L, Azeze GG et al.. “Microbiota-targeted interventions and clinical implications for maternal-offspring health: An umbrella review of systematic reviews and meta-analyses of randomised controlled trials.” Journal of global health (2024). PMID: 39269153 ↗
L1SR_MA_RCTCited in: Special Populations - [520]
Buppasiri P, Lumbiganon P, Thinkhamrop J et al.. “Calcium supplementation (other than for preventing or treating hypertension) for improving pregnancy and infant outcomes.” The Cochrane database of systematic reviews (2011). PMID: 21975761 ↗
L1SR_OBSCited in: Special Populations - [521]
Cristófalo MM, de Almeida Garcia JO, Aldrighi JFS et al.. “Prevalence of Vitamin D Deficiency in Pregnant Women: Systematic Review and Meta-analysis.” Nutrition reviews (2026). PMID: 40973701 ↗
L2SR_OBSCited in: Special Populations - [522]
Hakimi S, Turfan EC, Allahqoli L et al.. “Maternal and newborn health inequality among Syrian refugees in Turkey: a systematic review and meta-analysis.” International journal for equity in health (2025). PMID: 40457273 ↗
L2SR_OBSCited in: Special Populations - [523]
Varmaghani M, Pourtaheri A, Ahangari H et al.. “The prevalence of adolescent pregnancy and its associated consequences in the Eastern Mediterranean region: a systematic review and meta-analysis.” Reproductive health (2024). PMID: 39085959 ↗
L2SR_OBSCited in: Special Populations - [524]
Xu M, Wang HX, Zu P et al.. “Association Between Preeclampsia and Blood Pressure in Offspring: A Systematic Review and Meta-Analysis.” Current hypertension reports (2024). PMID: 38780756 ↗
L2SR_OBSCited in: Special Populations - [525]
Eminov E, Eminov A. “Prevalence of adolescent pregnancy and evaluation of pregnancy outcomes: a retrospective study.” Archives of gynecology and obstetrics (2025). PMID: 39828776 ↗
L2COHORTCited in: Special Populations - [526]
Dutra TA, Fragoso MBT, Wanderley TM et al.. “Diet's total antioxidant capacity and women's health: systematic review and meta-analysis.” The British journal of nutrition (2025). PMID: 40045768 ↗
L2SR_OBSCited in: Special Populations - [527]
Elawad T, Scott G, Bone JN et al.. “Risk factors for pre-eclampsia in clinical practice guidelines: Comparison with the evidence.” BJOG : an international journal of obstetrics and gynaecology (2022). PMID: 36209504 ↗
L2GUIDELINECited in: Prevention, Screening & Surveillance - [528]
Winsloe C, Elhindi J, Vieira MC et al.. “Differences in Factors Associated With Preterm and Term Stillbirth: A Secondary Cohort Analysis of the DESiGN Trial.” BJOG : an international journal of obstetrics and gynaecology (2024). PMID: 39291344 ↗
L2RCTCited in: Prevention, Screening & Surveillance - [529]
Richards EMF, Giorgione V, Stevens O et al.. “Low-dose aspirin for the prevention of superimposed preeclampsia in women with chronic hypertension: a systematic review and meta-analysis.” American journal of obstetrics and gynecology (2022). PMID: 36209937 ↗
L1SR_OBSCited in: Prevention, Screening & Surveillance - [530]
von Dadelszen P, Bhutta ZA, Sharma S et al.. “The Community-Level Interventions for Pre-eclampsia (CLIP) cluster randomised trials in Mozambique, Pakistan, and India: an individual participant-level meta-analysis.” Lancet (London, England) (2020). PMID: 32828187 ↗
L1SR_OBSCited in: Prevention, Screening & Surveillance - [531]
Lailler G, Grave C, Gabet A et al.. “Recurrence of hypertensive disorders of pregnancy: results from a nationwide prospective cohort study (CONCEPTION).” BJOG : an international journal of obstetrics and gynaecology (2023). PMID: 36802131 ↗
L2COHORTCited in: Prevention, Screening & Surveillance - [532]
Nakimuli A, Okello E, Kesiiga A et al.. “Postpartum Cardiovascular Health in African Women Following Pre-Eclampsia: A Prospective Cohort Study.” BJOG : an international journal of obstetrics and gynaecology (2025). PMID: 40292525 ↗
L2COHORTCited in: Prevention, Screening & Surveillance - [533]
Nzelu D, Palmer T, Stott D et al.. “First trimester screening for pre-eclampsia and targeted aspirin prophylaxis: a cost-effectiveness cohort study.” BJOG : an international journal of obstetrics and gynaecology (2023). PMID: 37431533 ↗
L3COHORTCited in: Prevention, Screening & Surveillance - [534]
Ayala NK, Rouse DJ. “A Nudge Toward Universal Aspirin for Preeclampsia Prevention.” Obstetrics and gynecology (2019). PMID: 30870274 ↗
L5OTHERCited in: Prevention, Screening & Surveillance - [535]
Lambert K, Rees K, Seed PT et al.. “Macroprolactinomas and Nonfunctioning Pituitary Adenomas and Pregnancy Outcomes.” Obstetrics and gynecology (2017). PMID: 27926659 ↗
L4OTHERCited in: Prevention, Screening & Surveillance - [536]
. “Committee Opinion No. 638: First-Trimester Risk Assessment for Early-Onset Preeclampsia.” Obstetrics and gynecology (2015). PMID: 26287789 ↗
L1REVIEW_NARRATIVECited in: Prevention, Screening & Surveillance - [537]
Bujold E, Rolnik DL, Poon L et al.. “The effect of aspirin on the risk of preeclampsia based on the Fetal Medicine Foundation first-trimester risk.” American journal of obstetrics and gynecology (2025). PMID: 41177290 ↗
L2RCTCited in: Prevention, Screening & Surveillance - [538]
Bonacina E, Armengol-Alsina M, Dalmau M et al.. “Cost-benefit analysis of first-trimester pre-eclampsia screening: comparison of multivariable Gaussian algorithm with and without placental growth factor.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2026). PMID: 41483012 ↗
L2OTHERCited in: Prevention, Screening & Surveillance - [539]
Tan MY, Poon LC, Rolnik DL et al.. “Prediction and prevention of small-for-gestational-age neonates: evidence from SPREE and ASPRE.” Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology (2018). PMID: 29704277 ↗
L2OTHERCited in: Prevention, Screening & Surveillance - [540]
Tieu J, McPhee AJ, Crowther CA et al.. “Screening for gestational diabetes mellitus based on different risk profiles and settings for improving maternal and infant health.” The Cochrane database of systematic reviews (2017). PMID: 28771289 ↗
L1SR_OBSCited in: Prevention, Screening & Surveillance - [541]
Spencer L, Bubner T, Bain E et al.. “Screening and subsequent management for thyroid dysfunction pre-pregnancy and during pregnancy for improving maternal and infant health.” The Cochrane database of systematic reviews (2015). PMID: 26387772 ↗
L1SR_OBSCited in: Prevention, Screening & Surveillance - [542]
Wojcieszek AM, Stock OM, Flenady V. “Antibiotics for prelabour rupture of membranes at or near term.” The Cochrane database of systematic reviews (2014). PMID: 25352443 ↗
L1SR_OBSCited in: Prevention, Screening & Surveillance - [543]
Diaz V, Long Q, Oladapo OT. “Alternative magnesium sulphate regimens for women with pre-eclampsia and eclampsia.” The Cochrane database of systematic reviews (2023). PMID: 37815037 ↗
L1SR_OBSCited in: Prevention, Screening & Surveillance - [544]
Kirkham K, Gkini E, Moakes C et al.. “Timing of birth to improve outcomes in chronic or gestational hypertension: the WILL RCT.” Health technology assessment (Winchester, England) (2026). PMID: 41556143 ↗
L1TRIAL_NONRANDOMCited in: Prevention, Screening & Surveillance - [545]
Oliveira Barbosa P, Aniceto V, Lima-Júnior LS et al.. “NIT_CH: A study protocol for evaluating the effect of inorganic nitrate capsules in chronic hypertensive pregnancies - a triple-blind placebo-controlled randomized trial.” BMC pregnancy and childbirth (2026). PMID: 41514223 ↗
L5TRIAL_NONRANDOMCited in: Prevention, Screening & Surveillance - [546]
Japecanga RR, da-Costa-Santos J, Nobrega GM et al.. “Testing the use of a biomarker (PlGF) to evaluate superimposed preeclampsia in pregnant women with chronic hypertension (B.I.P.E.S.): a randomized clinical trial study protocol.” BMC pregnancy and childbirth (2025). PMID: 41454303 ↗
L5TRIAL_NONRANDOMCited in: Prevention, Screening & Surveillance - [547]
Mohta M, Jain A, Chilkoti GT. “Three initial prophylactic phenylephrine infusion rates and physician interventions in patients with preeclampsia undergoing caesarean delivery under spinal anaesthesia: a randomised double-blind trial.” International journal of obstetric anesthesia (2025). PMID: 41529537 ↗
L1RCTCited in: Prevention, Screening & Surveillance - [548]
Salvi S, Mandolini D, Bloemenkamp KWM et al.. “Eclampsia Incidence, Management and Outcomes Across Multi-Country Surveillance Cohorts: Individual Participant Data Meta-Analysis.” BJOG : an international journal of obstetrics and gynaecology (2026). PMID: 41885141 ↗
L2SR_OBSCited in: Prevention, Screening & Surveillance - [549]
Zha Y, Mikhailov NJ, Brucia KH et al.. “Low-Dose Aspirin Recommendations for Preeclampsia Risk Reduction: A Systematic Review Focused on Black Patients : Current Hypertension Reports.” Current hypertension reports (2026). PMID: 41857233 ↗
L2SR_OBSCited in: Prevention, Screening & Surveillance